WO2010039850A1 - Improved method of rna display - Google Patents

Improved method of rna display Download PDF

Info

Publication number
WO2010039850A1
WO2010039850A1 PCT/US2009/059057 US2009059057W WO2010039850A1 WO 2010039850 A1 WO2010039850 A1 WO 2010039850A1 US 2009059057 W US2009059057 W US 2009059057W WO 2010039850 A1 WO2010039850 A1 WO 2010039850A1
Authority
WO
WIPO (PCT)
Prior art keywords
scfv
mrna
antibody
library
protein
Prior art date
Application number
PCT/US2009/059057
Other languages
French (fr)
Inventor
Chung-Ming Hsieh
Yuliya A. Kutskova
John E. Memmott
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2737035A priority Critical patent/CA2737035A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to BRPI0919426A priority patent/BRPI0919426A2/en
Priority to EP09818450.0A priority patent/EP2342562B1/en
Priority to ES09818450T priority patent/ES2434850T3/en
Priority to JP2011530178A priority patent/JP5968624B2/en
Priority to CN200980147651.0A priority patent/CN102227638B/en
Priority to MX2011003381A priority patent/MX2011003381A/en
Priority to AU2009298499A priority patent/AU2009298499A1/en
Priority to NZ591544A priority patent/NZ591544A/en
Publication of WO2010039850A1 publication Critical patent/WO2010039850A1/en
Priority to IL211551A priority patent/IL211551A/en
Priority to ZA2011/02120A priority patent/ZA201102120B/en
Priority to HK11113810.8A priority patent/HK1159250A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label

Definitions

  • the present disclosure relates to RNA display, and particularly to methods of RNA display that allow selection of soluble and cell surface antigens.
  • Antibodies can be selected that bind with high specificity and affinity to almost any structural epitope and are routinely used as research tools and as FDA approved therapeutics. As a result, therapeutic and diagnostic monoclonal antibodies constitute a multi-billion dollar market worldwide.
  • RNA display expressed proteins or peptides are linked covalently or by tight non-covalent interaction to their encoding mRNA to form RNA/protein fusion molecules.
  • the protein or peptide component of an RNA/protein fusion can be selected for binding to a desired target and the identity of the protein or peptide determined by sequencing of the attached encoding mRNA component.
  • the invention solves the foregoing problems by providing improved methods of in vitro RNA display to allow reliable expression and selection of scFv molecules from expression libraries.
  • the methods of the invention are also expedient for in vitro display of all classes of protein, including both soluble and cell surface antigens.
  • the invention has several advantages which include, but are not limited to, providing improved in vitro RNA display methods that are simpler and less time consuming to perform than previously described methods. Additionally, the methods of the invention allow for enhanced functional expression of proteins containing intra-chain disulphide bonds, for example, scFv antibody molecules.
  • the invention provides a method of screening an scFv antibody RNA display library, the method comprising the steps of (a) providing a puromycin or analogue thereof crosslinked scFv mRNA molecule, said molecule comprising an mRNA encoding a 5' scFv and a 3' spacer sequence, which molecule is crosslinked to a single stranded nucleic acid linker, the linker comprising a puromycin, or analogue thereof, at a 3' end and a Psoralen C6 at the 5' end; (b) in vitro translating the puromycin-crosslinked scFv mRNA in the presence of a label, in the presence of GSSG (oxidized glutathione) /GSH (reduced glutathione) and PDI (protein disulphide isomerase) and in the absence of dithiothreitol under conditions such that a labeled puromycin-crosslinked scFv mRNA/
  • the method further comprises the step of (g) reverse transcribing the scFv mRNA after antigen selection to make a cDNA. In another embodiment, the method further comprises the step of (h) amplifying the cDNA.
  • the label is a radioactive label, such as, for example, 35 S methionine or cysteine.
  • the 3' spacer sequence comprises about 0 to about 200 amino acids, for example, about 16 amino acids, and/or the 3' spacer comprises an affinity tag.
  • the linker comprises, from 5' to 3': Psoralen C6, 2'0Me ribonucleotides comprising the sequence UAGCGGAUGC (SEQ ID NO: 20), six Triethylene glycol or PEG-150 moieties, two cytidine residues, and puromycin.
  • the scFv mRNA molecule is photocrosslinked to the DNA linker by UVA.
  • the scFv mRNA molecule comprises a 5' promoter selected from the group consisting of T7, SP6, and T3.
  • the scFv mRNA molecule comprises a tobacco mosaic virus 5' untranslated region.
  • the labeled puromycin-crosslinked scFv mRNA/protein molecule is purified by oligo-dT chromatography. In another embodiment, labeled puromycin-crosslinked scFv mRNA/protein molecule is purified using anti-FLAG M2 monoclonal antibody agarose beads. In yet another embodiment, the labeled puromycin- crosslinked scFv mRNA/protein molecule is purified by oligo-dT chromatography and anti-FLAG M2 monoclonal antibody agarose beads.
  • the antigen is a biotinylated peptide, protein, or hapten.
  • the antigen is a fusion protein with human immunoglobulin fragment crystallizable (Fc) or with murine immunoglobulin fragment crystallizable (Fc), or the antigen is a population of cells.
  • the antibody according to the invention is an anti-IL-12 antibody, an anti-hemaglutinin (anti-HA) antibody, a murine antibody, or a human antibody.
  • the in vitro translation of the puromycin-crosslinked scFv mRNA is performed in the presence of GSSH/GSH.
  • the method does not comprise an mRNA capping step. In another embodiment, the method does not comprise an in vitro reverse transcription step prior to the purification step. In yet another embodiment, an RNase inhibitor is added before, during, or after any of steps (a) through (g). In an embodiment, the purification step comprises reverse transcription of the mRNA in the absence of dithiothreitol (DTT) to produce a cDNA.
  • DTT dithiothreitol
  • the cDNA is amplified by polymerase chain reaction.
  • the polymerization chain reaction employs a thermostable DNA polymerase or DNA polymerases selected from the group consisting of Platinum HiFi and KOD.
  • the beads are selected from the group consisting of streptavidin-M280, neutravidin-M280, SA-M270, NA-M270, SA-MyOne, NA-MyOne, SA-agarose, and NA-agarose.
  • Figure 1 depicts a general scheme for the mRNA-scFv display technology in some embodiments of the invention.
  • Figure 2 depicts a general scheme for the mRNA-scFv display technology in other embodiments of the invention.
  • Figure 3 depicts a general depiction of the library DNA construct.
  • Figure 4a depicts results showing that functional scFv can be generated as mRNA-scFv molecules.
  • Figure 4b depicts models of free scFv molecules and mRNA-scFv molecules.
  • Figure 5 depicts results showing that the scFv attached in the mRNA-scFv molecule format is functionally equivalent to the free scFv molecule.
  • Figure 6 depicts the three D2E7 mRNA-scFv constructs with different 3' spacer lengths.
  • Figure 7 depicts results showing that shorter spacer length improved mRNA- scFv binding to antigens and the yield of mRNA-scFv antibody molecules.
  • Figure 8 depicts the sequences of the D2E7 short, medium and long length Ck 3' spacers (SEQ ID NOS 42-44, respectively in order of appearance).
  • Figure 9a depicts the 17/9 mRNA-scFv constructs with short and long spacer lengths.
  • Figure 9b depicts results showing that shorter spacer length improved 17/9 mRNA-scFv molecule binding to target antigen and yield of mRNA-scFv antibody molecules.
  • Figure 10 depicts results showing that PDI activity was required for some scFv function.
  • Figure 11 depicts results showing that the presence of DTT during reverse transcription inhibited 17/9 scFv binding to hemaglutinin (HA) antigen.
  • Figure 12 depicts agarose gel electrophoresis results showing that DTT did not significantly alter the reverse transcription process.
  • Figure 13 depicts agarose gel electrophoresis results from different RT conditions with or without DTT and RNaseOUTTM both before and after selection.
  • Figure 14 depicts agarose gel electrophoresis results showing recovery of the Phylos 40 VH sequence when reverse transcribed either before or after selection compared with pre- selection RT and alkaline elution of cDNA (left lane).
  • Figure 15 depicts agarose gel electrophoresis results showing that an RNase inhibitor preserved RNA template recovery by reverse transcription after antigen selection.
  • Figure 16 depicts results of a side-by- side comparison of a CL- long and a CL- short spacer in the presence or absence of RNaseOUTTM.
  • Figure 17 depicts agarose gel electrophoresis results showing side-by-side comparison of recovery of a CL-long and CL-short spacer in the presence or absence of RNaseOUTTM.
  • Figure 18 depicts agarose gel electrophoresis results quantifying 17/9 scFv before and after one round of mRNA-scFv selection.
  • Figure 19 depicts general depiction of chimeras between D2E7 and 2SD4.
  • Figure 20a depicts the percent of recovery after antigen binding between the different chimeras, showing that rriRNA display technology can be used to discriminate binders with different affinity.
  • Figure 20b depicts normalized percent of recovery after antigen selection, showing that rriRNA display technology can be used to discriminate binders with different affinity.
  • Figure 21 depicts the thermostability of mRNA-scFv molecules.
  • Figure 22 depicts agarose gel electrophoresis results showing that RNA can be recovered after high temperature treatment of mRNA-scFv molecules.
  • Figure 23 depicts the mRNA-scFv Y61 constructs with short and long spacer lengths as well as the PF-y61scGene3 construct comprising a poly- A tail at the DNA linker between the mRNA and scFv protein.
  • Figure 24 depicts a general scheme for the mRNA-scFv display technology in other embodiments of the invention.
  • SEQ ID NO:1 Amino acid sequence of MAK195 scFv protein sequence.
  • SEQ ID NO:2 Amino acid sequence of Y61 scFv short protein sequence.
  • SEQ ID NO: 3 Amino acid sequence of Y61 scFv long protein sequence.
  • SEQ ID NO:4 Amino acid sequence of Y61 scFv Gene3 protein sequence.
  • SEQ ID NO: 5 Amino acid sequence of D2E7 scFv short protein sequence.
  • SEQ ID NO: 6 Amino acid sequence of D2E7 scFv medium protein sequence.
  • SEQ ID NO:7 Amino acid sequence of D2E7 scFv long protein sequence.
  • SEQ ID NO: 8 Amino acid sequence of 17/9 scFv short protein sequence.
  • SEQ ID NO:9 Amino acid sequence of 17/9 scFv long protein sequence.
  • SEQ ID NO: 10 Nucleic acid sequence of MAK195 scFv nucleotide sequence.
  • SEQ ID NO: 11 Nucleic acid sequence of Y61 scFv short nucleotide sequence.
  • SEQ ID NO: 12 Nucleic acid sequence of Y61 scFv long nucleotide sequence.
  • SEQ ID NO: 13 Nucleic acid sequence of Y61 scFv Gene3PA nucleotide sequence.
  • SEQ ID NO: 14 Nucleic acid sequence of Y61 scFv Gene3 nucleotide sequence.
  • SEQ ID NO: 15 Nucleic acid sequence of D2E7 scFv short nucleotide sequence.
  • SEQ ID NO: 16 Nucleic acid sequence of D2E7 scFv medium nucleotide sequence.
  • SEQ ID NO: 17 Nucleic acid sequence of D2E7 scFv long nucleotide sequence.
  • SEQ ID NO:18 Nucleic acid sequence of 17/9 scFv short nucleotide sequence.
  • SEQ ID NO: 19 Nucleic acid sequence of 17/9 scFv long nucleotide sequence.
  • antibody includes monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), chimeric antibodies, CDR-grafted antibodies, humanized antibodies, human antibodies, murine antibodies and fragments thereof, for example, an antibody light chain (VL), an antibody heavy chain (VH), a single chain antibody (scFv), a F(ab')2 fragment, a Fab fragment, an Fd fragment, an Fv fragment, and a single domain antibody fragment (dAb).
  • VL antibody light chain
  • VH antibody heavy chain
  • scFv single chain antibody
  • Fab fragment fragment
  • FdAb single domain antibody fragment
  • antibody library refers to a plurality of DNA or RNA molecules containing an open reading frame (ORF) which encodes an antibody or fragment thereof. It also includes a plurality of antibody proteins and nucleic acid/antibody fusion molecules expressed from said DNA or RNA molecules.
  • ORF open reading frame
  • heavy chain variable domain refers to the nucleic acid encoding an antibody heavy chain variable region and to the protein product of said nucleic acid.
  • light chain variable domain refers to the nucleic acid encoding an antibody light chain variable region and to the protein product of said nucleic acid.
  • epitope tag refers to a short amino acid sequence specifically recognized by an antibody that is attached chemically or genetically to a molecule to allow for its detection by said antibody, for example, FLAG tag, HA tag, Myc tag or T7 tag,
  • non-antibody sequences refers to any nucleic acid or amino acid sequences that appear in the antibody libraries of the invention, which are not part of the original antibody sequence. Such sequences include, for example, epitope tags.
  • control sequences refers to DNA sequences or genetic elements necessary for the expression of an operably linked coding sequence in a particular host organism or in vitro expression system. Such sequences are well known in the art.
  • the control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site.
  • Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
  • nucleic acid is "operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence, or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • operably linked means that the DNA sequences being linked are contiguous. However, enhancers do not have to be contiguous.
  • binding' refers to the ability of a binding molecule to bind to a target with an affinity of at least 1 x 10 ⁇ 6 M, 1 x 10 ⁇ 7 M, 1 x 10 "8 M, 1 x 10 "9 M, 1 x 10 "10 M, 1 x 10 "11 M, 1 x 10 "12 M, or less, and/or bind to a target with an affinity that is at least two-fold greater than its affinity for a nonspecific antigen.
  • target refers to an antigen or epitope recognized by an antibody.
  • Targets include any peptide, proteins, saccharides, nucleic acids, or other molecule, including small molecules for which a specific antibody can be generated.
  • antibodies are against a human protein, for example, TNF ⁇ , IL- 12, ILl 8, IL-l ⁇ or lL-l ⁇ .
  • a “conservative amino acid substitution” is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
  • RNA display or "mRNA display” refers to an in vitro technique wherein expressed proteins or peptides are linked covalently or by tight non-covalent interaction to their encoding mRNA to form "RNA/protein fusion" molecules.
  • the protein or peptide component of an RNA/protein fusion can be selected for binding to a desired target and the identity of the protein or peptide determined by sequencing of the attached encoding mRNA component. Such methods are well known in the art and are described, for example, in U.S. Patent Nos.
  • single chain antibody refers to an antigen binding portion of a light chain variable region and an antigen binding portion of a heavy chain variable region, joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. ScL U.S.A 85:5879-5883).
  • scFv single chain Fv
  • the term "functional moiety” refers to any biological or chemical entity that imparts additional functionality to a molecule to which it is attached.
  • a “selecting” step refers to substantially partitioning a molecule from other molecules in a population.
  • a “selecting” step provides at least a 2-fold, preferably, a 30-fold, more preferably, a 100-fold, and, most preferably, a 1000-fold enrichment of a desired molecule relative to undesired molecules in a population following the selection step.
  • a selection step may be repeated any number of times, and different types of selection steps may be combined in a given approach.
  • pause sequence refers to a nucleic acid sequence that causes a ribosome to slow or stop its rate of translation.
  • solid support refers to, without limitation, any column (or column material), bead, test tube, microtiter dish, solid particle (for example, agarose or sepharose), microchip (for example, silicon, silicon-glass, or gold chip), or membrane (for example, the membrane of a liposome or vesicle) to which an affinity complex may be bound, either directly or indirectly (for example, through other binding partner intermediates such as other antibodies or Protein A), or in which an affinity complex may be embedded (for example, through a receptor or channel).
  • linker region refers to a region of nucleic acid connecting the nucleic acid sequences encoding antibody VH and VL domains in a scFv antibody gene.
  • a linker region is in-frame with the nucleic acid sequences encoding antibody VH and VL such that a continuous open reading frame containing the VH, VL and linker regions is formed.
  • the term also refers to the region connecting the VH and VL in an scFv protein.
  • peptide acceptor refers to any molecule capable of being added to the C-terminus of a growing protein chain by the catalytic activity of the ribosomal peptidyl transferase function.
  • such molecules contain (i) a nucleotide or nucleotide- like moiety (for example, puromycin and analogues thereof), (ii) an amino acid or amino acid-like moiety (for example, any of the 20 D- or L-amino acids or any amino acid analog thereof (for example, O-methyl tyrosine or any of the analogs described by Ellman et al., Meth. Enzymol.
  • a linkage between the two for example, an ester, amide, or ketone linkage at the 3' position or, less preferably, the 2' position; preferably, this linkage does not significantly perturb the structure of the ring from the natural ribonucleotide conformation.
  • this term encompasses, without limitation, a peptide acceptor molecule that is covalently bonded (either directly or indirectly through intervening nucleic acid sequence) to the protein coding sequence, as well as one that is joined to the protein coding sequence by some non-covalent means, for example, through hybridization using a second nucleic acid sequence that binds at or near the 3' end of the protein coding sequence and that itself is bound to a peptide acceptor molecule.
  • the present invention features improved methods of in vitro RNA display that allow reliable expression and selection of scFv antibody molecules from expression libraries.
  • RNA display methods generally involve expression of a library of proteins or peptides, wherein the expressed proteins or peptides are linked covalently or by tight non-covalent interaction to their encoding mRNA to form RNA/protein fusion molecules.
  • the protein or peptide component of an RNA/protein fusion can be selected for binding to a desired target and the identity of the protein or peptide determined by sequencing of the attached encoding mRNA component.
  • Current methods of RNA display are not optimal for scFv antibody expression since several of the steps are performed under reducing conditions which prevents formation of scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Current methods additionally make use of either VH or VL antibody fragments in the selection process.
  • the present invention solves this technical problem by performing the in vitro RNA display assay under mildly reducing conditions that favor an scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules.
  • Using the scFv format rather than single variable domains e.g., a single variable heavy (VH) domain
  • VH single variable heavy
  • VL compatible variable light
  • the methods of the invention are also expedient for in vitro RNA display of all classes of protein.
  • the methods of the invention also provide a shorter and simpler protocol for performing RNA display. This is achieved, in part, by avoiding the time consuming step of reverse transcribing the mRNA in an RNA-protein fusion into cDNA prior to selection with a target.
  • the invention features improved in vitro RNA-display screening methods.
  • the general method is as follows: /) Formation of RNA/Protein Fusions
  • One or more in vitro antibody DNA expression libraries are transcribed to generate mRNA.
  • Any in vitro antibody expression library is suitable (e.g., VH, VL or scFv libraries), however, the methods of the invention are particularly well suited to scFv libraries.
  • Any art recognized methods of transcription are suitable.
  • the DNA library templates are removed. This may be accomplished using any art recognized methods, for example, by digestion with DNase I.
  • a peptide acceptor is attached to the 3' end of the library mRNA. This may be accomplished using any art recognized methods.
  • a linker comprising 5' (Psoralen C6) 2'0Me(U AGC GGA UGC) XXX XXX CC (Puromycin) 3' (SEQ ID NO: 20),(where X is a Triethylene glycol or PEG- 150 and CC is standard DNA backbone) is used.
  • the linker is first allowed to bind to the 3' end of the library mRNA through complementary base pairing.
  • the linker is then crosslinked to the mRNA by UV activation of the Psoralen C6 molecule.
  • the library mRNA is then translated in an in vitro system.
  • Any art recognized methods of in vitro translation are suitable, for example, rabbit reticulocyte lysate.
  • a protein disulphide isomerase (PDI) is added to the in vitro translation reaction and/or the reaction is performed under mildly oxidizing conditions.
  • a mild oxidizing agent for example, GSSG/GSH, for example 10OmM GSSG /1OmM GSH
  • reducing agents for example, dithiothreitol (DTT) are omitted from the in vitro translation reaction.
  • One or more labeled amino acids, or derivatives thereof, may be added to the in vitro translation system such that the labeled amino acid becomes incorporated into the resultant antibody.
  • Any art recognized labeled amino acid is contemplated, for example, a radiolabeled amino acid, for example, 35 S-labelled methionine or cysteine.
  • RNA/protein fusion molecules become covalently linked to their protein products via the peptide acceptor (e.g., puromycin) fused at the 3' end.
  • peptide acceptor e.g., puromycin
  • RNA/protein fusion molecules are purified away from the in vitro translation reaction mixture. Any art recognized methods of separation of RNA/protein fusion molecules from a reaction mixture are contemplated.
  • the RNA/protein fusion proteins are separated by chromatography using a polydeoxythimidine (polydT) resin.
  • polydT polydeoxythimidine
  • the RNA-antibody fusion proteins are separated by binding to an antibody specific for an epitope present in the antibody component of the RNA/protein fusion protein.
  • the epitope may be an amino acid sequence tag, for example, FLAG or HA tags, incorporated into the amino acid sequence of the antibody component of the RNA-antibody fusion protein, for example, at the N-terminal, C-terminal or in the inter variable region linker.
  • an amino acid sequence tag for example, FLAG or HA tags
  • RNA/protein fusions of the invention involve the use of naked RNA.
  • all reagents that contact the RNA/protein fusions are treated with RNase inhibitor reagents, for example, RNaseOUTTM, yeast tRNA, SUPERaselnTM, RNasin®, and other RNase inhibitors known in the art.
  • the library of RNA/protein fusions is screened for in vitro binding to a desired target.
  • the target molecules are bound to a solid support, for example, agarose beads.
  • the target molecule is directly linked to a solid substrate.
  • the target molecule is first modified, for example, biotinylated, then the modified target molecule is bound via the modification to a solid substrate, for example, streptavidin-M280, neutravidin-M280, SA-M270, NA-M270, SA-MyOne, NA-MyOne, SA-agarose, and NA-agarose.
  • the solid support further includes magnetic beads, for example Dynabeads. Such magnetic beads allow separation of the solid support, and any bound RNA/antibody fusion, from an assay mixture using a magnet.
  • RNA that is physically associated with an antibody or plurality of antibodies is amplified to produce more mRNA. Any art recognized method of RNA replication is contemplated, for example, using an RNA replicase enzyme.
  • mRNA that is physically associated with an antibody or plurality of antibodies may be transcribed into cDNA before being amplified by PCR. The PCR amplified pool can be subject to one or more rounds of screening to enrich for the highest affinity antibodies.
  • the RNA/protein fusions may be eluted from the solid support prior to amplification of the nucleic acid component. Any art recognized method of elution is contemplated. In one embodiment, the RNA/protein fusions are eluted using alkaline conditions, for example, using a pH of about 8.0 to 10.0. In another embodiment, the RNA/protein fusions are eluted using acid conditions, for example, using a pH of about 3.0 to 6.0. In one embodiment, the RNA/protein fusions are not eluted prior to amplification of the nucleic acid component, but instead the RNA/protein fusions are added directly to the amplification reaction mixture.
  • PCR amplified pool of nucleic acids may be sequenced using single molecule sequencing methods to determine the nucleic sequences of every selected RNA/protein molecule.
  • PCR amplification may be accomplished using a high fidelity, proof -reading polymerase, for example, the KODl thermostable DNA polymerase from Thermococcus kodakaraensis or Platinum Taq DNA Polymerase High Fidelity (Invitrogen).
  • the nucleic acid sequences may be amplified under conditions that result in the introduction of mutations into amplified DNA, thereby introducing further diversity into the selected nucleic acid sequences.
  • This mutated pool of DNA molecules may be subjected to further rounds of screening.
  • Libraries of the invention may be generated from any antibody fragment capable of binding to a target.
  • libraries of antibody variable domains are generated. These may be VH and/or VL domains.
  • scFv libraries are generated.
  • the libraries of the invention may also include antibody nucleic acid sequences encoding regions outside of the variable regions, for example, a constant region or fragment thereof, or a hinge region.
  • Nucleic acid libraries of the invention may comprise RNA, DNA or hydrids containing both RNA and DNA elements. Linkage Of Nucleic Acid To Peptide Acceptors
  • the antibody nucleic acid libraries may be modified to contain a peptide acceptor moiety. This may facilitate the covalent attachment of individual member of nucleic acid expression libraries to their cognate protein products. Any art recognized means of attachment of a peptide acceptor to a nucleic acid are contemplated, including the means described, for example, in U.S. Patent No. 5,643,768, U.S. Patent No. 5,658,754, U.S. Patent No. 7,195,880, and U.S. Patent No. 6,951,725, the contents of which are incorporated herein by reference.
  • a linking molecule may be synthesized that comprises a Psoralen C6 molecule and a peptide acceptor molecule, wherein the Psoralen C6 molecule and a peptide acceptor molecule are fused to a nucleic acid sequence, wherein the nucleic acid sequence is complementary to sequences at the 3' end of the nucleic acid library.
  • Such linking molecules can bind, via complementary base pairing, to the 3' end of nucleic acid library clones.
  • Psoralen C6 is sensitive to ultraviolet (UV) light and will cross link the linker to the nucleic acid library clones, thus covalently linking the peptide acceptor to the nucleic acid library clones.
  • the nucleic acid portion of the linker molecule may contain modified nucleotides, for example, 2 prime methoxy (2'0Me) ribonucleotides.
  • the linker molecule further comprises a Triethylene glycol or PEG- 150 linker separating the nucleic acid region containing the Psoralen C6 molecule and a peptide acceptor molecule.
  • the linker may comprise, from 5' to 3': Psoralen C6, 2'0Me) ribonucleotides comprising the sequence UAGCGGAUGC (SEQ ID NO: 20), six Triethylene glycol or PEG- 150 moeities, two cytidine residues, and Puromycin.
  • Such linkers may be custom- synthesized by, for example, TriLink BioTechnologies, Inc. V. General Screening Methods
  • the invention features methods of screening the expression libraries of the invention to identify antibodies capable of binding to a desired target. Any in vitro or in vivo screening method that allows for selection of an antibody from an expression library, based upon antibody binding to a target molecule, is contemplated.
  • the expression libraries of the invention may be screened using an art recognized in vitro cell-free phenotype-genotype linked display.
  • Such methods are well known in the art and are described, for example, in U.S. Pat. Nos. 7,195,880; 6,951,725; 7,078,197; 7,022,479, 6,518,018; 7,125,669; 6,846,655; 6,281,344; 6,207,446; 6,214,553; 6,258,558; 6,261,804; 6,429,300; 6,489,116; 6,436,665; 6,537,749; 6,602,685; 6,623,926; 6,416,950; 6,660,473; 6,312,927; 5,922,545; and 6,348,315.
  • These methods involve transcription of protein in vitro from a nucleic acid in such a way that the protein is physically associated or bound to the nucleic acid from which it originated. By selecting for an expressed protein with a target molecule, the nucleic acid that codes for the protein is also selected.
  • protein disulphide isomerase enzymes may be added to the in vitro expression system to improve the production of functional scFv molecules.
  • a mild oxidizing agent for example, GSSG/GSH, for example 10OmM GSSG /1OmM GSH
  • reducing agents for example, dithiothreitol (DTT)
  • DTT dithiothreitol
  • one or more labeled amino acids, or derivatives thereof may be added to the in vitro translation system such that the labeled amino acid becomes incorporated into the resultant antibody.
  • Any art recognized labeled amino acid is contemplated, for example, a radiolabeled amino acid, for example, 35 S-labelled methionine or cysteine.
  • the in vitro screening assays of the invention require that after in vitro selection of an antibody or plurality of antibodies the mRNA that is physically associated with the antibody or plurality of antibodies may be reverse transcribed to generate cDNA encoding said antibody or plurality of antibodies.
  • Any suitable method for reverse transcription is contemplated, for example, enzyme mediated reverse transcription, for example, Moloney murine leukemia virus reverse transcriptase.
  • Screening methods employed in the invention may require amplification of the nucleic acid that encodes antibodies that bind specifically to a desired target.
  • mRNA that is physically associated with an antibody or plurality of antibodies may be amplified to produce more mRNA.
  • RNA replication is contemplated, for example, using an RNA replicase enzyme.
  • mRNA that is physically associated with an antibody or plurality of antibodies may be first reverse transcribed into cDNA before being amplified by PCR.
  • PCR amplification may be accomplished using a high fidelity, proof -reading polymerase, for example, the KODl thermostable DNA polymerase from Thermococcus kodakaraensis or Platinum Taq DNA Polymerase High Fidelity (Invitrogen).
  • PCR amplification may be performed under conditions that introduce mutations into the amplified DNA, e.g., error-prone PCR.
  • the expression libraries of the invention may be screened by display on the surface of a cell, virus or bacteriophage and subject to selection using immobilized target molecules. Suitable methods of screening are described in U.S. patent numbers 7,063,943; 6,699,658; 6,423,538; 6,696,251; 6,300,065; 6,399,763; 6,114,147 and 5,866,344.
  • Screening methods employed in the invention may require introduction of diversity into the antibody library by introducing nucleic substitutions and/or deletions that may result in one or more amino acid substitutions and/or deletions in the expressed antibodies molecules.
  • Any art recognized methods of mutagenesis are contemplated, for example, random mutagenesis, "walk through” mutagenesis, and "look through” mutagenesis.
  • Such mutagenesis of an antibody can be achieved using, for example, error-prone PCR, "mutator” strains of yeast or bacteria, or incorporation of random or defined nucleic acid changes during ab inito synthesis of all or part of an antibody.
  • a library of antibody molecules may be created in which one or more amino acids are randomly mutated.
  • a library of antibody molecules may be created in which one or more amino acids are mutated to one or more predetermined amino acids. Screening methods employed in the invention may also require that the stringency of the target-binding screening assay be increased to select for antibodies with improved affinity for the target. Any art recognized methods of increasing the stringency of an antibody-target interaction assay may be considered.
  • one or more of the assay conditions may be varied (for example, the salt concentration of the assay buffer) to reduce the affinity of the antibody molecules for the desired target.
  • the length of time permitted for the antibodies to bind to the desired target may be reduced.
  • a competitive binding step may be added to the antibody-target interaction assay.
  • the antibodies may first be allowed to bind to a desired immobilized target.
  • a specific concentration of non-immobilized target may then be added which serves to compete for binding with the immobilized target such that antibodies with the lowest affinity for antigen are eluted from the immobilized target resulting in an enrichment for antibodies with improved antigen binding affinity.
  • the stringency of the assay conditions may be further increased by increasing the concentration of non-immobilized target that is added to the assay.
  • Screening methods of the invention may also require multiple rounds of selection to enrich for one or more antibodies with improved target binding.
  • further amino acid mutations may be introduced into the antibodies using art recognized methods.
  • the stringency of binding to the desired target may be increased to select for antibodies with increased affinity for a desired target.
  • RNA-antibody fusion proteins may be separated by chromatography using a polydeoxythimidine (polydT) resin.
  • polydT polydeoxythimidine
  • the RNA-antibody fusion proteins may be separated by chromatography using an antibody specific for an epitope present in the antibody component of the RNA-antibody fusion protein.
  • the epitope may be an amino acid sequence tag, for example, FLAG, Myc, or HA tags, incorporated into the amino acid sequence of the antibody component of the RNA-antibody fusion protein, for example, at the N-terminal, C-terminal or in the inter variable region linker.
  • Selection of antibodies from the libraries of the invention may require the use of immobilized target molecules.
  • the target molecule is directly linked to a solid substrate for example, agarose beads.
  • the target molecule is first modified, for example, biotinylated, then the modified target molecule is bound via the modification to a solid support, for example, streptavidin-M280, neutravidin-M280, SA-M270, NA-M270, SA-MyOne, NA-MyOne, SA-agarose, and NA-agarose.
  • a solid support for example, streptavidin-M280, neutravidin-M280, SA-M270, NA-M270, SA-MyOne, NA-MyOne, SA-agarose, and NA-agarose.
  • the practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, recombinant DNA technology, immunology (especially, e.g., immunoglobulin technology), and animal husbandry.
  • conventional techniques of chemistry, molecular biology, recombinant DNA technology, immunology (especially, e.g., immunoglobulin technology), and animal husbandry See, e.g., Sambrook, Fritsch and Maniatis, Molecular Cloning: Cold Spring Harbor Laboratory Press (1989); Antibody Engineering Protocols (Methods in Molecular Biology), 510, Paul, S., Humana Pr (1996); Antibody Engineering: A Practical Approach (Practical Approach Series, 169), McCafferty, Ed., IrI Pr (1996); Antibodies: A Laboratory Manual, Harlow et al., C.S.H.L. Press, Pub. (1999); Current Protocols in Molecular Biology, eds. Ausubel et al., John Wiley & Sons (1992
  • mRNA Display Protocol for scFv mRNA display may be conducted according to the method shown in Figure 2. Particular embodiments of this method are described in greater detail below. These embodiments are intended to illustrate the methods of the invention, and should not be construed as limiting.
  • Library DNA constructs may be designed according to methods of antibody library generation known in the art.
  • the library constructs may encode antibody fragments, i.e., antibody light chain fragments (VL) or antibody heavy chain fragments (VH).
  • the library constructs may encode single chain variable fragments (scFv).
  • the mRNA display antibody library may be selected against biotinylated antigen. While the best antigen for each target should be determined on a case-by-case basis, the following considerations may be used as a general guideline.
  • a target antigen is typically well characterized, and is the relevant or dominant genetic isotype, as determined by polymorphism (SNP and haplotype) and/or pharmacogenetic analysis.
  • a target antigen additionally may have reasonable bioactivity (comparable to native antigen), good solubility and good chemical and physical properties, and may be prepared in sufficient quantities for library selections or screenings and downstream bioassays.
  • PCR amplification may be performed using methods known in the art. PCR reactions typically contain DNA template, reaction buffer, dNTP, primers used for amplification, DNA polymerase, and water. Multiple reaction tubes may be set up simultaneously from a master mix to increased amplified DNA yield. 25 cycles of PCR typically give sufficient amplification, but as many as 35 cycles may be used to gain more products.
  • products are the correct size (-850 bp for scFv, -500 bp for VH or VL library) and contain minimal non-specific products
  • the products may be used directly in the transcription reaction.
  • the products may be purified on a preparative agarose gel by cutting out the specific band of the correct size. DNA concentration may be measured on a spectrophotometer.
  • RNA transcription from library DNA may be performed using standard methods known in the art. A large reaction volume may be used to transcribe sufficient DNA templates to sample the entire library diversity. In an exemplary embodiment, 1 x 10 13 copies of library templates may be used in the RNA transcription reaction.
  • An RNA transcription typically contains 5-10 ⁇ g of PCR product, reaction buffer, ATP, CTP, GTP, UTP, and T7 RNA polymerase. The RNA transcription reaction may be run at 37°C for between 2 hours to overnight. Shorter times may be used following initial rounds of selection, however, overnight incubations may maximize the RNA yield of the reaction. Following RNA transcription, DNA templates may be removed from the reaction mixture by DNase I digestion.
  • RNA may be fractionated using a NAP-10 column. Up to about 1 mL of transcription reaction may be loaded onto a NAP-10 column for RNA purification. The column may be equilibrated using DEPC-treated dH 2 O prior to fractionation. RNA may be eluted from the column using about 1.5X the reaction volume DEPC-treated dH 2 O (e.g. 750 ⁇ L per 500 ⁇ L transcription reaction). The total elution volume may be less than about 150% of the transcription reaction volume. RNA may be additionally or alternatively fractionated using a NAP-25 column.
  • RNA samples may be analyzed using gel electrophoresis, or alternatively by measuring the OD at 260 nm (OD 26 o) of RNA concentration in collected fractions.
  • molar concentration of scFv RNA may be calculated as follows:
  • RNA yield (nmol) [RNA] ( ⁇ M) x Volume ( ⁇ L) / 1000 The RNA yield typically reaches a maximum at about 20 nmol/mL per 500 ⁇ L transcription reaction.
  • a DNA linker that contains a peptide acceptor molecule at its 3' end may be covalently ligated to the 3' ends of each RNA molecule by UV crosslinking.
  • the peptide acceptor which may enter the ribosomal A site and covalently couple to the carboxyl terminus of the nascent polypeptide chain, may ultimately enable the covalent association of the mRNA (genotype) to the protein encoded by this mRNA (phenotype).
  • An exemplary PEG6/10 linker may be used which has the following formula: 5' (Psoralen C6) 2'OMe(U AGC GGA UGC) XXX XX CC (Puromycin) 3' (SEQ ID NO: 20)
  • the Psoralen C6 5' modification is light sensitive and functions to create a covalent bond between the linker and the mRNA by UV crosslinking.
  • a 2'0Me(U AGC GGA UGC) (SEQ ID NO: 20) backbone region anneals to the linker annealing site 3' to the FLAG sequence on mRNA (see Figure 1).
  • X denotes "Spacer 9", alternatively known as Triethylene glycol or PEG- 150. This spacer has been optimized to provide flexibility for puromycin insertion into the eukaryotic ribosome A site.
  • CC comprises a standard DNA backbone.
  • a puromycin 3' modification inserts into the ribosome A site to create a stable link between the linker and the nascent peptide.
  • the extinction coefficient for the linker described herein may be about 147.7 OD 26 o/ ⁇ i ⁇ iole. Since this linker is light sensitive, solutions containing this linker should be protected from light.
  • RNA ligation reaction may contain the following components: RNA, water, chemical ligation buffer, and the PEG6/puromycin linker (ImM). In an exemplary embodiment, the total reaction volume is about 100 ⁇ L.
  • the linker/RNA molar ratio may be greater than about 1.5.
  • the annealing reaction (which anneals the linker to the transcribed RNA) may be performed in a thermal cycler.
  • the annealing reaction may be conducted by incubating samples at about 85 0 C for about 30 seconds, then at about 4°C, using a ramp rate of about 0.3 0 C per second. Reactions may then be held at about 4°C.
  • Ligation of the annealed linker/RNA may be accomplished by UV crosslinking. This may be conducted using any method known to one of skill in the art. In one embodiment, reaction tubes may be placed on top of a frozen freezer pack and placed directly under a handheld long wavelength (about 365 nm) UV lamp and crosslinked for about 15 minutes in the dark. Typical ligation efficiency is about 50 - 90%. Generally purification is not required. The ligation products may be stored at -80 0 C.
  • RNA display molecules In an exemplary embodiment, about -0.1% of input RNA may be made into mRNA display molecules after all reactions and purifications.
  • In vitro translation is conducted using methods and reagents known to one of skill in the art.
  • the translation reaction using the scFv library uses about 5 nmol of RNA template with about 10 mL of reticulocyte Iy sate in a reaction volume of about 15 mL.
  • solutions of GSSG/GSH may be prepared at a final concentration of about 100 mM GSSG/10 mM GSH.
  • PDI is prepared by dissolving PDI powder into dH 2 O to reach a concentration of about 1 Unit/ ⁇ L.
  • the PDI solution may be stored at -20 0 C.
  • An exemplary translation reaction may be set up as follows:
  • RNA (100-120 pmol/300 ⁇ L or 500-600 pmol/1.5 ml ) X X ⁇ L dH 2 O to 73.7 to 370 ⁇ L
  • Translation reactions may be incubated in 30 0 C water bath for 1 - 2 hours, and the to RNA/protein fusion formation should be performed without delay. A significant decrease in RNA/protein fusion yield may be observed when the translation volume exceeds 3 mL; consequently, a master mix of the translation reaction may be prepared if the reaction volume is larger than 3 mL, and then divided into smaller aliquots.
  • about 100 ⁇ L 2M KCl and about 20 ⁇ L IM MgCl 2 may be added for every 300- ⁇ L of translation reaction mixture, and incubated for about 1 hour at room temperature, or at -2O 0 C overnight.
  • about 500 ⁇ L 2M KCl and about 100 ⁇ L IM MgCl 2 may be added for every 1.5 ml of translation reaction mixture, and incubated for about 1 hour at room temperature, or at -2O 0 C overnight. This stabilizes the paused ribosomes at the end of mRNA templates and allows puromycin at the end of the DNA linker to enter the A sites of paused ribosomes, which permanently links the translated scFv proteins to their mRNA templates.
  • the room temperature incubation may be shortened if the reaction is stored at -2O 0 C overnight.
  • the reaction may be terminated by adding about 50 ⁇ L or about 250 ⁇ L 0.5 M EDTA per 300 ⁇ L or 1.5 ml translation reaction, respectively, to disrupt the ribosomes. Reactions may be stored at -20 0 C. A 5-10 ⁇ L aliquot may be removed for scintillation counting later.
  • This step is included to purify mRNA display molecules and remaining RNA templates from the translation/fusion reaction.
  • the amount of pre- washed oligo-dT cellulose needed to capture all RNA templates should be estimated.
  • a sufficient volume of oligo-dT binding buffer may be added to the fusion reaction to reach about a IX final concentration.
  • Pre- washed oligo-dT cellulose may then be added, and the reactions are rotated for 1 hour at 4°C. Reactions may optionally be spun down at about 1500 rpm for 5 min at 4°C, and the supernatant is discarded.
  • Oligo-dT cellulose beads may be transferred and washed about 6 times with IX Oligo-dT binding buffer using spin columns, and buffer is typically removed by spinning columns at about 1000 rpm for 10 seconds. The flow-through may be discarded, but the last wash may be saved for scintillation counting.
  • 1/10 of the initial slurry volume of dH 2 O may be added to the dry oligo-dT beads, which may be centrifuged immediately for 10 seconds and the flow through may be discarded.
  • mRNA display molecules and free RNA templates
  • Eluate is collected by spinning at about 4000 rpm (or higher) for 20 seconds. The elution is typically repeated once, and the eluates are combined. 5 ⁇ L of eluate may be removed for scintillation counting.
  • the efficiency of oligo-dT purification may also be assessed by OD at 260 nm (OD260) on a NanoDrop spectrophotometer machine. All remaining RNA templates and mRNA display molecules are theoretically recovered by the oligo-dT beads.
  • 5X FLAG binding buffer is added to the eluates to reach about a IX final concentration. Samples may be stored at -80 0 C if not proceeding to the next FLAG purification step.
  • Oligo-dT recovery may be calculated as follows. About 5 ⁇ L of input (from fusion reaction), about 100 ⁇ L from the last wash, and about 5 ⁇ L of output (eluate from oligo-dT purification). The last wash is used to assess extent of washing, and the other two counts are used to calculate RNA/protein fusion recovery from original RNA template input.
  • RNA/protein fusion yield (pmol) (CPM ou t P ut x Volume ou tput x 5 ⁇ M x Volumeiysate) / [CPMmput x Volume mput x (# of methionine in product)].
  • This step is designed to purify mRNA display molecules from remaining RNA templates. It is not necessary to proceed to this step if the library will be selected by antigen off-rate competition or by antigen-expressing cells.
  • the amount of pre- washed anti-FLAG M2 agarose beads needed to capture all mRNA display molecules may be estimated.
  • the binding capacity of the beads may be about 6 nmol fusion protein per mL of 50% slurry. To have sufficient bead volume for manipulation during binding and washing, it is recommended to use at least about 200 ⁇ L of pre- washed beads. The example given below is for an initial 300- ⁇ L translation reaction.
  • a wide-bore pipette tip may be used to transfer 300 ⁇ L pre- washed anti-FLAG M2 agarose to the oligo-dT purified output, which may then be rotated for 1 hour at 4 0 C. Incubation with anti-FLAG M2 agarose may continue overnight. Anti-FLAG M2 agarose may optionally be spun at about 1500 rpm in a centrifuge for about 1 minute at 4°C, and the supernatant may be discarded. Anti-FLAG beads may be washed about 5-6 times with about 500-700 ⁇ L IX FLAG binding buffer, using spin columns (e.g.
  • InvitrogenTM Microcentrifuge Spin Column and centrifuged at about 1000 rpm for 10 seconds for each wash (note that the InvitrogenTM column may be spun at higher speeds, e.g. about 10,000 rpm). The flow-through may be discarded. The beads may additionally be washed 2 times with 700 ⁇ L Selection Buffer (see below) by centrifugation at about 1000 rpm for 10 seconds. The last wash may be saved for scintillation counting. mRNA display molecules may be eluted by adding about 400 ⁇ L 100 ⁇ g/mL FLAG peptide (in Selection Buffer) and incubating for 5 minutes at room temperature. Elute may be collected by spinning at about 3000 rpm (or higher if possible) for 20 seconds.
  • the elution step may be repeated one more time by adding about 400 ⁇ L 100 ⁇ g/mL FLAG peptide. Both eluates may be combined, and about 5 ⁇ L may be removed for scintillation counting. This volume of FLAG peptide may be sufficient for elution from up to about 1 mL of 50% slurry and may be cut in half (200 ⁇ L) if less slurry is used and/or higher RNA/protein fusion concentration is desired.
  • an appropriate amount of RNase inhibitor known in the art i.e., 1 - 2 U/ ⁇ L RNaseOUT and 0.02 ⁇ g/mL yeast tRNA
  • Selection is designed to enrich for molecules that specifically bind to a target of interest when library binding to an antigen reaches equilibrium.
  • a negative selection may be necessary to remove non-specific and matrix binders from a na ⁇ ve scFv library, but may be omitted if using a library made from a single template, e.g., but not limited to, libraries made for affinity maturation doing affinity maturation based on a single scFv template.
  • the selection protocol varies. The following is an exemplary selection protocol for use with biotinylated targets. This protocol may be modified to accommodate target antigens in other formats, and may be scaled up or down depending on the desired output.
  • Streptavidin (SA) magnetic beads may be used for capture, and are typically pre- blocked prior to use.
  • SA beads may be transferred from the original bottle to 1.5 or 2 mL tubes, and washed twice with 2 mL of IX FLAG binding buffer. Beads may be blocked with 2 mL of Selection buffer (2 hours to overnight) at 4 0 C with rotation. It is important to prepare enough beads for both, the pre-clear and selection captures. Pre- blocked beads may be stored at 4 0 C. About 100 ⁇ L of beads are typically used for every 10 pmol of biotinylated antigen, but one of skill in the art will appreciate that capture bead volume should be calculated in view of the binding capacity of free biotin ⁇ e.g. 650-900 pmoles/mg beads, where the bead concentration is typically 10 mg/ml) relative to the reaction yield.
  • 1.5 mL or 2 mL microfuge tubes may be pre-blocked with IX FLAG binding buffer for about 1 hour to overnight.
  • Pre-blocked tubes may be used for all pre-clear and selection steps. Typically four tubes are needed for each sample: 2 for pre-clearing, 1 for the beads, and 1 for selection.
  • Optimal results may be obtained by pre-clearing the library.
  • FLAG purified mRNA display library may be added to beads (separated from buffer), using SA bead volume equal to half of the capture volume. Beads may be rotated at 30 0 C for about 30 minutes.
  • Pre-cleared mRNA display library may be separated from beads using a magnet, and the pre-clear may be repeated one more time.
  • the second pre-clear SA beads may be washed and counted as described in above to determine if background is high. This may also serve as a 'No antigen' negative control.
  • biotinylated target (100 nM) may be added to the whole pre-cleared library, and rotated at 30 0 C for 1 hour.
  • the pre-cleared library may be divided into 2 equal aliquots.
  • Biotinylated antigen may be added to one aliquot, and the other may serve as the 'No antigen' negative control.
  • the washed second pre-clear beads may also be considered as a 'No antigen' control, as noted above, although these beads will have one less 'pre-clear'.
  • the antigen concentration in later rounds may be dropped when recovery of antigen-binding molecules exceeds 5%.
  • antigen concentration should be reduced if the antigen appears to be 'sticky' and significant recovery was observed in early rounds.
  • Antigen concentration may be reduced in later rounds when recovery of antigen-binding molecules becomes significantly higher than background (e.g. relative to a no antigen control). It is important to pay attention to the stoichiometry between library and antigen to ensure that there is at least a 5-fold molar excess of antigen over library PROfusion molecules, especially at lower antigen concentration
  • the selection buffer used for blocking the SA beads for library capture may be removed by centrifugation and magnetic separation.
  • the antigen-bound library may be transferred to pre-blocked SA beads (separated from buffer), and then to the binding reaction, and rotated at 3O 0 C for 5 to 10 minutes.
  • the amount of SA beads for capture should be calculated based on the capacity and the target concentration used in selection (see above). The amount of SA beads should be lowered when lowering the target concentration to avoid the SA bead binders, but typically not less than 50 ⁇ L of beads is used.
  • the SA beads may be collected using a magnet, and washed with about 1 mL of Selection buffer for 1 minute. This step may be repeated about 5 times (about 6 times total). The wash time may be increased in later rounds to incorporate off rate selection strategy to some targets.
  • the beads may be washed one last time with about 1 mL of IX buffer suitable for reverse transcription, collected with a magnet, and re- suspended in water (one fourth of the capture bead volume calculated above).
  • DynabeadsTM (Invitrogen) may be used, but one of skill in the art will appreciate that other beads may be equally suitable.
  • the DynabeadsTM may be separated from the unbound library by centrifugation and magnetic separation. The supernatant may be removed with a 1 mL tip, using one new filtered tip for each library selection tube to eliminate cross -contamination.
  • the DynabeadsTM may be washed with 1 mL of Selection buffer, and re- suspended by gentle pipetting or by inverting tubes multiple times. The tubes may be put back onto the magnetic holder for bead separation while the next library is processed.
  • DynabeadsTM may be washed two times with 1 mL of IX First Strand buffer (Superscript II, Invitrogen) as described above. At the last wash, removed 1/10 of the library to a separate tube for counting to determine library recovery if so desired. DynabeadsTM may be captured by magnetic separation and about 100 ⁇ l wash buffer may be saved for background count. DynabeadsTM may be re- suspended in water, using 1 A of the capture bead volume as calculated above).
  • Selection recovery % 100 x CPM To tai Beads / CPM To tai input 14. Equilibrium Library Selection by Fc fusion proteins
  • library selection may be performed for target antigens that have been fused to an antibody Fc domain (e.g. Fc fusion proteins).
  • Fc domain e.g. Fc fusion proteins
  • a negative selection pre-clear
  • Selection specificity may be improved by fusing target antigens to both human IgGl and mouse IgG2a.
  • the target Fc fusion protein may also be biotinylated, and selected either by the method described here or by the method described above in section 13. It should be noted that protein A magnetic beads may not be suitable for selecting against Fc fusion protein targets because of cross-reactivity to certain portions of the antibody VH domain (e.g. VH originated from human VH3 family germline sequences).
  • Suitable magnetic beads for pulling down antigen binding scFv-PROfusion molecules include, but are not limited to, Dynabeads Protein G, Dynabeads Pan mouse IgG, and other available Dynabeads M-280 to human or to mouse IgGs.
  • protein G beads capacity is considered to be about 25 ⁇ g of human IgGl (-167 pmol) per 100 ⁇ L of protein A/G magnetic beads.
  • Dynabeads Protein G or Dynabeads Pan mouse IgG may be used for capture, and are typically pre-blocked prior to use.
  • the amount of Dynabeads needed for library pre-clear and selection may be calculated.
  • Dynabeads may be transferred from the original bottle to 1.5 or 2 mL microfuge tubes and remove buffer. Beads may be blocked with 1 mL selection buffer (2 hours to overnight) at 4 0 C, or 1 hour at room temperature. It is important to prepare enough beads for both the pre-clear and selection captures.
  • 1.5 mL or 2 mL microfuge tubes may be pre-blocked with selection buffer for 1 hour to overnight, and pre-blocked tubes should be used for all pre-clear and library selection steps.
  • FLAG purified scFv PROfusion library may be added to pre-blocked beads (separated from buffer), Dynabead (protein G or pan mouse IgG) volume equal to half of the capture volume (as calculated above) may be used and the reaction rotated at 30 0 C for 30 minutes.
  • the pre-cleared fusion library may be separated from beads with magnet, and the pre-clear repeated one more time.
  • the second pre-cleared Dynabeads may be washed and counted as described above to determine if background is high. This may also serve as a 'No antigen' negative control.
  • biotinylated target (100 nM) may be added to the whole pre-cleared library, and rotated at 30 0 C for 1 hour.
  • the pre-cleared library may be divided into two aliquots (from 50/50 to 80/20 depending on the library counts).
  • Biotinylated antigen may be added to one aliquot (50 to 80% of whole), while the other aliquots may serve as the 'no antigen' negative control.
  • the washed second pre-clear beads may also be considered as a 'No antigen' control, as noted above, except that it will have one less 'pre-clear'.
  • the antigen concentration may be reduced if the antigen appears to be 'sticky' and significant recovery was observed in early rounds. Additionally, antigen concentration may be reduced in later rounds when recovery of antigen-binding molecules becomes significantly higher than background (no antigen control). It is important to pay attention to the stoichiometry between library and antigen to ensure that there is at least a 5-fold molar excess of antigen over library PROfusion molecules, especially at lower antigen concentration.
  • the selection buffer used for blocking the Dynabeads for library capture may be removed by centrifugation and magnetic separation.
  • the antigen-bound library may be transferred to pre -blocked Dynabeads (separated from buffer), and then to binding reaction, and rotated at 3O 0 C for 20 minutes.
  • the amount of Dynabeads used for capture may be calculated as described above based on the bead capacity, and the target antigen concentration used in the selection. To avoid pulling down bead binders, the amount of Dynabeads should be reduced (but not to less than 500 ⁇ g or 50 ⁇ l) when the target antigen concentration is reduced.
  • the DynabeadsTM may be separated from the unbound library by centrifugation and magnetic separation.
  • the supernatant may be removed with a 1 mL tip, and one new filtered tip may be used for each library selection tube to eliminate cross- contamination.
  • New pipette tips may be used to wash the DynabeadsTM with aboutl mL of Selection buffer, and the DynabeadsTM may be re- suspended by gentle pipetting or by inverting tubes multiple times.
  • the tubes may be placed back onto magnetic holder for bead separation while the next library is processed.
  • supernatant may be removed with a 1 mL tip (use one new filtered tip for each library selection tube to eliminate cross -contamination). This step may be repeated for five washes.
  • DynabeadsTM may be washed two times with 1 mL of IX First Strand buffer (Superscript II, Invitrogen) as described above. At the last wash, 1/10 of library may be removed to a separate tube for counting to determine library recovery if so desired. DynabeadsTM may be captured by magnetic separation and about 100 ⁇ l of wash buffer may be saved for background count. DynabeadsTM may be re-suspended in water, using 1 A of the capture bead volume as calculated above). E. Library Selection: Counting
  • the major difference between off -rate selections and equilibrium selections is that the library binds to the selecting antigen first before FLAG purification.
  • the library may be incubated with an excess amount of competitor antigens or antibodies (e.g. when competitor antigens are not available) such that any pre-bound antigen that becomes unbound from the PROfusion molecules during off-rate competition is replaced by the competitors.
  • the competitor is distinct from the pre- bound antigen in that competitor-bound PROfusion molecules may not be recovered in the subsequent recovery step. They may be un-modified antigens or antigens in a different format.
  • antibodies may also be competitors, typically they are not as efficient competitors as antigen, and their efficiency decreases as the library's affinity to antigen increases. It is advantageous for the off -rate of the library to be determined just prior to selection in order to identify the proper duration of competition. This duration may range from several hours to several weeks.
  • PROfusion molecules may be translated and purified by oligo-dT as described above.
  • the oligo-dT purified library may be equilibrated by adding 5X FLAG binding buffer to a final concentration of IX (simply add 25% of the library volume).
  • Antigens biotinylated or Fc-fusion
  • PROfusion molecules may be purified by anti-FLAG M2 agarose as described above. It is important to note that a FLAG-purified PROfusion library should be kept on ice, but not frozen. It is important to pre -block sufficient amounts of capture beads as described above.
  • B Determine competitor concentration and library baseline recovery
  • the amount of recovered library from the above step may be calculated to determine its molar concentration. This represents the maximal amount of library-bound antigen, and may be used to calculate the amounts needed (500x to 100Ox) for off -rate competition.
  • 10% pre-blocked beads may be added to a 10% aliquot from antigen-bound PROfusion library and rotated for about 20 min at about 4 0 C.
  • the beads may be washed 5 times with 1 mL of Selection Buffer as described above.
  • the beads may be counted to determine the percentage of PROfusion library bound by antigen before off -rate selection as follows:
  • the selection buffer used for blocking the Dynabeads for library capture may be removed by centrifugation and magnetic separation.
  • the antigen-bound library may be transferred to pre-blocked Dynabeads (separated from buffer), and rotated at 4 0 C for about 20 minutes.
  • the Dynabeads may be collected by centrifugation and magnetic separation from library.
  • the supernatant may be removed with a 1 mL tip (use one new filtered tip for each library selection tube to eliminate cross-contamination, as described above).
  • Beads may be washed two times with about 1 mL of IX First Strand buffer (Superscript II, Invitrogen) as described above. At the last wash, 10 to 20% of library may be removed to a separate tube for counting to determine library recovery if so desired. Dynabeads may be captured by magnetic separation and 100 ⁇ l wash buffer may be saved for background count. Beads may be re-suspended in water (1/4 of the capture bead volume as calculated above).
  • F Library selection: Counting and Recovery Calculation 10 - 20% of the last wash and the beads may be counted. It is advisable to avoid using more than 100 ⁇ L beads, as it may quench the counts. Library selection recovery may be calculated using the following formula:
  • Selection recovery % 100 x CPM To tai Beads / CPM To tai input
  • Reverse transcription may be done with Superscript II Reverse Transcriptase (InvitrogenTM). The volume of each reaction may be scaled up according to the bead volume after selection. Outputs may be analyzed by reverse transcription (RT) with appropriate primer pairs.
  • RT reverse transcription
  • 'Ck Reverse' or 'Ck5-FLAGA20 Rev' primers may be used for kappa libraries
  • 'CJL Reverse' or 'CL5FLAGA20 Rev' primers may be used for lambda libraries
  • 'Lib-GS-Rev' or 'VH-GSFLAGA20-Rev' primers may be used for the human PBMC VH library.
  • the reverse transcription primer should have at least the same 5' end sequence as the subsequent PCR reverse primer, to avoid residual primers left over from the reverse transcription reaction creating amplification products that have different 3' end sequences. This is especially important if the shorter 'Ck Reverse', 'CJL Reverse', or 'Lib-GS-Rev' primers are used for RT because any residual amount of these primers may participate in the following PCR and create products that lack the poly-A tail.
  • a RT reaction may be set up as follows: Beads (in water) X ⁇ L dH 2 O to 108 ⁇ L
  • the reaction may be incubated at 42 0 C for 2 minutes prior to adding 10 ⁇ L Superscript II reverse transcriptase.
  • the reaction may be divided into 100 ⁇ L aliquots and incubated at 42 0 C for 50 minutes with occasional agitation. Tubes may then be incubated at 95 0 C for 5 min after the reaction. Beads may be isolated and the supernatant transferred to new tubes. Typically samples may be pooled if they are from same selection output. Re-suspend beads in water (half of RT volume). Tubes may be incubated at 95 0 C for 5 minutes after reaction, and the beads may be captured by magnet, and the supernatant may be pooled with previously transferred supernatant. This represents the cDNA template for PCR amplification of selection outputs.
  • the major distinctions between selecting PROfusion library against cell surface antigens and soluble biotinylated antigens are that the mRNA moieties in the PROfusion molecules are protected from cellular RNase degradations by cDNA complementation, and thus need to be reverse-transcribed into cDNA before library selections.
  • the reverse transcription reaction may be carried out before or after the FLAG purification depending on the volume of library after oligo-dT purification. It is important to note that the reducing agent DTT should not be included in the reverse transcription, or any step prior to library selection, in order to preserve the intrachain disulfide bonds of the scFv molecule.
  • an initial 10 ml translation volume appropriate for first round selection may be used, but it should be noted that the following methodology may be easily adapted for smaller translation reactions.
  • PROfusion molecules may be translated and purified by oligo dT as described above.
  • the purified library should be recovered in a dE ⁇ O volume equal to or less than the reticulate lysate volume used for translation. Input, last wash buffer, and 10 ⁇ l of library may be counted to determine yield and percent recovery as described above.
  • the oligo dT-purified library may be equilibrated to a final concentration of IX PBS by adding 1/4 library volume 5X PBS.
  • the amount of anti-FLAG M2 agarose beads needed to capture all PROfusion molecules may be estimated ⁇ e.g. estimating the binding capacity of the beads at approximately 6 nmol fusion protein per mL of 50% slurry). In order to have sufficient bead volume for manipulation during binding and washing, it is inadvisable to use less than 200 ⁇ L of the pre- washed beads.
  • a wide-bore pipette tip may be used to transfer anti-FLAG M2 agarose to a new tube. The beads may be spun down (1500 rpm for 1 minute) and the buffer removed.
  • the beads may be washed two to three times with 1 ml PBS to remove any trace amount of detergent present in the storage buffer.
  • the oligo-dT purified library may be transferred in IX PBS to the washed anti-FLAG M2 agarose beads, and rotated at 4°C for 1 hour to overnight.
  • the anti-FLAG M2 agarose beads may be spun down at 1500 rpm for 1 minute, 4°C and the supernatant discarded.
  • IX PBS may be used to transfer beads onto a Bio-RadTM Mini-spin column or InvitrogenTM Microcentrifuge Spin Column, and then the buffer may be removed by spinning at 1000 rpm for 10 seconds.
  • the InvitrogenTM column may be spun at higher speed (e.g. 10,000 RPM is possible).
  • Beads may be washed 4X by 500 - 600 ⁇ L 1 X PBS and the PBS spun through the column. Beads may be washed 2X by 500 - 600 1 X RT first strand buffer (without DTT). The flow-through may be discarded, but it is advisable to save the last wash for scintillation counting.
  • D FLAG elution
  • PROfusion molecules may be eluted by adding 450 ⁇ L (note that 230 ⁇ L may be used for smaller M2 agarose volumes) of 100 ⁇ g/mL FLAG peptide in First Strand Buffer (without DDT) that contains RNaseOUT at a 1:20 dilution, and then incubating the mixture for 10 minutes at room temperature. Eluate may be collected by spinning at 3000 rpm or faster for 20 seconds. This step may be repeated once, and then the libraries from both elutions may be pooled. E: FLAG recovery calculation
  • PROfusion molecule recovery % may be calculated as follows (note that 10- 30%, or higher, recovery is expected):
  • Reaction may be incubated at 37 0 C for 1 hour, with or without agitation.
  • the library may be equilibrated for selection against cell surface antigens as follows. After the reverse transcription reaction has been completed, 5 M NaCl may be added to the reaction mixture to 75 mM (15.3 ⁇ L to 1 mL and 7.6 to 500 ⁇ L reaction). An additional IX PBS may be added to the library if there is a need to increase volume. The following blocking reagent may be added to library before selection.
  • a pre-clear step may be required for na ⁇ ve library selection, but may be omitted if using a library made from a single template, e.g. a library made for affinity maturation.
  • Cells used for library pre-clearing should be confirmed not to have target antigen expression on cell surface by flow-cytometry or Western blot analysis.
  • this could be the parental cells used for generating the antigen- expressing stable cell lines, which present a situation where the only know surface protein difference between the cells used for pre-clearing and for selection should be the target antigen itself.
  • the cell numbers needed for pre-clearing library should be calculated. This is the number of antigen-na ⁇ ve cells needed for pre-clearing library and is the same number as for library selection.
  • one particular antigen has an estimated cell surface copy number of 1 x 10 4 , and in a 10 pmol na ⁇ ve antibody library less than 0.05% (5 x 10 "4 ) of the library can be recovered by antigen binding or background sticking.
  • the number of cells needed for pre-clear and selection is
  • the number of cells should be 5 x 10 6 or more to ensure cell pellet can be seen after pelleting.
  • Cell density may be counted by hemocytometer or Coulter counter and sufficient cells may be transferred to a centrifuge tube.
  • Cells may be spun down at 1500 rpm at 4°C, and very gently re-suspended in 1 mL ice-chilled PBS.
  • the cell suspension may be transferred to a 1.7 mL screw-top microfuge tube. Be careful not to shear cells by pipetting.
  • Cells may be spun down at 1500 rpm and the PBS removed.
  • the wash step with PBS may be repeated once more.
  • the library from step 13.3.3 should be immediately added to gently re- suspended cells.
  • the tubes may then be immersed into an ice-water bath, and agitated for about 60 minutes.
  • Cells may be spun down at 1500 rpm and the library transferred to a new tube of cells for second pre-clear or for antigen selection.
  • H Library selection against antigen-expressing cells
  • Antigen-expressing cell density may be counted by hemocytometer or Coulter counter and sufficient antigen-expressing cells may be transferred to a centrifuge tube.
  • Cells may be spun down at 1500 rpm at 4°C, and very gently re- suspend cells in 1 rriL ice-chilled PBS.
  • the cell suspension may be transferred to a 1.7 mL screw-top microfuge tube. Be careful not to shear cells by pipetting.
  • the purified and/or pre-cleared library may be immediately used to gently resuspend cells.
  • the tubes may be immersed into ice- water bath, and rotated for 2 hours.
  • RNase H 5 ⁇ L RNase H (2 U/ ⁇ L) may be added to the re-suspended cells and incubated at 37 0 C for 20 minutes. This will digest the RNA and release cDNA from the cell surface. Cells may be spun down at 1500 rpm for 30 seconds and the supernatant transferred to a new tube. Cells may now be discarded. 5 ⁇ L of RNase A (20 mg/ml) may be added to the supernatant and incubated at 37 0 C for 30 minutes. This degrades any cellular RNA that may have come from broken cells during the selection process. The degraded RNA may be removed by dialysis later and thereby prevented from interfering with library amplification by PCR.
  • phenol/CHCVisoamylalcohol 25:24:1
  • the bottom organic phase may be separated from top aqueous phase by centrifugation in Phase Lock Gel Heavy 2 ml tube (Eppendorf) at maximal speed for 5 minutes.
  • the top aqueous phase may be transferred to a new tube and the extraction repeated once with phenol/CHCVisoamylalcohol (25:24:1) and once by CHCl 3 .
  • the top aqueous phase after the CHCI 3 extraction may be transferred to Mini Dialysis Kit, 8 kDa cut-off, 2 mL (GE healthcare) and dialyzed overnight at 4 0 C against 4 liter of dH 2 O.
  • K Counting and library selection recovery calculation
  • Selection recovery % 100 x CPM To tai ceils / CPM To tai input 18. Reamplification of Library DNA by RT-PCR
  • Reverse transcription may be performed using the material captured from the library. Reagents and protocols known in the art are suitable for performing the reverse transcription reaction.
  • the volume of the reaction may be scaled up or down according to the bead volume after selection.
  • Primers used for reverse transcription may be any suitable reverse- complementary sequences located at the 3' end invariable region of the antibody library and may be the same or further 3' to the reverse primer to be used in a subsequent amplifying PCR.
  • An exemplary reverse transcription reaction contains the beads from the library selection (in water), reverse primer, and dNTP. Reactions are incubated at 65 0 C for about 5 minutes and chilled on ice. First strand synthesis buffer, about 0.1M DTT, and RNase inhibitor are then typically added to the reaction. The reverse transcription reactions are incubated at about 42 0 C for 2 minutes before adding reverse transcriptase enzyme. Reactions are incubated at about 42 0 C for 50 minutes with occasional agitation. Reactions are then incubated at 95 0 C for 5 min. Beads are then collected by magnet, and the supernatant is transferred to new tubes, which is pooled if it is from same selection output.
  • Beads are resuspended in water (half of RT volume), and incubated in tubes at 95 0 C for 5 minutes. Beads are again collected using a magnet, and the supernatant is pooled with the previously transferred supernatant. This contains the cDNA template for PCR amplification of selection output. After PCR, 10-DL of PCR product is loaded onto a 2% agarose gel to confirm that the reaction was successful.
  • cDNA (supernatants from RT reactions) may be dialyzed against water using an 8 kDa cut-off, and the entire amount of cDNA may be used as PCR template.
  • 10% of cDNA may typically be used as template for PCR, and dialysis is typically not necessary.
  • Reactions may be performed in 1 mL PCR volumes for round 1 and 2 outputs (using all RT products), while reaction volumes may be scaled down for outputs from later rounds. Aliquots for 100- ⁇ L reactions should be made from a master mix.
  • An exemplary PCR reaction for library DNA template amplification is shown in Table 7 below.
  • Table 2 Exemplary PCR reaction for library DNA template amplification
  • DNA template X ⁇ L dH 2 O add to 740 ⁇ L
  • 1 mL PCR reactions are used for round 1 and 2 outputs, and 0.5 mL reactions are used for outputs from later rounds. Aliquots of 100- ⁇ L reactions should be made from a master mix. Exemplary thermal cycling conditions for library DNA template amplification are shown in Table 8 below.
  • Table 3 Exemplary alternative PCR reaction for library DNA template amplification cDNA template X ⁇ L dH 2 O add to 790 ⁇ L
  • 1 mL PCR reactions are used for round 1 and 2 outputs, and 0.5 mL reactions are used for outputs from later rounds. Aliquots of 100- DL reactions should be made from a master mix. Exemplary thermal cycling conditions for library DNA template amplification are shown in Table 8 below.
  • DNA template X ⁇ L dH 2 O add to 660 ⁇ L
  • 25 cycles typically give sufficient amplification but it may be increased to as many as 35 cycles to gain more products. Non-specific products of various sizes may become more apparent with additional amplification cycles, and the product may need to be gel purified. If possible, it may be helpful to increase the DNA template input rather than the number of amplification cycles.
  • the size of the PCR product is confirmed by, e.g., agarose gel electrophoresis. If products are the correct size ( ⁇ 850 bp for scFv, ⁇ 500 bp for VH or VL library) and minimal non-specific products are present, the products can generally be used either directly in transcription reaction of the next round, or after purification with a spin column (e.g. QiagenTM QIAquick PCR Purification Kit). In some cases, the PCR products may need to be gel purified. If gel purification is to be used for PCR products, separate all remaining products on a preparative agarose gel and cut out the specific band for gel extraction.
  • Quantitation of gel purified DNA may be misleading, as residual EtBr in the DNA tends to interfere with the UV absorbance. A more extensive wash step during gel extraction may help alleviate this interference. If possible, DNA concentration should be measured on a spectrophotometer, as the UV scanning traces are quite different between a clean DNA sample and a DNA with residual EtBr. This protocol is subsequently repeated to conduct multiple rounds of selection.
  • Spectratyping PCR may be used to analyze the VH CDR3 size distributions in the library, or its selection outputs. It is a useful tool to assess the library diversity, as well as the progression of the selections. The initial few rounds of library selection outputs and the library before selection should be very diverse and the CDR3 size distribution approximates a Gaussian distribution. Table 6: Spectratyping PCR primers
  • Total volume 30.0 ⁇ L Promega GoTaq DNA polymerase is used in this setup but may be substituted by thermal stable DNA polymerases from other sources.
  • the final Mg 2+ concentration is 1.5 mM.
  • 10- ⁇ L product may be loaded onto a 2% agarose gel to confirm successful reaction and the remaining product may be submitted to sequencing core facility for spectratyping electrophoresis on a sequencing machine, along with a ROX- labeled DNA size marker, which in generally underestimates the size of the DNA product by 3-bp, possibly due to the difference in the labeling dyes.
  • the amplified DNA product has the following organization:
  • VH CDR3 size is deduced from the apparent DNA produce size as determined by the Rox dye size marker by the following calculation:
  • SizevH CDR3 (SizeApparent DNA product size - 60) / 3
  • Yeast tRNA (optional, add before use) 20 ng/mL
  • Yeast tRNA (optional, add before use) 20 ng/mL
  • IX binding buffer containing 1 mg/mL BSA and 100 mg/mL salmon sperm DNA.
  • mRNA-scFv Four known antibodies were used to demonstrate that functional mRNA-scFv molecules can be displayed and bind to their respective antigen: D2E7 (human anti- hTNF), Y61 (human anti-hIL-12), 17/9 (mouse anti-HA), and MAK195 (mouse anti- hTNF).
  • D2E7 human anti- hTNF
  • Y61 human anti-hIL-12
  • 17/9 human anti-HA
  • MAK195 mouse anti- hTNF
  • AAACC SEQ ID NO: 26
  • AAAGTG (SEQ ID NO: 36) 17/9 VL-4 Rev CGGTAAAGCGATCCGGCACGCCGCTTTCGCGGG
  • GGCC (SEQ ID NO: 37) 17/9 VL-5 Fwd TGCCGGATCGCTTTACCGGCAGCGGCAGCGGCA
  • CGGA (SEQ ID NO: 38) 17/9 VL-6 Rev AAAGGTCAGCGGGTTGCTATAATCGTTCTGGCA
  • 17/9 antibody sequence was retrieved from NCBI database using the accession numbers A31790 and B31790.
  • DNA constructs for these scFv were transcribed in vitro and then translated by rabbit reticulocyte Iy sate either as mRNA-scFv (protein was attached to mRNA via linker with puromycin modification) or as free scFv (protein was not attached to mRNA). Both types of molecules were purified and subjected to pull-down assays by corresponding biotinylated antigens (see Figure 4).
  • the library size is 1 x 10 ⁇ 12.
  • About 20 pmol of the fused protein e.g., 1.2 x 10 13
  • Recovery following FLAG-purification is typically about 30%. Therefore, about 60 pmol of the fused protein is needed following Oligo-dT purification to input into FLAG purification.
  • about 1.2 pmol fused protein is obtained per 100 pmol RNA following Oligo-dT purification.
  • about 5 nmol RNA (which covers the library size 3000 times) is necessary to obtain 60 pmol of the fused protein. Note that this calculation does not take into account the observation that only about 20-30% of fused mRNA display molecules are functional (can be recovered after selection).
  • the translation reaction was optimized to maximize protein recovery. Varying the initial amount of RNA input into the translation reaction was evaluated following FLAG purification. Protein recovery was assessed by measuring the percentage of S 35 methionine incorporated during the translation reaction, and by calculating the ratio of pmol protein (output) to pmol RNA (input). The starting amounts of input RNA tested, as well as the resulting protein recovery, are shown in Table 12. As demonstrated by this analysis, a lower RNA input surprisingly leads to a higher percentage of protein recovery.
  • the translation reaction was also performed using different amounts of the free amino acid mixture to determine the effect on protein recovery.
  • the relative starting amounts of the amino acid mixture tested, as well as the resulting protein recovery, are shown in Table 13.
  • the RNA input in each case was 50 pmol. As demonstrated by this analysis, increasing the amino acid pool leads to a decrease in translation efficiency.
  • RNA input in each case was 50 pmol. As demonstrated by this analysis, increasing the input of cold methionine does not lead to an increase in translation efficiency.
  • RNA input and amino acid concentration should therefore be taken into consideration when planning the translation reaction for mRNA display. While decreasing the RNA input in each reaction may improve protein recovery, it may also impact library size.
  • An exemplary RNA translation reaction that may be useful in practicing the mRNA display method of the invention is shown in Table 15.
  • RNA yields were also lower with a longer spacer: short spacer yielded 6 nmol RNA; medium spacer yielded 3.4 nmol RNA; and long spacer yielded 1.7 nmol.
  • a short spacer is preferred for scFv library construction.
  • 17/9 requires PDI during translation to be functional, and DTT in the reverse transcription reaction before selection was shown to affect its antigen binding. As these results indicate, disulfide bonds are essential for 17/9 function, and this makes 17/9 a good candidate to investigate spacer length requirements.
  • Figure 9 shows that although longer spacer length does not improve mRNA-scFv molecule binding to antigen, it reduces its yield.
  • Messenger RNA display technology in the art includes a chemical capping reaction on free cysteine residues to prevent formation of undesirable cysteine disulfide bonds by 2-nitro-5-thiocyanatobenzoic acid, which resulted in cyanylation, or by N- ethylmaleimide, which covalently links to the sulfhydryl group. While this capping reaction eliminates potential protein misfolding caused by random crosslinking of free cysteine residues, the present invention eliminates the artificial preservation of free cysteine within an antibody which can be a detriment to its future manufacturability due to unpredictable physical or chemical properties. The step of chemical capping was eliminated such that any extra free cysteine beyond the four cysteines required for scFv Ig domain folding are not actively preserved during the library selection.
  • D2E7, Y61, and 17/9 scFv were used to test their requirement of PDI activity in the mRNA display system.
  • the results showed that two of the scFv (D2E7 and 17/9) would not bind to their cognate antigen without PDI during their generation whereas Y61 appeared to be unaffected (see Figure 10). It was concluded that at a large antibody library level, the high diversity would require PDI activity to ensure maximal scFv function.
  • the recovery and functionality of D2E7 scFv translated with or without additional PDI added was also tested.
  • the translation reaction included 1 tube lysate (200 ⁇ l), 100 pmol D2E7 short spacer RNA and PDI and GSSG/GSH. Translation without PDI excluded PDI and GSSG/GSH.
  • the translated protein was recovered with FLAG purification, and the recovery amount was quantified.
  • Antigen binding/recovery was then performed with 50 mM biotinylated TNF ⁇ and equal inputs for each, 100000 cpm. The results are shown in below in Table 17. Table 14: Testing D2E7 scFv +/- PDI
  • Dithiothreitol is a reducing agent commonly introduced to enzymatic reactions to minimize protein aggregation and reduced protein oxidation. It is also typically used in the reverse transcription (RT) reaction following in vitro translation step of the mRNA scFv molecules. Since its inclusion may reduce the two intrachain disulfide bonds in a scFv molecule that are produced by PDI activity, the potential effect of DTT on the scFv antigen binding function was investigated (see Figure 11). The presence of DTT significantly abolished the antigen binding activity of 17/9 scFv after RT, which is consistent with the dependence of PDI activity for 17/9 function shown in Figure 11.
  • DTT is not present in the RT or alternatively the RT is delayed until after antigen selection to maximize production of functional scFv yield from the mRNA-scFv library.
  • Tables 22 and 23 below show the results of delaying the RT step until after the antigen selection step for Y61-ScCL-long and Y61 -ScCL- short, respectively.
  • Table 19 Comparing Y61-ScCL-long with or without RT step
  • RT double- stranded mRNA-cDNA
  • RT double- stranded mRNA-cDNA
  • the cDNA can be recovered by alkaline hydrolysis of the rriRNA and serves as amplification template by PCR.
  • alternative methods need to be employed to protect the mRNA for amplification after selection.
  • FIG. 14 shows results of reverse transcription following antigen selection comparing the standard method of RT-PCR following oligoDT with acid elution followed by RT-PCR and RT-PCR directly off of beads following capture. Dilution with free beads at 1:10, 1:100 and 1:1000 showed that strong re-amplification was achieved at a dilution of 1:1000.
  • RNaseOUTTM Invitrogen, cat.#10777-019 was included at 1:20 dilution during the antigen selection step and followed by RT-PCR to compare the mRNA recovery (see Figure 15). Compare to performing RT before antigen selection, the mRNA template recovery again was reduced if RT was carried out after antigen selection without RNase inhibitor. Interestingly, the inclusion of RNase inhibitor to the antigen selection not only restored but also significantly enhanced mRNA recovery.
  • this enhancement is at least partly due to a better efficiency of capturing a lighter -280 kDa mRNA-scFv molecule than that of a heavier -560 kDa mRNA-scFv molecule with the additional cDNA.
  • FIG. 16 depicts the experiment performed to compare Y61-CL-long with Y61 -CL- short in the presence or absence of RNase OUT. The results can be seen in Table 24 below as well as in Figure 17.
  • a scFv library with a diversity of 25 was constructed by overlapping PCR.
  • equal amounts of the VH and VL fragments of 17/9, D2E7, 2SD4, Y61 and MAK195 were mixed and combined into a scFv library with a maximal diversity of 25 and used as described above.
  • the 17/9 scFv was then selected from this library by biotinylated HA tag peptide. After selection, 17/9 enrichment was examined by cloning and colony PCR.
  • 2SD4 is the D2E7 scFv precursor which exhibits low affinity (KD ⁇ 200 nM as free protein) for TNF ⁇ .
  • Figure 19 depicts the chimeras.
  • Figure 20a shows the percent of recovery after antigen binding between the different chimeras
  • figure 20b depicts the normalized percent of recovery after antigen selection. The above results show that mRNA display technology as described herein can be used to discriminate binders with different affinity.
  • thermostability of mRNA-scFv molecules D2E7-scCk and Y61-scCk were translated and purified in mRNA-scFv format, as described herein. The mRNA-scFv molecules were then incubated at different temperatures for 30 minutes prior to antigen selection. The normalized percent of recovery after antigen selection is shown in Figure 21.
  • Figure 22 shows that RNA can be recovered after high temperature treatment of mRNA-scFv molecules.
  • RT-PCR was performed on the beads with recovered Y61-scCl mRNA-scFv molecules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention features improved methods of in vitro RNA display to allow reliable expression and selection of scFv antibody molecules from expression libraries. The improved methods, in part, involve the use of mildly reducing conditions, which favor of scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Although particularly suited to expression and selection of scFv antibody molecules, the methods of the invention are also expedient for in vitro RNA display of all classes of protein.

Description

IMPROVED METHODS OF RNA DISPLAY
RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application No. 61/101471, filed September 30, 2008, the contents of which are hereby incorporated by reference.
FIELD OF THE INVENTION
The present disclosure relates to RNA display, and particularly to methods of RNA display that allow selection of soluble and cell surface antigens.
BACKGROUND OF THE INVENTION
Antibodies can be selected that bind with high specificity and affinity to almost any structural epitope and are routinely used as research tools and as FDA approved therapeutics. As a result, therapeutic and diagnostic monoclonal antibodies constitute a multi-billion dollar market worldwide.
Classical methods of immunizing animals to obtain antibodies are slow and cumbersome. As a consequence, methods have been developed for ex vivo selection of an antibody to a desired target molecule using synthetic antibody libraries. In some methods, libraries of antibodies, or fragments thereof, are displayed on the surface of an organism, (for example, a bacteriophage, virus, yeast cell, bacterial cell or mammalian cell), and the organism is selected for expression of the desired antibody. In other methods, antibody libraries are expressed and selected in a cell free in vitro system. In one such system, termed RNA display, expressed proteins or peptides are linked covalently or by tight non-covalent interaction to their encoding mRNA to form RNA/protein fusion molecules. The protein or peptide component of an RNA/protein fusion can be selected for binding to a desired target and the identity of the protein or peptide determined by sequencing of the attached encoding mRNA component.
Current in vitro RNA display systems, although good at expressing single antibody variable domains, are inefficient at expressing multi-domain antibodies such as single chain antibody (scFv) molecules. This is mainly due to the reaction conditions of the current in vitro expression systems and the tendency to lose full length scFv cDNA from the library through repeated amplification by PCR. There is, therefore, a need in the art for improved in vitro display methods for selection of scFv antibodies against a desired target.
SUMMARY OF THE INVENTION
The invention solves the foregoing problems by providing improved methods of in vitro RNA display to allow reliable expression and selection of scFv molecules from expression libraries. Although, particularly suited to expression and selection of scFv molecules, the methods of the invention are also expedient for in vitro display of all classes of protein, including both soluble and cell surface antigens.
Accordingly the invention has several advantages which include, but are not limited to, providing improved in vitro RNA display methods that are simpler and less time consuming to perform than previously described methods. Additionally, the methods of the invention allow for enhanced functional expression of proteins containing intra-chain disulphide bonds, for example, scFv antibody molecules.
In one aspect, the invention provides a method of screening an scFv antibody RNA display library, the method comprising the steps of (a) providing a puromycin or analogue thereof crosslinked scFv mRNA molecule, said molecule comprising an mRNA encoding a 5' scFv and a 3' spacer sequence, which molecule is crosslinked to a single stranded nucleic acid linker, the linker comprising a puromycin, or analogue thereof, at a 3' end and a Psoralen C6 at the 5' end; (b) in vitro translating the puromycin-crosslinked scFv mRNA in the presence of a label, in the presence of GSSG (oxidized glutathione) /GSH (reduced glutathione) and PDI (protein disulphide isomerase) and in the absence of dithiothreitol under conditions such that a labeled puromycin-crosslinked scFv mRNA/protein molecule is formed; (c) purifying the labeled puromycin-crosslinked scFv mRNA/protein molecule; (d) subjecting the purified labeled puromycin-crosslinked scFv mRNA/protein molecule to antigen selection with at least one antigen; and (e) recovering the purified labeled puromycin-crosslinked scFv mRNA/protein molecules using affinity based magnetic beads.
In an embodiment, the method further comprises the step of (g) reverse transcribing the scFv mRNA after antigen selection to make a cDNA. In another embodiment, the method further comprises the step of (h) amplifying the cDNA.
In an embodiment, the label is a radioactive label, such as, for example, 35S methionine or cysteine. In an embodiment, the 3' spacer sequence comprises about 0 to about 200 amino acids, for example, about 16 amino acids, and/or the 3' spacer comprises an affinity tag.
In an embodiment, the linker comprises, from 5' to 3': Psoralen C6, 2'0Me ribonucleotides comprising the sequence UAGCGGAUGC (SEQ ID NO: 20), six Triethylene glycol or PEG-150 moieties, two cytidine residues, and puromycin.
In an embodiment, the scFv mRNA molecule is photocrosslinked to the DNA linker by UVA. In another embodiment, the scFv mRNA molecule comprises a 5' promoter selected from the group consisting of T7, SP6, and T3. In a particular embodiment, the scFv mRNA molecule comprises a tobacco mosaic virus 5' untranslated region.
In an embodiment, the labeled puromycin-crosslinked scFv mRNA/protein molecule is purified by oligo-dT chromatography. In another embodiment, labeled puromycin-crosslinked scFv mRNA/protein molecule is purified using anti-FLAG M2 monoclonal antibody agarose beads. In yet another embodiment, the labeled puromycin- crosslinked scFv mRNA/protein molecule is purified by oligo-dT chromatography and anti-FLAG M2 monoclonal antibody agarose beads.
In an embodiment, the antigen is a biotinylated peptide, protein, or hapten. In another embodiment, the antigen is a fusion protein with human immunoglobulin fragment crystallizable (Fc) or with murine immunoglobulin fragment crystallizable (Fc), or the antigen is a population of cells. In a particular embodiment, the antibody according to the invention is an anti-IL-12 antibody, an anti-hemaglutinin (anti-HA) antibody, a murine antibody, or a human antibody.
In an embodiment, the in vitro translation of the puromycin-crosslinked scFv mRNA is performed in the presence of GSSH/GSH.
In an embodiment, the method does not comprise an mRNA capping step. In another embodiment, the method does not comprise an in vitro reverse transcription step prior to the purification step. In yet another embodiment, an RNase inhibitor is added before, during, or after any of steps (a) through (g). In an embodiment, the purification step comprises reverse transcription of the mRNA in the absence of dithiothreitol (DTT) to produce a cDNA.
In certain embodiments, the cDNA is eluted by alkaline hydrolysis at about pH=8.0 to about pH=10.0. Alternatively, the cDNA is eluted by heat sufficient to denature DNA:RNA hybrids, by acid at about pH=3.0 to about pH=6.0, or by RNase H digestion.
In an embodiment, the cDNA is amplified by polymerase chain reaction. In an embodiment, the polymerization chain reaction employs a thermostable DNA polymerase or DNA polymerases selected from the group consisting of Platinum HiFi and KOD.
In another embodiment, the beads are selected from the group consisting of streptavidin-M280, neutravidin-M280, SA-M270, NA-M270, SA-MyOne, NA-MyOne, SA-agarose, and NA-agarose.
Other features and advantages of the invention will be apparent from the following detailed description and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts a general scheme for the mRNA-scFv display technology in some embodiments of the invention.
Figure 2 depicts a general scheme for the mRNA-scFv display technology in other embodiments of the invention.
Figure 3 depicts a general depiction of the library DNA construct.
Figure 4a depicts results showing that functional scFv can be generated as mRNA-scFv molecules.
Figure 4b depicts models of free scFv molecules and mRNA-scFv molecules.
Figure 5 depicts results showing that the scFv attached in the mRNA-scFv molecule format is functionally equivalent to the free scFv molecule.
Figure 6 depicts the three D2E7 mRNA-scFv constructs with different 3' spacer lengths.
Figure 7 depicts results showing that shorter spacer length improved mRNA- scFv binding to antigens and the yield of mRNA-scFv antibody molecules.
Figure 8 depicts the sequences of the D2E7 short, medium and long length Ck 3' spacers (SEQ ID NOS 42-44, respectively in order of appearance).
Figure 9a depicts the 17/9 mRNA-scFv constructs with short and long spacer lengths. Figure 9b depicts results showing that shorter spacer length improved 17/9 mRNA-scFv molecule binding to target antigen and yield of mRNA-scFv antibody molecules.
Figure 10 depicts results showing that PDI activity was required for some scFv function.
Figure 11 depicts results showing that the presence of DTT during reverse transcription inhibited 17/9 scFv binding to hemaglutinin (HA) antigen.
Figure 12 depicts agarose gel electrophoresis results showing that DTT did not significantly alter the reverse transcription process.
Figure 13 depicts agarose gel electrophoresis results from different RT conditions with or without DTT and RNaseOUT™ both before and after selection.
Figure 14 depicts agarose gel electrophoresis results showing recovery of the Phylos 40 VH sequence when reverse transcribed either before or after selection compared with pre- selection RT and alkaline elution of cDNA (left lane).
Figure 15 depicts agarose gel electrophoresis results showing that an RNase inhibitor preserved RNA template recovery by reverse transcription after antigen selection.
Figure 16 depicts results of a side-by- side comparison of a CL- long and a CL- short spacer in the presence or absence of RNaseOUT™.
Figure 17 depicts agarose gel electrophoresis results showing side-by-side comparison of recovery of a CL-long and CL-short spacer in the presence or absence of RNaseOUT™.
Figure 18 depicts agarose gel electrophoresis results quantifying 17/9 scFv before and after one round of mRNA-scFv selection.
Figure 19 depicts general depiction of chimeras between D2E7 and 2SD4.
Figure 20a depicts the percent of recovery after antigen binding between the different chimeras, showing that rriRNA display technology can be used to discriminate binders with different affinity.
Figure 20b depicts normalized percent of recovery after antigen selection, showing that rriRNA display technology can be used to discriminate binders with different affinity.
Figure 21 depicts the thermostability of mRNA-scFv molecules. Figure 22 depicts agarose gel electrophoresis results showing that RNA can be recovered after high temperature treatment of mRNA-scFv molecules.
Figure 23 depicts the mRNA-scFv Y61 constructs with short and long spacer lengths as well as the PF-y61scGene3 construct comprising a poly- A tail at the DNA linker between the mRNA and scFv protein.
Figure 24 depicts a general scheme for the mRNA-scFv display technology in other embodiments of the invention.
DETAILED DESCRIPTION OF THE INVENTION Sequence Identification Numbers
Nucleotide and amino acid sequences referred to in the specification have been given the following sequence identification numbers:
SEQ ID NO:1 - Amino acid sequence of MAK195 scFv protein sequence.
SEQ ID NO:2 -Amino acid sequence of Y61 scFv short protein sequence.
SEQ ID NO: 3 - Amino acid sequence of Y61 scFv long protein sequence.
SEQ ID NO:4 - Amino acid sequence of Y61 scFv Gene3 protein sequence.
SEQ ID NO: 5 - Amino acid sequence of D2E7 scFv short protein sequence.
SEQ ID NO: 6 - Amino acid sequence of D2E7 scFv medium protein sequence.
SEQ ID NO:7 - Amino acid sequence of D2E7 scFv long protein sequence.
SEQ ID NO: 8 - Amino acid sequence of 17/9 scFv short protein sequence.
SEQ ID NO:9 - Amino acid sequence of 17/9 scFv long protein sequence.
SEQ ID NO: 10 - Nucleic acid sequence of MAK195 scFv nucleotide sequence.
SEQ ID NO: 11 -Nucleic acid sequence of Y61 scFv short nucleotide sequence.
SEQ ID NO: 12 - Nucleic acid sequence of Y61 scFv long nucleotide sequence.
SEQ ID NO: 13 - Nucleic acid sequence of Y61 scFv Gene3PA nucleotide sequence.
SEQ ID NO: 14 - Nucleic acid sequence of Y61 scFv Gene3 nucleotide sequence.
SEQ ID NO: 15 - Nucleic acid sequence of D2E7 scFv short nucleotide sequence.
SEQ ID NO: 16 - Nucleic acid sequence of D2E7 scFv medium nucleotide sequence.
SEQ ID NO: 17 - Nucleic acid sequence of D2E7 scFv long nucleotide sequence. SEQ ID NO:18 - Nucleic acid sequence of 17/9 scFv short nucleotide sequence. SEQ ID NO: 19 - Nucleic acid sequence of 17/9 scFv long nucleotide sequence.
In order that the present invention may be more readily understood, certain terms are first defined.
I. Definitions
The term "antibody" includes monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), chimeric antibodies, CDR-grafted antibodies, humanized antibodies, human antibodies, murine antibodies and fragments thereof, for example, an antibody light chain (VL), an antibody heavy chain (VH), a single chain antibody (scFv), a F(ab')2 fragment, a Fab fragment, an Fd fragment, an Fv fragment, and a single domain antibody fragment (dAb).
The term "antibody library" refers to a plurality of DNA or RNA molecules containing an open reading frame (ORF) which encodes an antibody or fragment thereof. It also includes a plurality of antibody proteins and nucleic acid/antibody fusion molecules expressed from said DNA or RNA molecules.
The term "heavy chain variable domain" refers to the nucleic acid encoding an antibody heavy chain variable region and to the protein product of said nucleic acid.
The term "light chain variable domain" refers to the nucleic acid encoding an antibody light chain variable region and to the protein product of said nucleic acid.
The term "epitope tag" refers to a short amino acid sequence specifically recognized by an antibody that is attached chemically or genetically to a molecule to allow for its detection by said antibody, for example, FLAG tag, HA tag, Myc tag or T7 tag,
The term "non-antibody sequences" refers to any nucleic acid or amino acid sequences that appear in the antibody libraries of the invention, which are not part of the original antibody sequence. Such sequences include, for example, epitope tags.
The term "control sequences" refers to DNA sequences or genetic elements necessary for the expression of an operably linked coding sequence in a particular host organism or in vitro expression system. Such sequences are well known in the art. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. For example, nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence, or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous. However, enhancers do not have to be contiguous.
The term "specific binding'" or "specifically binds to" refers to the ability of a binding molecule to bind to a target with an affinity of at least 1 x 10~6 M, 1 x 10~7 M, 1 x 10"8 M, 1 x 10"9 M, 1 x 10"10 M, 1 x 10"11 M, 1 x 10"12 M, or less, and/or bind to a target with an affinity that is at least two-fold greater than its affinity for a nonspecific antigen.
The term "target" refers to an antigen or epitope recognized by an antibody. Targets include any peptide, proteins, saccharides, nucleic acids, or other molecule, including small molecules for which a specific antibody can be generated. In one embodiment, antibodies are against a human protein, for example, TNFα, IL- 12, ILl 8, IL-lα or lL-lβ.
A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
The term "RNA display" or "mRNA display" refers to an in vitro technique wherein expressed proteins or peptides are linked covalently or by tight non-covalent interaction to their encoding mRNA to form "RNA/protein fusion" molecules. The protein or peptide component of an RNA/protein fusion can be selected for binding to a desired target and the identity of the protein or peptide determined by sequencing of the attached encoding mRNA component. Such methods are well known in the art and are described, for example, in U.S. Patent Nos. 7,195,880; 6,951,725; 7,078,197; 7,022,479, 6,518,018; 7,125,669; 6,846,655; 6,281,344; 6,207,446; 6,214,553; 6,258,558; 6,261,804; 6,429,300; 6,489,116; 6,436,665; 6,537,749; 6,602,685; 6,623,926; 6,416,950; 6,660,473; 6,312,927; 5,922,545; and 6,348,315; each of which are herein incorporated by reference in their entirety.
The term "single chain antibody" or "scFv" refers to an antigen binding portion of a light chain variable region and an antigen binding portion of a heavy chain variable region, joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. ScL U.S.A 85:5879-5883).
The term "functional moiety" refers to any biological or chemical entity that imparts additional functionality to a molecule to which it is attached.
The term "selecting" refers to substantially partitioning a molecule from other molecules in a population. As used herein, a "selecting" step provides at least a 2-fold, preferably, a 30-fold, more preferably, a 100-fold, and, most preferably, a 1000-fold enrichment of a desired molecule relative to undesired molecules in a population following the selection step. As indicated herein, a selection step may be repeated any number of times, and different types of selection steps may be combined in a given approach.
The term "pause sequence" refers to a nucleic acid sequence that causes a ribosome to slow or stop its rate of translation.
The term "solid support" refers to, without limitation, any column (or column material), bead, test tube, microtiter dish, solid particle (for example, agarose or sepharose), microchip (for example, silicon, silicon-glass, or gold chip), or membrane (for example, the membrane of a liposome or vesicle) to which an affinity complex may be bound, either directly or indirectly (for example, through other binding partner intermediates such as other antibodies or Protein A), or in which an affinity complex may be embedded (for example, through a receptor or channel).
The term "linker region" refers to a region of nucleic acid connecting the nucleic acid sequences encoding antibody VH and VL domains in a scFv antibody gene. A linker region is in-frame with the nucleic acid sequences encoding antibody VH and VL such that a continuous open reading frame containing the VH, VL and linker regions is formed. The term also refers to the region connecting the VH and VL in an scFv protein.
The term "peptide acceptor" refers to any molecule capable of being added to the C-terminus of a growing protein chain by the catalytic activity of the ribosomal peptidyl transferase function. Typically, such molecules contain (i) a nucleotide or nucleotide- like moiety (for example, puromycin and analogues thereof), (ii) an amino acid or amino acid-like moiety (for example, any of the 20 D- or L-amino acids or any amino acid analog thereof (for example, O-methyl tyrosine or any of the analogs described by Ellman et al., Meth. Enzymol. 202:301, 1991), and (iii) a linkage between the two (for example, an ester, amide, or ketone linkage at the 3' position or, less preferably, the 2' position); preferably, this linkage does not significantly perturb the structure of the ring from the natural ribonucleotide conformation. In addition, this term encompasses, without limitation, a peptide acceptor molecule that is covalently bonded (either directly or indirectly through intervening nucleic acid sequence) to the protein coding sequence, as well as one that is joined to the protein coding sequence by some non-covalent means, for example, through hybridization using a second nucleic acid sequence that binds at or near the 3' end of the protein coding sequence and that itself is bound to a peptide acceptor molecule.
II. Overview
The present invention features improved methods of in vitro RNA display that allow reliable expression and selection of scFv antibody molecules from expression libraries.
RNA display methods generally involve expression of a library of proteins or peptides, wherein the expressed proteins or peptides are linked covalently or by tight non-covalent interaction to their encoding mRNA to form RNA/protein fusion molecules. The protein or peptide component of an RNA/protein fusion can be selected for binding to a desired target and the identity of the protein or peptide determined by sequencing of the attached encoding mRNA component. Current methods of RNA display are not optimal for scFv antibody expression since several of the steps are performed under reducing conditions which prevents formation of scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Current methods additionally make use of either VH or VL antibody fragments in the selection process.
The present invention solves this technical problem by performing the in vitro RNA display assay under mildly reducing conditions that favor an scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Using the scFv format rather than single variable domains (e.g., a single variable heavy (VH) domain) also eliminates the need to identify a compatible variable light (VL) domain necessary for the conversion of the selected VH domain into a full IgG antibody. Accordingly, although particularly suited to expression and selection of scFv antibody molecules, the methods of the invention are also expedient for in vitro RNA display of all classes of protein.
The methods of the invention also provide a shorter and simpler protocol for performing RNA display. This is achieved, in part, by avoiding the time consuming step of reverse transcribing the mRNA in an RNA-protein fusion into cDNA prior to selection with a target.
III. Improved In Vitro RNA-Display Screening Method
In one aspect, the invention features improved in vitro RNA-display screening methods. The general method is as follows: /) Formation of RNA/Protein Fusions
One or more in vitro antibody DNA expression libraries are transcribed to generate mRNA. Any in vitro antibody expression library is suitable (e.g., VH, VL or scFv libraries), however, the methods of the invention are particularly well suited to scFv libraries. Any art recognized methods of transcription are suitable. After RNA transcription, the DNA library templates are removed. This may be accomplished using any art recognized methods, for example, by digestion with DNase I.
After DNA removal, a peptide acceptor is attached to the 3' end of the library mRNA. This may be accomplished using any art recognized methods. In one embodiment, a linker comprising 5' (Psoralen C6) 2'0Me(U AGC GGA UGC) XXX XXX CC (Puromycin) 3' (SEQ ID NO: 20),(where X is a Triethylene glycol or PEG- 150 and CC is standard DNA backbone) is used. The linker is first allowed to bind to the 3' end of the library mRNA through complementary base pairing. The linker is then crosslinked to the mRNA by UV activation of the Psoralen C6 molecule.
After addition of the peptide acceptor, the library mRNA is then translated in an in vitro system. Any art recognized methods of in vitro translation are suitable, for example, rabbit reticulocyte lysate. However, to allow the proper intra-chain disulphide bond formation in scFv molecules a protein disulphide isomerase (PDI) is added to the in vitro translation reaction and/or the reaction is performed under mildly oxidizing conditions. In one embodiment, a mild oxidizing agent (for example, GSSG/GSH, for example 10OmM GSSG /1OmM GSH) is added to in vitro translation reaction. In another embodiment, reducing agents (for example, dithiothreitol (DTT)) are omitted from the in vitro translation reaction.
One or more labeled amino acids, or derivatives thereof, may be added to the in vitro translation system such that the labeled amino acid becomes incorporated into the resultant antibody. Any art recognized labeled amino acid is contemplated, for example, a radiolabeled amino acid, for example, 35S-labelled methionine or cysteine.
During the in vitro translation reaction the rriRNA molecules become covalently linked to their protein products via the peptide acceptor (e.g., puromycin) fused at the 3' end. These RNA/protein fusion molecules are purified away from the in vitro translation reaction mixture. Any art recognized methods of separation of RNA/protein fusion molecules from a reaction mixture are contemplated. In one embodiment, the RNA/protein fusion proteins are separated by chromatography using a polydeoxythimidine (polydT) resin. In another embodiment, the RNA-antibody fusion proteins are separated by binding to an antibody specific for an epitope present in the antibody component of the RNA/protein fusion protein. The epitope may be an amino acid sequence tag, for example, FLAG or HA tags, incorporated into the amino acid sequence of the antibody component of the RNA-antibody fusion protein, for example, at the N-terminal, C-terminal or in the inter variable region linker.
The RNA/protein fusions of the invention, involve the use of naked RNA. In a preferred embodiment, all reagents that contact the RNA/protein fusions are treated with RNase inhibitor reagents, for example, RNaseOUT™, yeast tRNA, SUPERaseln™, RNasin®, and other RNase inhibitors known in the art.
2) Screening For Antibodies To A Desired Target
The library of RNA/protein fusions is screened for in vitro binding to a desired target. In general the target molecules are bound to a solid support, for example, agarose beads. In one embodiment, the target molecule is directly linked to a solid substrate. In another embodiment, the target molecule is first modified, for example, biotinylated, then the modified target molecule is bound via the modification to a solid substrate, for example, streptavidin-M280, neutravidin-M280, SA-M270, NA-M270, SA-MyOne, NA-MyOne, SA-agarose, and NA-agarose. In other embodiments, the solid support further includes magnetic beads, for example Dynabeads. Such magnetic beads allow separation of the solid support, and any bound RNA/antibody fusion, from an assay mixture using a magnet.
After binding of RN A/protein fusions, the solid support is washed one or more times to remove unbound RNA/protein fusions and the RNA is then amplified. In one embodiment, mRNA that is physically associated with an antibody or plurality of antibodies is amplified to produce more mRNA. Any art recognized method of RNA replication is contemplated, for example, using an RNA replicase enzyme. In another embodiment, mRNA that is physically associated with an antibody or plurality of antibodies may be transcribed into cDNA before being amplified by PCR. The PCR amplified pool can be subject to one or more rounds of screening to enrich for the highest affinity antibodies.
Additionally or alternatively, the RNA/protein fusions may be eluted from the solid support prior to amplification of the nucleic acid component. Any art recognized method of elution is contemplated. In one embodiment, the RNA/protein fusions are eluted using alkaline conditions, for example, using a pH of about 8.0 to 10.0. In another embodiment, the RNA/protein fusions are eluted using acid conditions, for example, using a pH of about 3.0 to 6.0. In one embodiment, the RNA/protein fusions are not eluted prior to amplification of the nucleic acid component, but instead the RNA/protein fusions are added directly to the amplification reaction mixture.
Additionally or alternatively the PCR amplified pool of nucleic acids may be sequenced using single molecule sequencing methods to determine the nucleic sequences of every selected RNA/protein molecule. In one embodiment, PCR amplification may be accomplished using a high fidelity, proof -reading polymerase, for example, the KODl thermostable DNA polymerase from Thermococcus kodakaraensis or Platinum Taq DNA Polymerase High Fidelity (Invitrogen).
Additionally or alternatively, the nucleic acid sequences may be amplified under conditions that result in the introduction of mutations into amplified DNA, thereby introducing further diversity into the selected nucleic acid sequences. This mutated pool of DNA molecules may be subjected to further rounds of screening.
IV. Library Construction
Libraries of the invention may be generated from any antibody fragment capable of binding to a target. In one embodiment, libraries of antibody variable domains are generated. These may be VH and/or VL domains. In another embodiment, scFv libraries are generated.
The libraries of the invention may also include antibody nucleic acid sequences encoding regions outside of the variable regions, for example, a constant region or fragment thereof, or a hinge region.
Nucleic acid libraries of the invention may comprise RNA, DNA or hydrids containing both RNA and DNA elements. Linkage Of Nucleic Acid To Peptide Acceptors
The antibody nucleic acid libraries may be modified to contain a peptide acceptor moiety. This may facilitate the covalent attachment of individual member of nucleic acid expression libraries to their cognate protein products. Any art recognized means of attachment of a peptide acceptor to a nucleic acid are contemplated, including the means described, for example, in U.S. Patent No. 5,643,768, U.S. Patent No. 5,658,754, U.S. Patent No. 7,195,880, and U.S. Patent No. 6,951,725, the contents of which are incorporated herein by reference.
In one aspect the invention features novel methods and compositions for the attachment of a peptide acceptor to nucleic acid libraries. In one embodiment, a linking molecule may be synthesized that comprises a Psoralen C6 molecule and a peptide acceptor molecule, wherein the Psoralen C6 molecule and a peptide acceptor molecule are fused to a nucleic acid sequence, wherein the nucleic acid sequence is complementary to sequences at the 3' end of the nucleic acid library. Such linking molecules can bind, via complementary base pairing, to the 3' end of nucleic acid library clones. Psoralen C6 is sensitive to ultraviolet (UV) light and will cross link the linker to the nucleic acid library clones, thus covalently linking the peptide acceptor to the nucleic acid library clones. In another embodiment, the nucleic acid portion of the linker molecule may contain modified nucleotides, for example, 2 prime methoxy (2'0Me) ribonucleotides. In another embodiment, the linker molecule further comprises a Triethylene glycol or PEG- 150 linker separating the nucleic acid region containing the Psoralen C6 molecule and a peptide acceptor molecule. In one embodiment the linker may comprise, from 5' to 3': Psoralen C6, 2'0Me) ribonucleotides comprising the sequence UAGCGGAUGC (SEQ ID NO: 20), six Triethylene glycol or PEG- 150 moeities, two cytidine residues, and Puromycin. Such linkers may be custom- synthesized by, for example, TriLink BioTechnologies, Inc. V. General Screening Methods
In one aspect, the invention features methods of screening the expression libraries of the invention to identify antibodies capable of binding to a desired target. Any in vitro or in vivo screening method that allows for selection of an antibody from an expression library, based upon antibody binding to a target molecule, is contemplated.
In one embodiment, the expression libraries of the invention may be screened using an art recognized in vitro cell-free phenotype-genotype linked display. Such methods are well known in the art and are described, for example, in U.S. Pat. Nos. 7,195,880; 6,951,725; 7,078,197; 7,022,479, 6,518,018; 7,125,669; 6,846,655; 6,281,344; 6,207,446; 6,214,553; 6,258,558; 6,261,804; 6,429,300; 6,489,116; 6,436,665; 6,537,749; 6,602,685; 6,623,926; 6,416,950; 6,660,473; 6,312,927; 5,922,545; and 6,348,315. These methods involve transcription of protein in vitro from a nucleic acid in such a way that the protein is physically associated or bound to the nucleic acid from which it originated. By selecting for an expressed protein with a target molecule, the nucleic acid that codes for the protein is also selected.
To improve the expression of scFv proteins, the above referenced in vitro screening assays may require addition or removal of certain reagents. In one embodiment, protein disulphide isomerase enzymes may be added to the in vitro expression system to improve the production of functional scFv molecules. In another embodiment, a mild oxidizing agent (for example, GSSG/GSH, for example 10OmM GSSG /1OmM GSH) may be added to in vitro translation reaction mixture of the scFv proteins to allow intra-chain disulphide bond formation in the VH and VL regions of the scFv molecule. In another embodiment, reducing agents (for example, dithiothreitol (DTT)) may be removed from the in vitro translation reaction mixture of the scFv.
In another embodiment, one or more labeled amino acids, or derivatives thereof, may be added to the in vitro translation system such that the labeled amino acid becomes incorporated into the resultant antibody. Any art recognized labeled amino acid is contemplated, for example, a radiolabeled amino acid, for example, 35S-labelled methionine or cysteine.
In one embodiment, the in vitro screening assays of the invention require that after in vitro selection of an antibody or plurality of antibodies the mRNA that is physically associated with the antibody or plurality of antibodies may be reverse transcribed to generate cDNA encoding said antibody or plurality of antibodies. Any suitable method for reverse transcription is contemplated, for example, enzyme mediated reverse transcription, for example, Moloney murine leukemia virus reverse transcriptase. Screening methods employed in the invention may require amplification of the nucleic acid that encodes antibodies that bind specifically to a desired target. In one embodiment, mRNA that is physically associated with an antibody or plurality of antibodies may be amplified to produce more mRNA. Any art recognized method of RNA replication is contemplated, for example, using an RNA replicase enzyme. In another embodiment, mRNA that is physically associated with an antibody or plurality of antibodies may be first reverse transcribed into cDNA before being amplified by PCR. In one embodiment, PCR amplification may be accomplished using a high fidelity, proof -reading polymerase, for example, the KODl thermostable DNA polymerase from Thermococcus kodakaraensis or Platinum Taq DNA Polymerase High Fidelity (Invitrogen). In another embodiment, PCR amplification may be performed under conditions that introduce mutations into the amplified DNA, e.g., error-prone PCR.
In another embodiment, the expression libraries of the invention may be screened by display on the surface of a cell, virus or bacteriophage and subject to selection using immobilized target molecules. Suitable methods of screening are described in U.S. patent numbers 7,063,943; 6,699,658; 6,423,538; 6,696,251; 6,300,065; 6,399,763; 6,114,147 and 5,866,344.
Screening methods employed in the invention may require introduction of diversity into the antibody library by introducing nucleic substitutions and/or deletions that may result in one or more amino acid substitutions and/or deletions in the expressed antibodies molecules. Any art recognized methods of mutagenesis are contemplated, for example, random mutagenesis, "walk through" mutagenesis, and "look through" mutagenesis. Such mutagenesis of an antibody can be achieved using, for example, error-prone PCR, "mutator" strains of yeast or bacteria, or incorporation of random or defined nucleic acid changes during ab inito synthesis of all or part of an antibody. In one embodiment, a library of antibody molecules may be created in which one or more amino acids are randomly mutated. In another embodiment, a library of antibody molecules may be created in which one or more amino acids are mutated to one or more predetermined amino acids. Screening methods employed in the invention may also require that the stringency of the target-binding screening assay be increased to select for antibodies with improved affinity for the target. Any art recognized methods of increasing the stringency of an antibody-target interaction assay may be considered. In one embodiment, one or more of the assay conditions may be varied (for example, the salt concentration of the assay buffer) to reduce the affinity of the antibody molecules for the desired target. In another embodiment, the length of time permitted for the antibodies to bind to the desired target may be reduced. In another embodiment, a competitive binding step may be added to the antibody-target interaction assay. For example, the antibodies may first be allowed to bind to a desired immobilized target. A specific concentration of non-immobilized target may then be added which serves to compete for binding with the immobilized target such that antibodies with the lowest affinity for antigen are eluted from the immobilized target resulting in an enrichment for antibodies with improved antigen binding affinity. The stringency of the assay conditions may be further increased by increasing the concentration of non-immobilized target that is added to the assay.
Screening methods of the invention may also require multiple rounds of selection to enrich for one or more antibodies with improved target binding. In one embodiment, at each round of selection further amino acid mutations may be introduced into the antibodies using art recognized methods. In another embodiment, at each round of selection the stringency of binding to the desired target may be increased to select for antibodies with increased affinity for a desired target.
Screening methods of the invention may require purification of RNA-antibody fusion proteins from the components of an in vitro translation system. This may be accomplished using any art recognized method of separation. In one embodiment, the RNA-antibody fusion proteins may be separated by chromatography using a polydeoxythimidine (polydT) resin. In another embodiment, the RNA-antibody fusion proteins may be separated by chromatography using an antibody specific for an epitope present in the antibody component of the RNA-antibody fusion protein. The epitope may be an amino acid sequence tag, for example, FLAG, Myc, or HA tags, incorporated into the amino acid sequence of the antibody component of the RNA-antibody fusion protein, for example, at the N-terminal, C-terminal or in the inter variable region linker. Selection of antibodies from the libraries of the invention may require the use of immobilized target molecules. In one embodiment, the target molecule is directly linked to a solid substrate for example, agarose beads. In another embodiment, the target molecule is first modified, for example, biotinylated, then the modified target molecule is bound via the modification to a solid support, for example, streptavidin-M280, neutravidin-M280, SA-M270, NA-M270, SA-MyOne, NA-MyOne, SA-agarose, and NA-agarose.
EXEMPLIFACTION OF THE INVENTION
Throughout the examples, the following materials and methods were used unless otherwise stated.
Materials and Methods
In general, the practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, recombinant DNA technology, immunology (especially, e.g., immunoglobulin technology), and animal husbandry. See, e.g., Sambrook, Fritsch and Maniatis, Molecular Cloning: Cold Spring Harbor Laboratory Press (1989); Antibody Engineering Protocols (Methods in Molecular Biology), 510, Paul, S., Humana Pr (1996); Antibody Engineering: A Practical Approach (Practical Approach Series, 169), McCafferty, Ed., IrI Pr (1996); Antibodies: A Laboratory Manual, Harlow et al., C.S.H.L. Press, Pub. (1999); Current Protocols in Molecular Biology, eds. Ausubel et al., John Wiley & Sons (1992).
mRNA Display Protocol for scFv mRNA display may be conducted according to the method shown in Figure 2. Particular embodiments of this method are described in greater detail below. These embodiments are intended to illustrate the methods of the invention, and should not be construed as limiting.
1. Design of Antibody Library Templates
Library DNA constructs may be designed according to methods of antibody library generation known in the art. In one embodiment, the library constructs may encode antibody fragments, i.e., antibody light chain fragments (VL) or antibody heavy chain fragments (VH). In an exemplary embodiment, the library constructs may encode single chain variable fragments (scFv).
2. Preparation of Target Antigen
Generally the mRNA display antibody library may be selected against biotinylated antigen. While the best antigen for each target should be determined on a case-by-case basis, the following considerations may be used as a general guideline. A target antigen is typically well characterized, and is the relevant or dominant genetic isotype, as determined by polymorphism (SNP and haplotype) and/or pharmacogenetic analysis. A target antigen additionally may have reasonable bioactivity (comparable to native antigen), good solubility and good chemical and physical properties, and may be prepared in sufficient quantities for library selections or screenings and downstream bioassays.
3. Preparation of Library DNA
Library DNA and its selection outputs may be amplified by PCR. PCR amplification may be performed using methods known in the art. PCR reactions typically contain DNA template, reaction buffer, dNTP, primers used for amplification, DNA polymerase, and water. Multiple reaction tubes may be set up simultaneously from a master mix to increased amplified DNA yield. 25 cycles of PCR typically give sufficient amplification, but as many as 35 cycles may be used to gain more products.
4. Library DNA Purification
If products are the correct size (-850 bp for scFv, -500 bp for VH or VL library) and contain minimal non-specific products, the products may be used directly in the transcription reaction. Alternatively, the products may be purified on a preparative agarose gel by cutting out the specific band of the correct size. DNA concentration may be measured on a spectrophotometer.
5. RNA Transcription
RNA transcription from library DNA may be performed using standard methods known in the art. A large reaction volume may be used to transcribe sufficient DNA templates to sample the entire library diversity. In an exemplary embodiment, 1 x 1013 copies of library templates may be used in the RNA transcription reaction. An RNA transcription typically contains 5-10 μg of PCR product, reaction buffer, ATP, CTP, GTP, UTP, and T7 RNA polymerase. The RNA transcription reaction may be run at 37°C for between 2 hours to overnight. Shorter times may be used following initial rounds of selection, however, overnight incubations may maximize the RNA yield of the reaction. Following RNA transcription, DNA templates may be removed from the reaction mixture by DNase I digestion.
6. RNA Purification by NAP Column Chromatography
Following transcription, RNA may be fractionated using a NAP-10 column. Up to about 1 mL of transcription reaction may be loaded onto a NAP-10 column for RNA purification. The column may be equilibrated using DEPC-treated dH2O prior to fractionation. RNA may be eluted from the column using about 1.5X the reaction volume DEPC-treated dH2O (e.g. 750 μL per 500 μL transcription reaction). The total elution volume may be less than about 150% of the transcription reaction volume. RNA may be additionally or alternatively fractionated using a NAP-25 column.
7. RNA Quality Control and Quantitation
The size and yield of RNA samples may be analyzed using gel electrophoresis, or alternatively by measuring the OD at 260 nm (OD26o) of RNA concentration in collected fractions. For example, molar concentration of scFv RNA may be calculated as follows:
[RNA] (μM) = [RNA] (mg/mL) x 106 / (850 x 330) = OD260 x dilution factor x 40 (μg/mL) x 1000 / (850 x 330). RNA yield (nmol) = [RNA] (μM) x Volume (μL) / 1000 The RNA yield typically reaches a maximum at about 20 nmol/mL per 500 μL transcription reaction.
8. RNA Ligation to Linker
A DNA linker that contains a peptide acceptor molecule at its 3' end may be covalently ligated to the 3' ends of each RNA molecule by UV crosslinking. The peptide acceptor, which may enter the ribosomal A site and covalently couple to the carboxyl terminus of the nascent polypeptide chain, may ultimately enable the covalent association of the mRNA (genotype) to the protein encoded by this mRNA (phenotype). An exemplary PEG6/10 linker may be used which has the following formula: 5' (Psoralen C6) 2'OMe(U AGC GGA UGC) XXX XXX CC (Puromycin) 3' (SEQ ID NO: 20)
The Psoralen C6 5' modification is light sensitive and functions to create a covalent bond between the linker and the mRNA by UV crosslinking. A 2'0Me(U AGC GGA UGC) (SEQ ID NO: 20) backbone region anneals to the linker annealing site 3' to the FLAG sequence on mRNA (see Figure 1). In the sequence above, X denotes "Spacer 9", alternatively known as Triethylene glycol or PEG- 150. This spacer has been optimized to provide flexibility for puromycin insertion into the eukaryotic ribosome A site. CC comprises a standard DNA backbone. A puromycin 3' modification inserts into the ribosome A site to create a stable link between the linker and the nascent peptide. The extinction coefficient for the linker described herein may be about 147.7 OD26o/μiϊiole. Since this linker is light sensitive, solutions containing this linker should be protected from light.
For initial rounds of library selections, a large-scale ligation reaction (about 5 nmol or about 3.1 x 1015 transcribed RNA molecules) may be recommended to sample the entire diversity of a naϊve antibody library with an estimated diversity of about 1012 - 1013. This RNA quantity may ensure enough templates are incorporated into translation reactions to produce -10 pmol functional mRNA display molecules. In later rounds, RNA input may be reduced to about 0.5 nmol per selection. In an exemplary embodiment, an RNA ligation reaction may contain the following components: RNA, water, chemical ligation buffer, and the PEG6/puromycin linker (ImM). In an exemplary embodiment, the total reaction volume is about 100 μL. In a preferred embodiment, the linker/RNA molar ratio may be greater than about 1.5. In one embodiment, the final linker concentration in the reaction is about 15 μM, and the RNA concentration in the reaction may range from about 3 - 10 μM (= 0.3 - 1 nmol RNA input). As a reference, an 850 nt scFv RNA at 1 mg/mL = 3.56 μM, and the attainable maximal ligation concentration would be about 3.16 μM (about 0.32 nmol).
The annealing reaction (which anneals the linker to the transcribed RNA) may be performed in a thermal cycler. In a preferred embodiment, the annealing reaction may be conducted by incubating samples at about 85 0C for about 30 seconds, then at about 4°C, using a ramp rate of about 0.30C per second. Reactions may then be held at about 4°C.
Ligation of the annealed linker/RNA may be accomplished by UV crosslinking. This may be conducted using any method known to one of skill in the art. In one embodiment, reaction tubes may be placed on top of a frozen freezer pack and placed directly under a handheld long wavelength (about 365 nm) UV lamp and crosslinked for about 15 minutes in the dark. Typical ligation efficiency is about 50 - 90%. Generally purification is not required. The ligation products may be stored at -80 0C.
9. Translation Reaction
In an exemplary embodiment, about -0.1% of input RNA may be made into mRNA display molecules after all reactions and purifications. In vitro translation is conducted using methods and reagents known to one of skill in the art. In one embodiment, the translation reaction using the scFv library uses about 5 nmol of RNA template with about 10 mL of reticulocyte Iy sate in a reaction volume of about 15 mL.
In preparation for the translation reaction, solutions of GSSG/GSH (oxidized glutathione/reduced glutathione) may be prepared at a final concentration of about 100 mM GSSG/10 mM GSH. PDI is prepared by dissolving PDI powder into dH2O to reach a concentration of about 1 Unit/μL. The PDI solution may be stored at -200C.
An exemplary translation reaction may be set up as follows:
RNA (100-120 pmol/300 μL or 500-600 pmol/1.5 ml ) X X μL dH2O to 73.7 to 370 μL
Amino acid master mix (Met") 15 75 μL
100 mM GSSG/10 mM GSH 3.3 16.5 μL
PDI (1 U/μL) 6 30 μL
[35S]Methionine 2 10 μL
Reticulocyte lysate 200 1000 μL
Total volume 300 1500 μL
Translation reactions may be incubated in 30 0C water bath for 1 - 2 hours, and the to RNA/protein fusion formation should be performed without delay. A significant decrease in RNA/protein fusion yield may be observed when the translation volume exceeds 3 mL; consequently, a master mix of the translation reaction may be prepared if the reaction volume is larger than 3 mL, and then divided into smaller aliquots.
10. RN A/Protein Fusion Formation
After the translation reaction, about 100 μL 2M KCl and about 20 μL IM MgCl2 may be added for every 300-μL of translation reaction mixture, and incubated for about 1 hour at room temperature, or at -2O0C overnight. Alternatively, about 500 μL 2M KCl and about 100 μL IM MgCl2 may be added for every 1.5 ml of translation reaction mixture, and incubated for about 1 hour at room temperature, or at -2O0C overnight. This stabilizes the paused ribosomes at the end of mRNA templates and allows puromycin at the end of the DNA linker to enter the A sites of paused ribosomes, which permanently links the translated scFv proteins to their mRNA templates. The room temperature incubation may be shortened if the reaction is stored at -2O0C overnight. The reaction may be terminated by adding about 50 μL or about 250 μL 0.5 M EDTA per 300 μL or 1.5 ml translation reaction, respectively, to disrupt the ribosomes. Reactions may be stored at -20 0C. A 5-10 μL aliquot may be removed for scintillation counting later.
11. RNA/Protein Fusion Purification by Oligo-dT Cellulose
This step is included to purify mRNA display molecules and remaining RNA templates from the translation/fusion reaction. For oligo-dT binding, the amount of pre- washed oligo-dT cellulose needed to capture all RNA templates should be estimated. A sufficient volume of oligo-dT binding buffer may be added to the fusion reaction to reach about a IX final concentration. Pre- washed oligo-dT cellulose may then be added, and the reactions are rotated for 1 hour at 4°C. Reactions may optionally be spun down at about 1500 rpm for 5 min at 4°C, and the supernatant is discarded. Oligo-dT cellulose beads may be transferred and washed about 6 times with IX Oligo-dT binding buffer using spin columns, and buffer is typically removed by spinning columns at about 1000 rpm for 10 seconds. The flow-through may be discarded, but the last wash may be saved for scintillation counting. To reduce salt concentration and facilitate elution, 1/10 of the initial slurry volume of dH2O may be added to the dry oligo-dT beads, which may be centrifuged immediately for 10 seconds and the flow through may be discarded. mRNA display molecules (and free RNA templates) may be eluted by adding dH2O to beads and incubating for 5 minutes at room temperature. Eluate is collected by spinning at about 4000 rpm (or higher) for 20 seconds. The elution is typically repeated once, and the eluates are combined. 5 μL of eluate may be removed for scintillation counting. Optionally, the efficiency of oligo-dT purification may also be assessed by OD at 260 nm (OD260) on a NanoDrop spectrophotometer machine. All remaining RNA templates and mRNA display molecules are theoretically recovered by the oligo-dT beads. 5X FLAG binding buffer is added to the eluates to reach about a IX final concentration. Samples may be stored at -80 0C if not proceeding to the next FLAG purification step.
Oligo-dT recovery may be calculated as follows. About 5 μL of input (from fusion reaction), about 100 μL from the last wash, and about 5 μL of output (eluate from oligo-dT purification). The last wash is used to assess extent of washing, and the other two counts are used to calculate RNA/protein fusion recovery from original RNA template input. RNA/protein fusion yield (pmol) = (CPMoutPut x Volumeoutput x 5 μM x Volumeiysate) / [CPMmput x Volumemput x (# of methionine in product)]. This formula assumes a 5-μM methionine concentration in the reticulocyte lysate, and all volumes used in calculation expressed as μL. For earlier rounds of selection the yield of mRNA display molecules is typically 0.5 - 2%, but may increase to 10% in later rounds. For example, early rounds number of methionine in PROfusion library may be:
• About 3 μM for VH-VK SCFV,
• About 2 to 3 μM for VH-Vλ scFv,
• About 2 μM for VH,
• About 2 μM for VK, and
• About 1 μM for Vλ.
These numbers are averages and are based on germline sequences, and one of skill in the art will appreciate that they may change over selection rounds as the library is enriched toward specific sequences.
12. RN A/Protein Fusion Purification by anti-FLAG M2 Agarose
This step is designed to purify mRNA display molecules from remaining RNA templates. It is not necessary to proceed to this step if the library will be selected by antigen off-rate competition or by antigen-expressing cells. The amount of pre- washed anti-FLAG M2 agarose beads needed to capture all mRNA display molecules may be estimated. In one embodiment, the binding capacity of the beads may be about 6 nmol fusion protein per mL of 50% slurry. To have sufficient bead volume for manipulation during binding and washing, it is recommended to use at least about 200 μL of pre- washed beads. The example given below is for an initial 300-μL translation reaction.
FLAG purification: a wide-bore pipette tip may be used to transfer 300 μL pre- washed anti-FLAG M2 agarose to the oligo-dT purified output, which may then be rotated for 1 hour at 4 0C. Incubation with anti-FLAG M2 agarose may continue overnight. Anti-FLAG M2 agarose may optionally be spun at about 1500 rpm in a centrifuge for about 1 minute at 4°C, and the supernatant may be discarded. Anti-FLAG beads may be washed about 5-6 times with about 500-700 μL IX FLAG binding buffer, using spin columns (e.g. Invitrogen™ Microcentrifuge Spin Column) and centrifuged at about 1000 rpm for 10 seconds for each wash (note that the Invitrogen™ column may be spun at higher speeds, e.g. about 10,000 rpm). The flow-through may be discarded. The beads may additionally be washed 2 times with 700 μL Selection Buffer (see below) by centrifugation at about 1000 rpm for 10 seconds. The last wash may be saved for scintillation counting. mRNA display molecules may be eluted by adding about 400 μL 100 μg/mL FLAG peptide (in Selection Buffer) and incubating for 5 minutes at room temperature. Elute may be collected by spinning at about 3000 rpm (or higher if possible) for 20 seconds. The elution step may be repeated one more time by adding about 400 μL 100 μg/mL FLAG peptide. Both eluates may be combined, and about 5 μL may be removed for scintillation counting. This volume of FLAG peptide may be sufficient for elution from up to about 1 mL of 50% slurry and may be cut in half (200 μL) if less slurry is used and/or higher RNA/protein fusion concentration is desired. To prevent RNA degradation during storage and antigen selection, an appropriate amount of RNase inhibitor known in the art (i.e., 1 - 2 U/μL RNaseOUT and 0.02 μg/mL yeast tRNA) may be added to the purified mRNA display library. Store samples at -80 0C if not proceeding to the next antigen selection step.
To quantitate the FLAG recovery, about 5 μL elution output and about 100 μL from the last wash are counted on a beta counter. A recovery of 10-30% or higher may be expected, and may be calculated according to the following formula: PROfusion molecule recovery % = (CPMoutPut x VolumeoutPut) / (CPMinput x Volumemput) 13. Library Selection by Biotinylated antigens
Selection is designed to enrich for molecules that specifically bind to a target of interest when library binding to an antigen reaches equilibrium. A negative selection (pre-clear) may be necessary to remove non-specific and matrix binders from a naϊve scFv library, but may be omitted if using a library made from a single template, e.g., but not limited to, libraries made for affinity maturation doing affinity maturation based on a single scFv template. Depending on the target format, the selection protocol varies. The following is an exemplary selection protocol for use with biotinylated targets. This protocol may be modified to accommodate target antigens in other formats, and may be scaled up or down depending on the desired output.
A. Preparations before selection
Streptavidin (SA) magnetic beads may be used for capture, and are typically pre- blocked prior to use. SA beads may be transferred from the original bottle to 1.5 or 2 mL tubes, and washed twice with 2 mL of IX FLAG binding buffer. Beads may be blocked with 2 mL of Selection buffer (2 hours to overnight) at 4 0C with rotation. It is important to prepare enough beads for both, the pre-clear and selection captures. Pre- blocked beads may be stored at 4 0C. About 100 μL of beads are typically used for every 10 pmol of biotinylated antigen, but one of skill in the art will appreciate that capture bead volume should be calculated in view of the binding capacity of free biotin {e.g. 650-900 pmoles/mg beads, where the bead concentration is typically 10 mg/ml) relative to the reaction yield.
1.5 mL or 2 mL microfuge tubes may be pre-blocked with IX FLAG binding buffer for about 1 hour to overnight. Pre-blocked tubes may be used for all pre-clear and selection steps. Typically four tubes are needed for each sample: 2 for pre-clearing, 1 for the beads, and 1 for selection.
Optimal results may be obtained by pre-clearing the library. FLAG purified mRNA display library may be added to beads (separated from buffer), using SA bead volume equal to half of the capture volume. Beads may be rotated at 300C for about 30 minutes. Pre-cleared mRNA display library may be separated from beads using a magnet, and the pre-clear may be repeated one more time. The second pre-clear SA beads may be washed and counted as described in above to determine if background is high. This may also serve as a 'No antigen' negative control.
B. Library Selection: Binding
For first rounds of selection, biotinylated target (100 nM) may be added to the whole pre-cleared library, and rotated at 30 0C for 1 hour. For later selection rounds when recovery of antigen-binding molecules is expected to exceed 1%, the pre-cleared library may be divided into 2 equal aliquots. Biotinylated antigen may be added to one aliquot, and the other may serve as the 'No antigen' negative control. Alternatively, the washed second pre-clear beads may also be considered as a 'No antigen' control, as noted above, although these beads will have one less 'pre-clear'. The antigen concentration in later rounds may be dropped when recovery of antigen-binding molecules exceeds 5%. In particular, antigen concentration should be reduced if the antigen appears to be 'sticky' and significant recovery was observed in early rounds. Antigen concentration may be reduced in later rounds when recovery of antigen-binding molecules becomes significantly higher than background (e.g. relative to a no antigen control). It is important to pay attention to the stoichiometry between library and antigen to ensure that there is at least a 5-fold molar excess of antigen over library PROfusion molecules, especially at lower antigen concentration
C. Library Selection: Capture
The selection buffer used for blocking the SA beads for library capture may be removed by centrifugation and magnetic separation. The antigen-bound library may be transferred to pre-blocked SA beads (separated from buffer), and then to the binding reaction, and rotated at 3O0C for 5 to 10 minutes. The amount of SA beads for capture should be calculated based on the capacity and the target concentration used in selection (see above). The amount of SA beads should be lowered when lowering the target concentration to avoid the SA bead binders, but typically not less than 50 μL of beads is used.
D. Library Selection: Washing
The SA beads may be collected using a magnet, and washed with about 1 mL of Selection buffer for 1 minute. This step may be repeated about 5 times (about 6 times total). The wash time may be increased in later rounds to incorporate off rate selection strategy to some targets. The beads may be washed one last time with about 1 mL of IX buffer suitable for reverse transcription, collected with a magnet, and re- suspended in water (one fourth of the capture bead volume calculated above).
As another example, Dynabeads™ (Invitrogen) may be used, but one of skill in the art will appreciate that other beads may be equally suitable. The Dynabeads™ may be separated from the unbound library by centrifugation and magnetic separation. The supernatant may be removed with a 1 mL tip, using one new filtered tip for each library selection tube to eliminate cross -contamination. The Dynabeads™ may be washed with 1 mL of Selection buffer, and re- suspended by gentle pipetting or by inverting tubes multiple times. The tubes may be put back onto the magnetic holder for bead separation while the next library is processed. After all libraries are washed, supernatant may be removed by 1 mL tip using one new filtered tip for each library selection tube to eliminate cross-contamination. Repeat for five washes. Dynabeads™ may be washed two times with 1 mL of IX First Strand buffer (Superscript II, Invitrogen) as described above. At the last wash, removed 1/10 of the library to a separate tube for counting to determine library recovery if so desired. Dynabeads™ may be captured by magnetic separation and about 100 μl wash buffer may be saved for background count. Dynabeads™ may be re- suspended in water, using 1A of the capture bead volume as calculated above).
E. Library Selection: Counting and Recovery Calculation
Starting from Round 3, count about 10 - 20% of the last wash and the beads. It is not advisable to count more than 100 μL of beads, as this may quench the counts. Library selection recovery may be calculated according to the following formula: Selection recovery % = 100 x CPMTotai Beads / CPMTotai input 14. Equilibrium Library Selection by Fc fusion proteins
In another embodiment, library selection may be performed for target antigens that have been fused to an antibody Fc domain (e.g. Fc fusion proteins). A negative selection (pre-clear) may be necessary to remove non-specific and matrix binders from naϊve antibody library but may be omitted for affinity maturation. Selection specificity may be improved by fusing target antigens to both human IgGl and mouse IgG2a. By having different Fc domains in the Fc fusion proteins during library selection, the risk of identifying library binders specific to the Fc region may be minimized. This will also enable the library binder to be pulled down by two different magnetic beads (protein G and anti-mouse IgG), thereby further reducing the chance of recovering anti-protein G or anti-anti-mouse IgG binders. The target Fc fusion protein may also be biotinylated, and selected either by the method described here or by the method described above in section 13. It should be noted that protein A magnetic beads may not be suitable for selecting against Fc fusion protein targets because of cross-reactivity to certain portions of the antibody VH domain (e.g. VH originated from human VH3 family germline sequences). Suitable magnetic beads for pulling down antigen binding scFv-PROfusion molecules include, but are not limited to, Dynabeads Protein G, Dynabeads Pan mouse IgG, and other available Dynabeads M-280 to human or to mouse IgGs. In general, protein G beads capacity is considered to be about 25 μg of human IgGl (-167 pmol) per 100 μL of protein A/G magnetic beads.
A. Preparations before selection
Dynabeads Protein G or Dynabeads Pan mouse IgG (if target antigen is a mouse Fc fusion protein) may be used for capture, and are typically pre-blocked prior to use. The amount of Dynabeads needed for library pre-clear and selection may be calculated. Dynabeads may be transferred from the original bottle to 1.5 or 2 mL microfuge tubes and remove buffer. Beads may be blocked with 1 mL selection buffer (2 hours to overnight) at 4 0C, or 1 hour at room temperature. It is important to prepare enough beads for both the pre-clear and selection captures.
1.5 mL or 2 mL microfuge tubes may be pre-blocked with selection buffer for 1 hour to overnight, and pre-blocked tubes should be used for all pre-clear and library selection steps.
FLAG purified scFv PROfusion library may be added to pre-blocked beads (separated from buffer), Dynabead (protein G or pan mouse IgG) volume equal to half of the capture volume (as calculated above) may be used and the reaction rotated at 300C for 30 minutes. The pre-cleared fusion library may be separated from beads with magnet, and the pre-clear repeated one more time. The second pre-cleared Dynabeads may be washed and counted as described above to determine if background is high. This may also serve as a 'No antigen' negative control.
B. Library selection: binding
For the first rounds of selection, biotinylated target (100 nM) may be added to the whole pre-cleared library, and rotated at 30 0C for 1 hour. For later selection rounds when recovery of antigen-binding molecules is expected to exceed 1%, the pre-cleared library may be divided into two aliquots (from 50/50 to 80/20 depending on the library counts). Biotinylated antigen may be added to one aliquot (50 to 80% of whole), while the other aliquots may serve as the 'no antigen' negative control. Alternatively, the washed second pre-clear beads may also be considered as a 'No antigen' control, as noted above, except that it will have one less 'pre-clear'. The antigen concentration may be reduced if the antigen appears to be 'sticky' and significant recovery was observed in early rounds. Additionally, antigen concentration may be reduced in later rounds when recovery of antigen-binding molecules becomes significantly higher than background (no antigen control). It is important to pay attention to the stoichiometry between library and antigen to ensure that there is at least a 5-fold molar excess of antigen over library PROfusion molecules, especially at lower antigen concentration.
C. Library selection: Capture
The selection buffer used for blocking the Dynabeads for library capture may be removed by centrifugation and magnetic separation. The antigen-bound library may be transferred to pre -blocked Dynabeads (separated from buffer), and then to binding reaction, and rotated at 3O0C for 20 minutes. The amount of Dynabeads used for capture may be calculated as described above based on the bead capacity, and the target antigen concentration used in the selection. To avoid pulling down bead binders, the amount of Dynabeads should be reduced (but not to less than 500 μg or 50 μl) when the target antigen concentration is reduced.
D. Library selection: Washing
The Dynabeads™ may be separated from the unbound library by centrifugation and magnetic separation. The supernatant may be removed with a 1 mL tip, and one new filtered tip may be used for each library selection tube to eliminate cross- contamination. New pipette tips may be used to wash the Dynabeads™ with aboutl mL of Selection buffer, and the Dynabeads™ may be re- suspended by gentle pipetting or by inverting tubes multiple times. The tubes may be placed back onto magnetic holder for bead separation while the next library is processed. After all libraries are washed, supernatant may be removed with a 1 mL tip (use one new filtered tip for each library selection tube to eliminate cross -contamination). This step may be repeated for five washes. Dynabeads™ may be washed two times with 1 mL of IX First Strand buffer (Superscript II, Invitrogen) as described above. At the last wash, 1/10 of library may be removed to a separate tube for counting to determine library recovery if so desired. Dynabeads™ may be captured by magnetic separation and about 100 μl of wash buffer may be saved for background count. Dynabeads™ may be re-suspended in water, using 1A of the capture bead volume as calculated above). E. Library Selection: Counting
May be performed as described in section 13 (E) above. 15. Off-rate library selection by antigen competition
The major difference between off -rate selections and equilibrium selections is that the library binds to the selecting antigen first before FLAG purification. After FLAG purification the library may be incubated with an excess amount of competitor antigens or antibodies (e.g. when competitor antigens are not available) such that any pre-bound antigen that becomes unbound from the PROfusion molecules during off-rate competition is replaced by the competitors. The competitor is distinct from the pre- bound antigen in that competitor-bound PROfusion molecules may not be recovered in the subsequent recovery step. They may be un-modified antigens or antigens in a different format. Although antibodies may also be competitors, typically they are not as efficient competitors as antigen, and their efficiency decreases as the library's affinity to antigen increases. It is advantageous for the off -rate of the library to be determined just prior to selection in order to identify the proper duration of competition. This duration may range from several hours to several weeks. A: Preload library with biotinylated antigen or antigen-Fc fusion protein
PROfusion molecules may be translated and purified by oligo-dT as described above. The oligo-dT purified library may be equilibrated by adding 5X FLAG binding buffer to a final concentration of IX (simply add 25% of the library volume). Antigens (biotinylated or Fc-fusion) may be added to a sufficiently high concentration and rotated at 3O0C for 30 minutes to saturate antigen- antibody binding. PROfusion molecules may be purified by anti-FLAG M2 agarose as described above. It is important to note that a FLAG-purified PROfusion library should be kept on ice, but not frozen. It is important to pre -block sufficient amounts of capture beads as described above. B: Determine competitor concentration and library baseline recovery
The amount of recovered library from the above step may be calculated to determine its molar concentration. This represents the maximal amount of library-bound antigen, and may be used to calculate the amounts needed (500x to 100Ox) for off -rate competition.
10% pre-blocked beads may be added to a 10% aliquot from antigen-bound PROfusion library and rotated for about 20 min at about 40C. The beads may be washed 5 times with 1 mL of Selection Buffer as described above. The beads may be counted to determine the percentage of PROfusion library bound by antigen before off -rate selection as follows:
Recovery % = 100 x (CPM Beads / CPMinput) x 10 C: Library selection: Competition
1000-fold molar excess of competitor (e.g. unmodified antigen or antibody) may be added to FLAG-purified PROfusion library and rotated at about 3O0C for a predetermined duration that will apply sufficient selection pressure to select for clones with better off -rates. Chill library on ice for about 1 to 2 minutes to slow down off-rate before bead capture. D: Library selection: Capture
The selection buffer used for blocking the Dynabeads for library capture may be removed by centrifugation and magnetic separation. The antigen-bound library may be transferred to pre-blocked Dynabeads (separated from buffer), and rotated at 40C for about 20 minutes. E: Library selection: Washing
The Dynabeads may be collected by centrifugation and magnetic separation from library. The supernatant may be removed with a 1 mL tip (use one new filtered tip for each library selection tube to eliminate cross-contamination, as described above).
Beads may be washed two times with about 1 mL of IX First Strand buffer (Superscript II, Invitrogen) as described above. At the last wash, 10 to 20% of library may be removed to a separate tube for counting to determine library recovery if so desired. Dynabeads may be captured by magnetic separation and 100 μl wash buffer may be saved for background count. Beads may be re-suspended in water (1/4 of the capture bead volume as calculated above). F: Library selection: Counting and Recovery Calculation 10 - 20% of the last wash and the beads may be counted. It is advisable to avoid using more than 100 μL beads, as it may quench the counts. Library selection recovery may be calculated using the following formula:
Selection recovery % = 100 x CPMTotai Beads / CPMTotai input
16. Reverse transcription of library selection outputs
Reverse transcription may be done with Superscript II Reverse Transcriptase (Invitrogen™). The volume of each reaction may be scaled up according to the bead volume after selection. Outputs may be analyzed by reverse transcription (RT) with appropriate primer pairs. For example, 'Ck Reverse' or 'Ck5-FLAGA20 Rev' primers may be used for kappa libraries, 'CJL Reverse' or 'CL5FLAGA20 Rev' primers may be used for lambda libraries, and 'Lib-GS-Rev' or 'VH-GSFLAGA20-Rev' primers may be used for the human PBMC VH library.
The reverse transcription primer should have at least the same 5' end sequence as the subsequent PCR reverse primer, to avoid residual primers left over from the reverse transcription reaction creating amplification products that have different 3' end sequences. This is especially important if the shorter 'Ck Reverse', 'CJL Reverse', or 'Lib-GS-Rev' primers are used for RT because any residual amount of these primers may participate in the following PCR and create products that lack the poly-A tail.
Table 1: Oligonucleotide primers used for amplification of library selection outputs
Figure imgf000035_0001
Exemplary RT reaction conditions
For a reaction of a 200 μL final volume, a RT reaction may be set up as follows: Beads (in water) X μL dH2O to 108 μL
10 μM reverse primer 2 μL
10 mM dNTP 10 μL
Incubate at 65 0C for 5 min, chill on ice. Add: 5x First Strand Buffer 40 μL
0.1 M DTT 20 μL
RNase OUT 10 μL
The reaction may be incubated at 420C for 2 minutes prior to adding 10 μL Superscript II reverse transcriptase. The reaction may be divided into 100 μL aliquots and incubated at 420C for 50 minutes with occasional agitation. Tubes may then be incubated at 950C for 5 min after the reaction. Beads may be isolated and the supernatant transferred to new tubes. Typically samples may be pooled if they are from same selection output. Re-suspend beads in water (half of RT volume). Tubes may be incubated at 95 0C for 5 minutes after reaction, and the beads may be captured by magnet, and the supernatant may be pooled with previously transferred supernatant. This represents the cDNA template for PCR amplification of selection outputs.
17. Library selection against cell surface antigen
The major distinctions between selecting PROfusion library against cell surface antigens and soluble biotinylated antigens are that the mRNA moieties in the PROfusion molecules are protected from cellular RNase degradations by cDNA complementation, and thus need to be reverse-transcribed into cDNA before library selections. The reverse transcription reaction may be carried out before or after the FLAG purification depending on the volume of library after oligo-dT purification. It is important to note that the reducing agent DTT should not be included in the reverse transcription, or any step prior to library selection, in order to preserve the intrachain disulfide bonds of the scFv molecule. A: Library preparation after oligo dT purification
In one embodiment, an initial 10 ml translation volume appropriate for first round selection may be used, but it should be noted that the following methodology may be easily adapted for smaller translation reactions.
PROfusion molecules may be translated and purified by oligo dT as described above. The purified library should be recovered in a dE^O volume equal to or less than the reticulate lysate volume used for translation. Input, last wash buffer, and 10 μl of library may be counted to determine yield and percent recovery as described above. B: FLAG binding
The oligo dT-purified library may be equilibrated to a final concentration of IX PBS by adding 1/4 library volume 5X PBS. The amount of anti-FLAG M2 agarose beads needed to capture all PROfusion molecules may be estimated {e.g. estimating the binding capacity of the beads at approximately 6 nmol fusion protein per mL of 50% slurry). In order to have sufficient bead volume for manipulation during binding and washing, it is inadvisable to use less than 200 μL of the pre- washed beads. A wide-bore pipette tip may be used to transfer anti-FLAG M2 agarose to a new tube. The beads may be spun down (1500 rpm for 1 minute) and the buffer removed. The beads may be washed two to three times with 1 ml PBS to remove any trace amount of detergent present in the storage buffer. The oligo-dT purified library may be transferred in IX PBS to the washed anti-FLAG M2 agarose beads, and rotated at 4°C for 1 hour to overnight. C: FLAG washing
As an optional step, the anti-FLAG M2 agarose beads may be spun down at 1500 rpm for 1 minute, 4°C and the supernatant discarded. IX PBS may be used to transfer beads onto a Bio-Rad™ Mini-spin column or Invitrogen™ Microcentrifuge Spin Column, and then the buffer may be removed by spinning at 1000 rpm for 10 seconds. The Invitrogen™ column may be spun at higher speed (e.g. 10,000 RPM is possible). Beads may be washed 4X by 500 - 600 μL 1 X PBS and the PBS spun through the column. Beads may be washed 2X by 500 - 600 1 X RT first strand buffer (without DTT). The flow-through may be discarded, but it is advisable to save the last wash for scintillation counting. D: FLAG elution
PROfusion molecules may be eluted by adding 450 μL (note that 230 μL may be used for smaller M2 agarose volumes) of 100 μg/mL FLAG peptide in First Strand Buffer (without DDT) that contains RNaseOUT at a 1:20 dilution, and then incubating the mixture for 10 minutes at room temperature. Eluate may be collected by spinning at 3000 rpm or faster for 20 seconds. This step may be repeated once, and then the libraries from both elutions may be pooled. E: FLAG recovery calculation
Count 5 - 10 μL of elution output and 100 μL from the last wash on a beta counter. PROfusion molecule recovery % may be calculated as follows (note that 10- 30%, or higher, recovery is expected):
= (CPMoutput x Volumeoutput) / (CPMinput x Volumeinput)
F: Reverse transcription
Primers described in section 16 above may be used. RT reaction conditions
Purified PROfusion library 445 μL 890 μL 10 μM reverse primer 5 μL 10 μL 10 mM dNTP 25 μL 50 μL Superscript II 25 μL 50 μL
Total volume 500 μL 1000 μL
Reaction may be incubated at 370C for 1 hour, with or without agitation. The library may be equilibrated for selection against cell surface antigens as follows. After the reverse transcription reaction has been completed, 5 M NaCl may be added to the reaction mixture to 75 mM (15.3 μL to 1 mL and 7.6 to 500 μL reaction). An additional IX PBS may be added to the library if there is a need to increase volume. The following blocking reagent may be added to library before selection.
Final concentration
BSA, 50 mg/ml 21 μL 1 mg/ml
Salmon sperm DNA, 10 mg/ml 10.5 μL 0.1 mg/ml
A pre-clear step may be required for naϊve library selection, but may be omitted if using a library made from a single template, e.g. a library made for affinity maturation.
Cells used for library pre-clearing (antigen-naϊve cells) should be confirmed not to have target antigen expression on cell surface by flow-cytometry or Western blot analysis. For example, this could be the parental cells used for generating the antigen- expressing stable cell lines, which present a situation where the only know surface protein difference between the cells used for pre-clearing and for selection should be the target antigen itself.
The cell numbers needed for pre-clearing library should be calculated. This is the number of antigen-naϊve cells needed for pre-clearing library and is the same number as for library selection. The cell number (X) is calculated from several numbers: copies of antigens on antigen-expressing cell surface (C), library size for selection (S = moles x 6 x 1023), and fraction of library that will bind to the target antigen (F). It can be roughly calculated by this formula to allow for 10 fold excess of target antigen or pre- clear power:
X = IO x S x F / C
For instance, assume one particular antigen has an estimated cell surface copy number of 1 x 104, and in a 10 pmol naϊve antibody library less than 0.05% (5 x 10"4) of the library can be recovered by antigen binding or background sticking. The number of cells needed for pre-clear and selection is
X = IO x (IO x 10"12 x 6 x 1023) x (5 x 10"4) / (1 x 104) = 3 x 106
In practice, the number of cells should be 5 x 106 or more to ensure cell pellet can be seen after pelleting. G: Pre-clear the library
Cell density may be counted by hemocytometer or Coulter counter and sufficient cells may be transferred to a centrifuge tube. Cells may be spun down at 1500 rpm at 4°C, and very gently re-suspended in 1 mL ice-chilled PBS. The cell suspension may be transferred to a 1.7 mL screw-top microfuge tube. Be careful not to shear cells by pipetting. Cells may be spun down at 1500 rpm and the PBS removed. The wash step with PBS may be repeated once more. The library from step 13.3.3 should be immediately added to gently re- suspended cells. The tubes may then be immersed into an ice-water bath, and agitated for about 60 minutes. Cells may be spun down at 1500 rpm and the library transferred to a new tube of cells for second pre-clear or for antigen selection. H: Library selection against antigen-expressing cells
Calculate the number of cells needed for antigen selection. This is the same number as for pre-clearing library as calculated above. The cell number (X) is calculated from several numbers: copies of antigens on antigen-expressing cell surface (C), library size for selection (S = moles x 6 x 1023), and fraction of library that will bind to the target antigen (F). It can be roughly calculated by this formula to allow for 10 fold excess of target antigen or pre-clear power:
X = IO x S x F / C I: Library selection
Antigen-expressing cell density may be counted by hemocytometer or Coulter counter and sufficient antigen-expressing cells may be transferred to a centrifuge tube. Cells may be spun down at 1500 rpm at 4°C, and very gently re- suspend cells in 1 rriL ice-chilled PBS. The cell suspension may be transferred to a 1.7 mL screw-top microfuge tube. Be careful not to shear cells by pipetting. Spin cells down at 1500 rpm and remove PBS and repeat wash with PBS once more. The purified and/or pre-cleared library may be immediately used to gently resuspend cells. The tubes may be immersed into ice- water bath, and rotated for 2 hours. Spun down at 1500 rpm and the supernatant discarded. Cells may be washed 4 times with 1 mL PBS, spun down at 1500 rpm and the supernatant discarded. Cells may be re-suspended in 500 μL of PBS. If desired, count up to 20% of cells and last wash. J: Library output recovery
5 μL RNase H (2 U/μL) may be added to the re-suspended cells and incubated at 37 0C for 20 minutes. This will digest the RNA and release cDNA from the cell surface. Cells may be spun down at 1500 rpm for 30 seconds and the supernatant transferred to a new tube. Cells may now be discarded. 5 μL of RNase A (20 mg/ml) may be added to the supernatant and incubated at 37 0C for 30 minutes. This degrades any cellular RNA that may have come from broken cells during the selection process. The degraded RNA may be removed by dialysis later and thereby prevented from interfering with library amplification by PCR. To the supernatant add equal volume of phenol/CHCVisoamylalcohol (25:24:1) and vortex for 30 seconds. The bottom organic phase may be separated from top aqueous phase by centrifugation in Phase Lock Gel Heavy 2 ml tube (Eppendorf) at maximal speed for 5 minutes. The top aqueous phase may be transferred to a new tube and the extraction repeated once with phenol/CHCVisoamylalcohol (25:24:1) and once by CHCl3. The top aqueous phase after the CHCI3 extraction may be transferred to Mini Dialysis Kit, 8 kDa cut-off, 2 mL (GE healthcare) and dialyzed overnight at 4 0C against 4 liter of dH2O. K: Counting and library selection recovery calculation
Starting from Round 3 count 10 - 20% of the last wash and the cells.
Selection recovery % = 100 x CPMTotai ceils / CPMTotai input 18. Reamplification of Library DNA by RT-PCR
Reverse transcription may be performed using the material captured from the library. Reagents and protocols known in the art are suitable for performing the reverse transcription reaction. The volume of the reaction may be scaled up or down according to the bead volume after selection.
Primers used for reverse transcription may be any suitable reverse- complementary sequences located at the 3' end invariable region of the antibody library and may be the same or further 3' to the reverse primer to be used in a subsequent amplifying PCR.
An exemplary reverse transcription reaction contains the beads from the library selection (in water), reverse primer, and dNTP. Reactions are incubated at 65 0C for about 5 minutes and chilled on ice. First strand synthesis buffer, about 0.1M DTT, and RNase inhibitor are then typically added to the reaction. The reverse transcription reactions are incubated at about 420C for 2 minutes before adding reverse transcriptase enzyme. Reactions are incubated at about 42 0C for 50 minutes with occasional agitation. Reactions are then incubated at 95 0C for 5 min. Beads are then collected by magnet, and the supernatant is transferred to new tubes, which is pooled if it is from same selection output. Beads are resuspended in water (half of RT volume), and incubated in tubes at 95 0C for 5 minutes. Beads are again collected using a magnet, and the supernatant is pooled with the previously transferred supernatant. This contains the cDNA template for PCR amplification of selection output. After PCR, 10-DL of PCR product is loaded onto a 2% agarose gel to confirm that the reaction was successful.
19. PCR for library DNA template amplification
For selection outputs from the first and second rounds, cDNA (supernatants from RT reactions) may be dialyzed against water using an 8 kDa cut-off, and the entire amount of cDNA may be used as PCR template. For selection outputs from later rounds, 10% of cDNA may typically be used as template for PCR, and dialysis is typically not necessary. Reactions may be performed in 1 mL PCR volumes for round 1 and 2 outputs (using all RT products), while reaction volumes may be scaled down for outputs from later rounds. Aliquots for 100-μL reactions should be made from a master mix. An exemplary PCR reaction for library DNA template amplification is shown in Table 7 below.
Table 2: Exemplary PCR reaction for library DNA template amplification
DNA template X μL dH2O add to 740 μL
1OX KOD buffer 100 μL
MgSO4 (25 mM) 60 μL
10 mM dNTP 20 μL
5' forward primer (10 μM) 30 μL
3' reverse primer (10 μM) 30 μL
KOD Hot Start DNA Polymerase 20 μL
Total volume 1000 μL*
In an exemplary embodiment, 1 mL PCR reactions are used for round 1 and 2 outputs, and 0.5 mL reactions are used for outputs from later rounds. Aliquots of 100- μL reactions should be made from a master mix. Exemplary thermal cycling conditions for library DNA template amplification are shown in Table 8 below.
Table 3: Exemplary alternative PCR reaction for library DNA template amplification cDNA template X μL dH2O add to 790 μL
1OX High Fidelity Taq DNA Polymerase buffer lOOμL MgSO4 (50 mM) 40 μL 10 mM dNTP 20 μL
5' forward primer (10 μM) 20 μL
3' reverse primer (10 μM) 20 μL
High Fidelity Taq DNA Polymerase 10 μL
Total volume 1000 μL
In an exemplary embodiment, 1 mL PCR reactions are used for round 1 and 2 outputs, and 0.5 mL reactions are used for outputs from later rounds. Aliquots of 100- DL reactions should be made from a master mix. Exemplary thermal cycling conditions for library DNA template amplification are shown in Table 8 below.
Table 4: Another exemplary alternative PCR reaction for library DNA template amplification
DNA template X μL dH2O add to 660 μL
1OX KOD buffer 100 μL
MgSO4 (25 mM) 60 μL
2 mM dNTP 100 μL
5' forward primer (10 μM) 30 μL
3' reverse primer (10 μM) 30 μL
KOD Hot Start DNA Polymerase 20 μL
Total volume 1000 μL*
Thermal cycling conditions for library DNA template amplification 95 0C 2 minutes i
95 0C 20 seconds ]
55 0C 10 seconds ϊ 20 cycles*
70 0C 15 seconds J i 70 0C 30 seconds i
4 0C Hold forever
*Note: 18 to 20 cycles of amplification may typically be used with KOD Hot Start DNA Polymerase, however, as few as 13 cycles may be successful in amplifying a sufficient quantity of library DNA. Non-specific products of various sizes may become more apparent with additional amplification cycles, and the product may need to be gel purified. If possible, it may be helpful to increase the DNA template input rather than the number of amplification cycles.
Table 5: Thermal cycling conditions for library DNA template amplification
94 0C 2 minutes i
94 0C 20 seconds ]
55 0C 20 seconds } 25 cycles*
68 0C 1 minute J i 68 0C 5 minute i
4 0C Hold forever
*Note: 25 cycles typically give sufficient amplification but it may be increased to as many as 35 cycles to gain more products. Non-specific products of various sizes may become more apparent with additional amplification cycles, and the product may need to be gel purified. If possible, it may be helpful to increase the DNA template input rather than the number of amplification cycles.
After PCR, the size of the PCR product is confirmed by, e.g., agarose gel electrophoresis. If products are the correct size (~ 850 bp for scFv, ~ 500 bp for VH or VL library) and minimal non-specific products are present, the products can generally be used either directly in transcription reaction of the next round, or after purification with a spin column (e.g. Qiagen™ QIAquick PCR Purification Kit). In some cases, the PCR products may need to be gel purified. If gel purification is to be used for PCR products, separate all remaining products on a preparative agarose gel and cut out the specific band for gel extraction. Quantitation of gel purified DNA may be misleading, as residual EtBr in the DNA tends to interfere with the UV absorbance. A more extensive wash step during gel extraction may help alleviate this interference. If possible, DNA concentration should be measured on a spectrophotometer, as the UV scanning traces are quite different between a clean DNA sample and a DNA with residual EtBr. This protocol is subsequently repeated to conduct multiple rounds of selection.
A: VH CDR3 spectratyping PCR
Spectratyping PCR may be used to analyze the VH CDR3 size distributions in the library, or its selection outputs. It is a useful tool to assess the library diversity, as well as the progression of the selections. The initial few rounds of library selection outputs and the library before selection should be very diverse and the CDR3 size distribution approximates a Gaussian distribution. Table 6: Spectratyping PCR primers
Figure imgf000045_0001
Spectratyping PCR setup cDNA template 2.0 μL dH2O 18.1 μL
5X GoTaq Flexi reaction buffer 6.0 μL
25 InM MgCl2 1.8 μL
10 mM dNTP 0.6 μL
5' forward primer (10 μM) 0.6 μL
3' reverse primer (10 μM) 0.6 μL
GoTaq Flexi DNA polymerase 0.3 μL
Total volume 30.0 μL Promega GoTaq DNA polymerase is used in this setup but may be substituted by thermal stable DNA polymerases from other sources. The final Mg2+ concentration is 1.5 mM.
Theraml cycling program
94 0C 2 minutes i
94 0C 20 seconds
55 0C 20 seconds 30 cycles
72 0C 30 seconds i
72 0C 5 minute i
4 ° 1C Hold forev
B: Spectratyping electrophoresis and analysis
After the PCR, 10-μL product may be loaded onto a 2% agarose gel to confirm successful reaction and the remaining product may be submitted to sequencing core facility for spectratyping electrophoresis on a sequencing machine, along with a ROX- labeled DNA size marker, which in generally underestimates the size of the DNA product by 3-bp, possibly due to the difference in the labeling dyes.
The amplified DNA product has the following organization:
5'-FR3 (27 bp)-VH CDR3-FR4 (35 bp)-3'
The VH CDR3 size is deduced from the apparent DNA produce size as determined by the Rox dye size marker by the following calculation:
SizevH CDR3 = (SizeApparent DNA product size - 60) / 3
Wnere OU — vO-^Frameworks on both ends ~~ -I3' A overhang "■" JDNA marker underestimationj
16. Exemplary Reagents and Buffer Compositions 1OX Chemical Ligation Buffer
Tris, pH 7 250 mM
NaCl 1 M
Oligo-dT Binding Buffer IX 2X 3X Tris, pH 8 100 200 300 mM
NaCl 1 2 3 M
Triton X-100 0.05 0.1 0.15%
FLAG Binding Buffer IX 5X
Phosphate-based buffer
PBS IX 5X
Triton X-100 0.025 0.125%
Alternative HEPES-based 1 Duffer
HEPES 50 25O mM
NaCl 150 75O mM
Triton X-100 0.025 0.125%
Selection Buffer
Phosphate-based buffer
PBS IX
BSA 1 mg/mL
Salmon sperm DNA 0.1 mg/mL
Triton X-100 0.025%
Yeast tRNA (optional, add before use) 20 ng/mL
Alternative HEPES-based buffer
HEPES 5O mM
NaCl 15O mM
BSA 1 mg/mL
Salmon sperm DNA 0.1 mg/mL
Triton X-100 0.025%
Yeast tRNA (optional, add before use) 20 ng/mL
First strand buffer
Tris-HCl, pH 8.3 25O mM
KCl 375 mM
MgCl2 15 mM 5OX FLAG stock solution
FLAG peptide 25 mg
Selection buffer 5 mL
Make 1 mL aliquots and store at -20 0C.
FLAG elution solution
50X FLAG stock solution 1 mL
Selection buffer 49 mL
Make 1 mL aliquots and store at -20 0C
Oligo-dT cellulose preparation
Weigh 2.5 g of oligo-dT cellulose in a 50 mL tube. Add 25 mL of 0.1 N NaOH and mix.
Spin down at 1500 rpm for 3 minutes, discard the supernatant. Wash the oligo-dT cellulose with 25 mL of IX Oligo-dT binding buffer. Spin down at 1500 rpm for 3 minutes, discard the supernatant. Repeat the wash 3 more times and measure the pH of the supernatant. The pH should be the same as wash buffer (~ pH 8.5). Re-suspend the oligo-dT cellulose to a final volume of 25 mL by adding IX Oligo-dT binding buffer. This may be an approximately 50% slurry. Store the pre-washed cellulose beads at 4 0C. Final concentration = 100 mg/mL = 1 nmol RNA capacity. Anti-FLAG M2 agarose preparation
Transfer 25 mL of M2 agarose beads into a 50 mL of tube.
Spin down beads for 5 minutes at 1000 rpm in a Beckman centrifuge and remove supernatant by aspiration.
Wash by re- suspending beads in equal volume of 10 mM glycine, pH
3.5.
Spin down beads for 5 minutes at 1000 rpm in a Beckman centrifuge and remove supernatant by aspiration.
Re-suspend with one column volume of IX FLAG binding buffer. Spin down slurry for 5 minutes at 1000 rpm in a Beckman centrifuge and remove supernatant by aspiration.
Repeat the wash 3 times.
Re-suspend with one column volume of IX binding buffer (containing 1 mg/mL BSA and 100 mg/mL salmon sperm DNA).
Tumble 1 hour or overnight at 4 0C.
Aliquot in 2 mL fractions if desired and keep at 4 0C.
EXAMPLE 1 DEMONSTRATION OF FUNCTIONAL MRNA-SCFV MOLECULES
Four known antibodies were used to demonstrate that functional mRNA-scFv molecules can be displayed and bind to their respective antigen: D2E7 (human anti- hTNF), Y61 (human anti-hIL-12), 17/9 (mouse anti-HA), and MAK195 (mouse anti- hTNF). The MAK- 195 scFv was generated by PCR from plasmid DNA using the primers shown in Table 9 below.
Table 7: Oligonucleotide Primers Used For The Construction Of MAK195 mRNA- scFv Constructs
Primers Sequences
T7-MAK195VH- TAATACGACTCACTATAGGGACAATTACTATTT
Fwd ACAATTACACCATGGAGGTGCAGCTGAAGGAG
TCAGG (SEQ ID NO: 22)
MAKl 95 VhGS- CGATCCGCC ACCGCCAG AGCC ACCTCCGCCTGA Rev ACCGCCTCCACCTGCAGAGACAGTGACCAGAGT
CC (SEQ ID NO: 23)
MAKl 95 VLGS- GGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGG Fwd CGGTGGCGGATCGGACATTGTGATGACCCAGTC
TC (SEQ ID NO: 24)
MAKl 95 VL-Rev GATGGTGCAGCCACCGTACGTTTTATTTCCAAC TTTGTCCCCGAG (SEQ ID NO: 25)
An anti-HA 17/9 scFv (see Schulze-Gahmen et al. (1993) J. MoI. Biol. 234(4): 1098- 118) was generated by PCR using the following primers based on protein sequences A31790 and B31790 downloaded from NCBFs database (see Table 10 below). Table 8: Oligonucleotide Primers Used For The Construction Of 17/9 mRNA-Scfv Constructs
Primers Sequences
T7TMVUTR- GGACAATTACTATTTACAATTACACCATGGAAG 17/9 VH-I Fwd TGCAGCTGGTGGAAAGCGGCGGCGATCTGGTG
AAACC (SEQ ID NO: 26)
17/9 VH-2 Rev GCTGCTAAAGCTAAAGCCGCTCGCCGCGCAGCT
CAGTTTCAGGCTGCCGCCCGGTTTCACCAGATC
GCCG (SEQ ID NO: 27)
17/9 VH-3 Fwd GGCTTTAGCTTTAGCAGCTATGGCATGAGCTGG
GTGCGCCAGACCCCGGATAAACGCCTGGAATG
GGTGG (SEQ ID NO: 28)
17/9 VH-4 Rev GCCTTTCACGCTATCCGGATAATAGGTATAGCC
GCCGCCGTTGCTAATGGTCGCCACCCATTCCAG
GCGT (SEQ ID NO: 29)
17/9 VH-5 Fwd CCGGATAGCGTGAAAGGCCGCTTTACCATTAGC
CGCGATAACGCGAAAAACACCCTGTATCTGCAG
ATG (SEQ ID NO: 30)
17/9 VH-6 Rev GTTCGCGGCGCGCGCAATAATACATCGCGCTAT
CTTCGCTTTTCAGGCTGCTCATCTGCAGATACA
GGGT (SEQ ID NO: 31)
17/9 VH-7 Fwd ATTGCGCGCGCCGCGAACGCTATGATGAAAAC
GGCTTTGCGTATTGGGGCCAGGGCACCCTGGTG
ACCGT (SEQ ID NO: 32)
17/9 VH-8 GS CGATCCGCCACCGCCGCTGCCACCTCCGCCTGA Rev ACCGCCTCCACCCGCGCTCACGGTCACCAGGGT
GCCC (SEQ ID NO: 33)
GS-17/9 VL-I AGCGGCGGTGGCGGATCGGATATTGTGATGACC Fwd CAGAGCCCGAGCAGCCTGACCGTGACCGCGGG
CGAAA (SEQ ID NO: 34)
17/9 VL-2 Rev TGTTTGCCGCTGTTAAACAGGCTCTGGCTGCTG
GTGCAGCTCATGGTCACTTTTTCGCCCGCGGTC
ACGG (SEQ ID NO: 35) Primers Sequences
17/9 VL-3 Fwd GTTTAACAGCGGCAAACAGAAAAACTATCTGA
CCTGGTATCAGCAGAAACCGGGCCAGCCGCCG
AAAGTG (SEQ ID NO: 36) 17/9 VL-4 Rev CGGTAAAGCGATCCGGCACGCCGCTTTCGCGGG
TGCTCGCCCAATAAATCAGCACTTTCGGCGGCT
GGCC (SEQ ID NO: 37) 17/9 VL-5 Fwd TGCCGGATCGCTTTACCGGCAGCGGCAGCGGCA
CCGATTTTACCCTGACCATTAGCAGCGTGCAGG
CGGA (SEQ ID NO: 38) 17/9 VL-6 Rev AAAGGTCAGCGGGTTGCTATAATCGTTCTGGCA
ATAATACACCGCCAGATCTTCCGCCTGCACGCT
GCTA (SEQ ID NO: 39) 17/9 VL-7 Fwd AGCAACCCGCTGACCTTTGGCGGCGGCACCAAA
CTGGAACTGAAACGTACGGTGGCTGCACCATCT
GTCT (SEQ ID NO: 40)
17/9 VL-8 FLAG TTAAATAGCGGATGCCTTGTCGTCGTCGTCCTT Rev GTAGTCGATGAAGACAGATGGTGCAGCCACC
(SEQ ID NO: 41)
17/9 antibody sequence was retrieved from NCBI database using the accession numbers A31790 and B31790.
DNA constructs for these scFv were transcribed in vitro and then translated by rabbit reticulocyte Iy sate either as mRNA-scFv (protein was attached to mRNA via linker with puromycin modification) or as free scFv (protein was not attached to mRNA). Both types of molecules were purified and subjected to pull-down assays by corresponding biotinylated antigens (see Figure 4).
The data in Figure 4 shows that functional m-RNA-scFv (bound to biotinylated antigen) can be pulled down by streptavidin-magnetic beads, albeit at lower percent recovery than free scFv. Further experiments showed that this difference is simply due to the heavy RNA tethered to the scFv. RNase degradation of the RNA portion from the mRNA-scFv molecule restored the scFv recovery by antigen to the same level as that of free scFv (see Figure 5). EXAMPLE 2
OPTIMIZATION OF THE MRNA DISPLAY TECHNOLOGY TO IMPROVE
THE TRANSLATION REACTION
In a preferred embodiment, the library size is 1 x 10 \12. About 20 pmol of the fused protein (e.g., 1.2 x 1013) is required for the selection in order to cover the library size 12 times. Recovery following FLAG-purification is typically about 30%. Therefore, about 60 pmol of the fused protein is needed following Oligo-dT purification to input into FLAG purification. In one embodiment, about 1.2 pmol fused protein is obtained per 100 pmol RNA following Oligo-dT purification. In this embodiment, about 5 nmol RNA (which covers the library size 3000 times) is necessary to obtain 60 pmol of the fused protein. Note that this calculation does not take into account the observation that only about 20-30% of fused mRNA display molecules are functional (can be recovered after selection).
Due to the aforementioned quantity of the fused protein needed for subsequent steps of the mRNA display method, the translation reaction was optimized to maximize protein recovery. Varying the initial amount of RNA input into the translation reaction was evaluated following FLAG purification. Protein recovery was assessed by measuring the percentage of S35 methionine incorporated during the translation reaction, and by calculating the ratio of pmol protein (output) to pmol RNA (input). The starting amounts of input RNA tested, as well as the resulting protein recovery, are shown in Table 12. As demonstrated by this analysis, a lower RNA input surprisingly leads to a higher percentage of protein recovery.
Table 9: Relationship Between RNA Input And Protein Recovery
Figure imgf000052_0001
The translation reaction was also performed using different amounts of the free amino acid mixture to determine the effect on protein recovery. The relative starting amounts of the amino acid mixture tested, as well as the resulting protein recovery, are shown in Table 13. The RNA input in each case was 50 pmol. As demonstrated by this analysis, increasing the amino acid pool leads to a decrease in translation efficiency.
Table 10: Relationship Between Amino Acid Concentration And Protein Recovery
Figure imgf000053_0001
Different amounts of "cold" (i.e., non-radioactive) methionine were also tested for their effect on translation efficiency. The different concentrations of cold methionine that were tested, as well as the resulting protein recovery, are shown in Table 14. The RNA input in each case was 50 pmol. As demonstrated by this analysis, increasing the input of cold methionine does not lead to an increase in translation efficiency.
Table 11: Relationship Between Cold Methionine Concentration And Protein Recovery
Figure imgf000053_0002
The RNA input and amino acid concentration should therefore be taken into consideration when planning the translation reaction for mRNA display. While decreasing the RNA input in each reaction may improve protein recovery, it may also impact library size. An exemplary RNA translation reaction that may be useful in practicing the mRNA display method of the invention is shown in Table 15.
Table 12: Exemplary RNA Translation Reaction
Figure imgf000054_0001
EXAMPLE 3
OPTIMIZATION OF THE MRNA DISPLAY TECHNOLOGY FOR SCFV
SELECTION - SPACER LENGTH
It has been previously proposed that a long spacer length between the scFv protein and the end of mRNA improved scFv folding and function (see Hanes et al. (1997) Proc. Natl. Acad. Sci. USA 94(10):4937-42). Therefore, the effect of the spacer length between the scFv and the linker annealing site on the mRNA-scFv molecule function and yield was investigated (see Figure 6). Three different D2E7 scFv constructs with short, medium and long 3' spacers and two short and long spacer constructs for Y61 and 17/9 scFv were made (see Figure 8 for D2E7 spacer constructs). The results, depicted in Figure 7, show that a longer spacer does not provide measurable advantage in the mRNA-scFV molecule's function as assessed by antigen binding. Moreover, longer spacer length significantly reduced the mRNA-scFv yield (see Figure 7). RNA yields were also lower with a longer spacer: short spacer yielded 6 nmol RNA; medium spacer yielded 3.4 nmol RNA; and long spacer yielded 1.7 nmol. Thus, in one embodiment, a short spacer is preferred for scFv library construction.
Comparison of different spacers and linkers was also performed using three different Y61 constructs (see Figure 23). The results, shown below in Table 16, show that RNA yields were also lower with a longer spacer. In addition, there was no difference in mRNA molecule purifications nor antigen binding by moving the poly-A tail from the mRNA itself (Y61-scGene3pA) to the DNA linker between mRNA and scFv protein (Y61-scGene3) as the scFv protein are identical between these two constructs as shown in SEQ ID NO: 10 and SEQ ID NO:4, respectively.
Table 13: Comparison of Different Spacers and Linkers
Figure imgf000055_0001
As shown below, 17/9 requires PDI during translation to be functional, and DTT in the reverse transcription reaction before selection was shown to affect its antigen binding. As these results indicate, disulfide bonds are essential for 17/9 function, and this makes 17/9 a good candidate to investigate spacer length requirements. Figure 9 shows that although longer spacer length does not improve mRNA-scFv molecule binding to antigen, it reduces its yield.
EXAMPLE 4
OPTIMIZATION OF THE MRNA DISPLAY TECHNOLOGY TO IMPROVE
SCFV PROTEIN FOLDING AND FUNCTION - OMISSION OF CHEMICAL
MODIFICATION ON CYSTEINE RESIDUES
Messenger RNA display technology in the art includes a chemical capping reaction on free cysteine residues to prevent formation of undesirable cysteine disulfide bonds by 2-nitro-5-thiocyanatobenzoic acid, which resulted in cyanylation, or by N- ethylmaleimide, which covalently links to the sulfhydryl group. While this capping reaction eliminates potential protein misfolding caused by random crosslinking of free cysteine residues, the present invention eliminates the artificial preservation of free cysteine within an antibody which can be a detriment to its future manufacturability due to unpredictable physical or chemical properties. The step of chemical capping was eliminated such that any extra free cysteine beyond the four cysteines required for scFv Ig domain folding are not actively preserved during the library selection.
EXAMPLE 5
OPTIMIZATION OF THE MRNA DISPLAY TECHNOLOGY TO IMPROVE
SCFV PROTEIN FOLDING AND FUNCTION - REQUIREMENT OF A CO-
TRANSLATIONAL PROTEIN DISULFIDE ISOMERASE ACTIVITY
It has been suggested that PDI contributes to better protein function and secretion by either isomerase or chaperone activity or both (see Shusta et al. Nat Biotechnol 16(8):773-7; Smith et al. Biotechnol Bioeng 85(3): 340-50). Two Ig intradomain disulfide bonds are encoded by every scFv sequence, one in the VH and the other in the VL domain. It has been suggested that a co-translational protein disulfide isomerase (PDI) activity is crucial for proper disulfide bond formation in vitro (see Ryabova et al. Nat Biotechnol 15(1): 79-84). mRNA display protocols in the art have stipulated the inclusion of (PDI) in the translation reaction.
D2E7, Y61, and 17/9 scFv were used to test their requirement of PDI activity in the mRNA display system. The results showed that two of the scFv (D2E7 and 17/9) would not bind to their cognate antigen without PDI during their generation whereas Y61 appeared to be unaffected (see Figure 10). It was concluded that at a large antibody library level, the high diversity would require PDI activity to ensure maximal scFv function.
The recovery and functionality of D2E7 scFv translated with or without additional PDI added was also tested. The translation reaction included 1 tube lysate (200 μl), 100 pmol D2E7 short spacer RNA and PDI and GSSG/GSH. Translation without PDI excluded PDI and GSSG/GSH. The translated protein was recovered with FLAG purification, and the recovery amount was quantified. Antigen binding/recovery was then performed with 50 mM biotinylated TNFα and equal inputs for each, 100000 cpm. The results are shown in below in Table 17. Table 14: Testing D2E7 scFv +/- PDI
Figure imgf000057_0001
The results showing that Y61 does not require PDI during translation for functionality are shown below in Table 18.
Table 15: Y61-Sccl-Short Does Not Require PDI During Translation For Functionality
Figure imgf000057_0002
The results showing that 17/9 requires PDI during translation for functionality are shown below in Table 19. Table 16: 17/9 Requires PDI During Translation For Functionality
Figure imgf000057_0003
EXAMPLE 6
OPTIMIZATION OF THE MRNA DISPLAY TECHNOLOGY TO IMPROVE
SCFV PROTEIN FOLDING AND FUNCTION - REMOVAL OF
DITHIOTHREITOL FROM REACTION
Dithiothreitol (DTT) is a reducing agent commonly introduced to enzymatic reactions to minimize protein aggregation and reduced protein oxidation. It is also typically used in the reverse transcription (RT) reaction following in vitro translation step of the mRNA scFv molecules. Since its inclusion may reduce the two intrachain disulfide bonds in a scFv molecule that are produced by PDI activity, the potential effect of DTT on the scFv antigen binding function was investigated (see Figure 11). The presence of DTT significantly abolished the antigen binding activity of 17/9 scFv after RT, which is consistent with the dependence of PDI activity for 17/9 function shown in Figure 11. This loss of antigen binding activity was not due to the RT reaction itself, since most antigen binding activity of 17/9 was preserved if DTT was omitted from the RT. Furthermore, the results show that the 17/9 scFv cDNA was indeed reverse transcribed from the mRNA in the absence of DTT by PCR, suggesting that DTT is dispensable from the RT reaction (data not shown).
The results showing that DTT in the RT reaction before selection impacts 17/9 functionality are shown below in Table 20. As shown in Figure 12, however, DTT does not impact the RT process. Table 17: DTT in RT reaction before selection impacts 17/9 functionality
Figure imgf000058_0001
In contrast to the 17/9 scFv, the anti-IL-12 Y61 scFv function was not affected by DTT (see Figure 11). This is consistent with its aforementioned insensitivity to PDI activity, and suggests that not all antibody scFv will require disulfide bonds for function. The different RT conditions explored for Y61-scCL-short and corresponding results are shown below in Table 21 and also in Figure 13. Table 18: Different RT conditions for Y61-scCL-short
Figure imgf000059_0001
In one embodiment, DTT is not present in the RT or alternatively the RT is delayed until after antigen selection to maximize production of functional scFv yield from the mRNA-scFv library. Tables 22 and 23 below show the results of delaying the RT step until after the antigen selection step for Y61-ScCL-long and Y61 -ScCL- short, respectively. Table 19: Comparing Y61-ScCL-long with or without RT step
Figure imgf000059_0002
Table 20: Comparing Y61-ScCL-short with or without RT step
Figure imgf000060_0001
EXAMPLE 7
OPTIMIZATION OF THE MRNA DISPLAY TECHNOLOGY TO IMPROVE
SCFV PROTEIN FOLDING AND FUNCTION - INCLUSION OF RNASE
INHIBITOR DURING ANTIGEN SELECTION
The production of double- stranded mRNA-cDNA by RT was thought to prepare the rriRNA-scFv molecules for antigen binding to prevent RNA degradation and reduce RNA secondary structures. After selection by antigen the cDNA can be recovered by alkaline hydrolysis of the rriRNA and serves as amplification template by PCR. To avoid the potential impact of DTT on scFv function by RT prior to antigen selection, alternative methods need to be employed to protect the mRNA for amplification after selection.
Therefore, it was investigated whether the mRNA in an mRNA- VH molecule lacking its protective cDNA strand would be sufficiently stable and accessible for amplification by RT-PCR after antigen selection. A previously validated IL- lα binding mRNA- VH molecule was used as a model molecule. Recovery of the Phylos40 VH sequence was compared when RT was done before or after antigen selection (see Figure 14). Compared to the method in the art (pre- selection RT and alkaline elution of cDNA, left lane), recovery of mRNA by RT-PCR after antigen selection appeared to be significantly reduced when the mRNA-IL-lα complex were captured on SA-magnetic beads and used directly for RT (right lane). This might be due to partial RNA degradation during antigen selection or poor mRNA accessibility on beads for RT. Attempts to interrupt IL-lα-Phylos40 VH interaction and dissociate the mRNA- VH molecule from SA beads by acid elution (at pH 3) for better mRNA accessibility appeared to worsen its recovery, possibly due to lowered mRNA stability or poor dissociation of the mRNA- VH molecule from its antigen into elution buffer before the complexes were removed with the SA beads. Figure 14 shows results of reverse transcription following antigen selection comparing the standard method of RT-PCR following oligoDT with acid elution followed by RT-PCR and RT-PCR directly off of beads following capture. Dilution with free beads at 1:10, 1:100 and 1:1000 showed that strong re-amplification was achieved at a dilution of 1:1000.
Since it is possible to omit the RT prior to antigen selection and subsequently recover the mRNA by RT-PCR, it was investigated whether the reduced recovery of mRNA template can be restored or enhanced by protecting the RNA from contaminating RNase activity by RNase inhibitor. RNaseOUT™ (Invitrogen, cat.#10777-019) was included at 1:20 dilution during the antigen selection step and followed by RT-PCR to compare the mRNA recovery (see Figure 15). Compare to performing RT before antigen selection, the mRNA template recovery again was reduced if RT was carried out after antigen selection without RNase inhibitor. Interestingly, the inclusion of RNase inhibitor to the antigen selection not only restored but also significantly enhanced mRNA recovery. Thus, it appears this enhancement is at least partly due to a better efficiency of capturing a lighter -280 kDa mRNA-scFv molecule than that of a heavier -560 kDa mRNA-scFv molecule with the additional cDNA.
Inclusion of RNase OUT was also tested with an mRNA-scFv molecule. Figure 16 depicts the experiment performed to compare Y61-CL-long with Y61 -CL- short in the presence or absence of RNase OUT. The results can be seen in Table 24 below as well as in Figure 17.
Table 21: Comparison Of CL-Long And CL-Short Spacer In The Presence Or Absence Of RNAseOUT
Figure imgf000061_0001
EXAMPLE 8
LIBRARY SELECTION FOR 17/9 SCFV
To demonstrate that an mRNA-scFv molecule can be enriched by several rounds of selection using the mRNA display methods described here, a scFv library with a diversity of 25 was constructed by overlapping PCR. To create the scFv library, equal amounts of the VH and VL fragments of 17/9, D2E7, 2SD4, Y61 and MAK195 were mixed and combined into a scFv library with a maximal diversity of 25 and used as described above. The 17/9 scFv was then selected from this library by biotinylated HA tag peptide. After selection, 17/9 enrichment was examined by cloning and colony PCR. The results quantifying 17/9 scFv before and after one round of mRNA-scFv selection are shown in Figure 18. After one round of selection against HA peptide all scFv sequences recovered from the selection output were that of 17/9 scFv.
EXAMPLE 9
MRNA DISPLAY TECHNOLOGY CAN BE USED TO DISCRIMINATE SCFV BINDERS WITH DIFFERENT AFFINITY
To determine whether mRNA display technology, i.e., as described above, can be used to discriminate scFv binders with different affinity, chimeras between D2E7 and 2SD4 were made. 2SD4 is the D2E7 scFv precursor which exhibits low affinity (KD ~ 200 nM as free protein) for TNFα. Figure 19 depicts the chimeras.
Titration was performed for free proteins. Figure 20a shows the percent of recovery after antigen binding between the different chimeras, while figure 20b depicts the normalized percent of recovery after antigen selection. The above results show that mRNA display technology as described herein can be used to discriminate binders with different affinity.
EXAMPLE 10 THERMOSTABILITY OF MRNA-SCFV MOLECULES
To determine the thermostability of mRNA-scFv molecules, D2E7-scCk and Y61-scCk were translated and purified in mRNA-scFv format, as described herein. The mRNA-scFv molecules were then incubated at different temperatures for 30 minutes prior to antigen selection. The normalized percent of recovery after antigen selection is shown in Figure 21.
Figure 22 shows that RNA can be recovered after high temperature treatment of mRNA-scFv molecules. Here, RT-PCR was performed on the beads with recovered Y61-scCl mRNA-scFv molecules.
Incorporation by Reference
The contents of all cited references (including literature references, patents, patent applications, and websites) that maybe cited throughout this application are hereby expressly incorporated by reference in their entirety for any purpose, as are the references cited therein. The practice of the present invention may employ, unless otherwise indicated, conventional techniques of cell culture and molecular biology, which are well known in the art.
Equivalents
The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting of the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are therefore intended to be embraced herein.

Claims

Claims
1. A method of screening an scFv antibody RNA display library, the method comprising the steps of:
(a) providing a puromycin or analogue thereof crosslinked single chain Fv (scFv) mRNA molecule, said molecule comprising an mRNA encoding a 5' scFv and a 3' spacer sequence, which molecule is crosslinked to a single stranded nucleic acid linker, the linker comprising a puromycin, or analogue thereof, at a 3' end and a Psoralen C6 at a 5' end;
(b) in vitro translating the puromycin-crosslinked scFv mRNA in the presence of a label under conditions such that a labeled puromycin-crosslinked scFv mRNA/protein molecule is formed;
(c) purifying the labeled puromycin-crosslinked scFv mRNA/protein molecule;
(d) subjecting the purified labeled puromycin-crosslinked scFv mRNA/protein molecule to antigen selection with at least one antigen; and
(e) recovering the purified labeled puromycin-crosslinked scFv mRNA/protein molecules using affinity based magnetic beads.
2. The method of claim 1, further comprising the step of (g) reverse transcribing the scFv mRNA after antigen selection to make a cDNA.
3. The method of claim 2, further comprising the step of (h) amplifying the cDNA.
4. The method of claim 1, wherein the label is a radioactive label.
5. The method of claim 4, wherein the label is 35S methionine or cysteine.
6. The method of claim 1, wherein the 3' spacer sequence comprises about 0 to about 200 amino acids.
7. The method of claim 1, wherein the 3' spacer sequence comprises about 16 amino acids.
8. The method of claim 1, wherein the 3' spacer sequence comprises an affinity tag.
9. The method of claim 1, wherein the nucleic acid linker comprises, from 5' to 3': -
- Psoralen C6;
- 2'0Me ribonucleotides comprising the sequence UAGCGGAUGC (SEQ ID NO: 20);
- six Triethylene glycol or PEG- 150 moeities;
- two deoxycytidine residues; and,
- Puromycin.
10. The method of claim 1, wherein the scFv mRNA molecule is photocrosslinked to the DNA linker by UVA.
11. The method of claim 1 , wherein the scFv mRNA molecule comprises a 5 ' promoter selected from the group consisting of T7, SP6, and T3.
12. The method of claim 1, wherein the scFv mRNA molecule comprises a tobacco mosaic virus 5' untranslated region.
13. The method of claim 1, wherein the labeled puromycin-crosslinked scFv mRNA/protein molecule is purified by oligodT chromatography.
14. The method of claim 1, wherein the labeled puromycin-crosslinked scFv mRNA/protein molecule is purified using anti-FLAG M2 monoclonal antibody agarose beads.
15. The method of claim 1, wherein the labeled puromycin-crosslinked scFv mRNA/protein molecule is purified by oligodT chromatography and anti-FLAG M2 monoclonal antibody agarose beads.
16. The method of claim 1, wherein the antigen is a biotinylated peptide, protein, or hapten.
17. The method of claim 1, wherein the antigen is a fusion protein with human immunoglobulin fragment crystallizable (Fc).
18. The method of claim 1, wherein the antigen is a fusion protein with murine immunoglobulin fragment crystallizable (Fc).
19. The method of claim 1, wherein the antigen is a biotinylated peptide, protein, or hapten.
20. The method of claim 1, wherein the antigen is a population of cells.
21. The method of claim 1, wherein the antibody is an anti-IL-12 antibody.
22. The method of claim 1, wherein the antibody is an anti-HA antibody.
23. The method of claim 1, wherein the antibody is a murine antibody.
24. The method of claim 1, wherein the antibody is a human antibody.
25. The method of claim 1, wherein the antibody is a humanized antibody.
26. The method of any one of claims 1-24, wherein in vitro translation of the puromycin-crosslinked scFv rriRNA is additionally performed in the presence of GSSH/GSH.
27. The method of claim 26, wherein in vitro translation of the puromycin- crosslinked scFv mRNA is additionally performed in the presence of protein disulphide isomerase (PDI).
28. The method of any one of claims 1-24, wherein in vitro translation of the puromycin-crosslinked scFv mRNA is additionally performed in the absence of dithiothreitol.
29. The method of claim 27, wherein in vitro translation of the puromycin- crosslinked scFv mRNA is additionally performed in the absence of dithiothreitol.
30. The method of claim 1, wherein the method does not comprise an mRNA capping step.
31. The method of claim 1, wherein the method does not comprise an in vitro reverse transcription step prior to the purification step.
32. The method of claim 1, wherein an RNase inhibitor is added before, during, or after any of steps (a) through (g).
33. The method of claim 1, wherein said purification step comprises reverse transcription of the mRNA in the absence of dithiothreitol to produce a cDNA.
34. The method of claim 2 or 33, wherein the cDNA is eluted by alkaline hydrolysis at about pH=8.0 to about pH=10.0.
35. The method of claim 2 or 33, wherein the cDNA is eluted by heat.
36. The method of claim 2 or 33, wherein the cDNA is eluted by acid at about pH=3.0 to about pH=6.0.
37. The method of claim 33, wherein the cDNA is amplified by polymerase chain reaction.
38. The method of claim 37, wherein the polymerization chain reaction employs a thermostable DNA polymerase.
39. The method of claim 37, wherein the polymerization chain reaction employs an amplification enzyme selected from the group consisting of Platinum HiFi and KOD.
40. The method of claim 1, wherein the beads are selected from the group consisting of streptavidin-M280, neutravidin-M280, SA-M270, NA-M270, SA-MyOne, NA- MyOne, SA-agarose, and NA-agarose.
PCT/US2009/059057 2008-09-30 2009-09-30 Improved method of rna display WO2010039850A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN200980147651.0A CN102227638B (en) 2008-09-30 2009-09-30 Improved method of RNA display
BRPI0919426A BRPI0919426A2 (en) 2008-09-30 2009-09-30 Enhanced RNA Exposure Methods
EP09818450.0A EP2342562B1 (en) 2008-09-30 2009-09-30 Improved method of rna display
ES09818450T ES2434850T3 (en) 2008-09-30 2009-09-30 Enhanced RNA presentation method
JP2011530178A JP5968624B2 (en) 2008-09-30 2009-09-30 Improved RNA display method
CA2737035A CA2737035A1 (en) 2008-09-30 2009-09-30 Improved method of rna display
MX2011003381A MX2011003381A (en) 2008-09-30 2009-09-30 Improved method of rna display.
AU2009298499A AU2009298499A1 (en) 2008-09-30 2009-09-30 Improved method of RNA display
NZ591544A NZ591544A (en) 2008-09-30 2009-09-30 Improved method of rna display
IL211551A IL211551A (en) 2008-09-30 2011-03-03 Method of rna display
ZA2011/02120A ZA201102120B (en) 2008-09-30 2011-03-22 Improved method of rna display
HK11113810.8A HK1159250A1 (en) 2008-09-30 2011-12-21 Improved method of rna display rna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10147108P 2008-09-30 2008-09-30
US61/101,471 2008-09-30

Publications (1)

Publication Number Publication Date
WO2010039850A1 true WO2010039850A1 (en) 2010-04-08

Family

ID=42073857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/059057 WO2010039850A1 (en) 2008-09-30 2009-09-30 Improved method of rna display

Country Status (17)

Country Link
US (1) US8916504B2 (en)
EP (1) EP2342562B1 (en)
JP (1) JP5968624B2 (en)
KR (1) KR20110076906A (en)
CN (1) CN102227638B (en)
AU (1) AU2009298499A1 (en)
BR (1) BRPI0919426A2 (en)
CA (1) CA2737035A1 (en)
ES (1) ES2434850T3 (en)
HK (1) HK1159250A1 (en)
IL (1) IL211551A (en)
MX (1) MX2011003381A (en)
NZ (1) NZ591544A (en)
RU (1) RU2011117210A (en)
TW (1) TW201024731A (en)
WO (1) WO2010039850A1 (en)
ZA (1) ZA201102120B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120058A2 (en) 2014-02-05 2015-08-13 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
US9347058B2 (en) 2011-05-17 2016-05-24 Bristol-Myers Squibb Company Methods for the selection of binding proteins

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
CN101277974A (en) * 2005-09-30 2008-10-01 阿伯特有限及两合公司 Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
EP2033971A1 (en) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
BRPI0910482A2 (en) * 2008-04-29 2019-09-24 Abbott Lab double variable domain immunoglobins and their uses
JP2011523853A (en) * 2008-06-03 2011-08-25 アボット・ラボラトリーズ Dual variable domain immunoglobulins and uses thereof
NZ589436A (en) * 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5674654B2 (en) * 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド Prostaglandin E2 double variable domain immunoglobulin and use thereof
CN102458459A (en) * 2009-05-01 2012-05-16 雅培制药有限公司 Dual variable domain immunoglobulins and uses thereof
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BR112012008833A2 (en) * 2009-10-15 2015-09-08 Abbott Lab double variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
PL2510001T3 (en) * 2009-12-08 2016-06-30 Abbvie Deutschland Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2809433A1 (en) * 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
ES2873375T3 (en) 2011-03-15 2021-11-03 X Body Inc Antibody screening methods
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
WO2013112922A1 (en) 2012-01-27 2013-08-01 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
KR101820699B1 (en) 2012-11-01 2018-01-22 애브비 인코포레이티드 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
JP6020865B2 (en) 2013-03-13 2016-11-02 国立大学法人 東京大学 Nucleic acid linker
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
US10370651B2 (en) * 2013-06-28 2019-08-06 X-Body, Inc. Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3549606A1 (en) * 2015-05-28 2019-10-09 Bio-rad Laboratories, Inc. Affinity ligands and methods relating thereto
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
SG11201810591VA (en) 2016-05-27 2018-12-28 Abbvie Biotherapeutics Inc Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
AU2018367622B2 (en) * 2017-11-20 2022-12-22 Nantbio, Inc. mRNA display antibody library and methods
EP3927823A4 (en) * 2019-02-22 2022-08-10 Epsilon Molecular Engineering, Inc. A novel immuno-pcr method using cdna display
CN114585736B (en) * 2020-10-27 2023-05-02 北京寻因生物科技有限公司 Puromycin linker and application thereof in-vitro nucleic acid display peptide synthesis
WO2022104001A1 (en) 2020-11-13 2022-05-19 Bristol-Myers Squibb Company Expanded protein libraries and uses thereof

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310652A (en) * 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US5580757A (en) * 1990-10-24 1996-12-03 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A as a fusion protein
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US20040018536A1 (en) * 2000-12-14 2004-01-29 Hiroshi Yanagawa Molecule for assigning genotype to phenotype and components thereof as well as method for constructing assigning molecule and method for utilizing assigning molecule
US20050042623A1 (en) * 2002-10-30 2005-02-24 Dana Ault-Riche Systems for capture and analysis of biological particles and methods using the systems
US20050123900A1 (en) * 2002-05-06 2005-06-09 Dimitrov Dimiter S. Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6927025B1 (en) * 1997-09-03 2005-08-09 Biovation Limited Methods for protein screening
US20050232936A1 (en) * 2001-07-27 2005-10-20 Chiron Corporation Meningococcus adhesins nada, app and orf 40
US7074557B2 (en) * 2000-03-31 2006-07-11 Cambridge Antibody Technology Limited Ribosome display
US20060246515A1 (en) 2002-08-12 2006-11-02 Li Zhu High throughput generation and affinity maturation of humanized antibody
US20060246549A1 (en) * 1999-07-27 2006-11-02 Markus Kurz Peptide acceptor ligation methods
US7264932B2 (en) * 1999-09-24 2007-09-04 Applera Corporation Nuclease inhibitor cocktail
US20070218478A1 (en) * 2005-12-16 2007-09-20 Affymetrix, Inc. Methods for fragmentation and analysis of nucleic acid
US20070269879A1 (en) * 2004-02-04 2007-11-22 Neose Technologies, Inc. Methods of Refolding Mammalian Glycosyltranferases
US20080050370A1 (en) * 2006-03-17 2008-02-28 Scott Glaser Stabilized polypeptide compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207093B2 (en) * 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
CA2291721C (en) * 1997-05-28 2011-08-09 Babraham Institute Ribosome complexes as selection particles for in vitro display and evolution of proteins
DE60040981D1 (en) * 1999-05-14 2009-01-15 Genentech Inc TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US6830902B1 (en) * 1999-07-02 2004-12-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
JP5006651B2 (en) * 2003-12-05 2012-08-22 ブリストル−マイヤーズ スクウィブ カンパニー Inhibitor of type 2 vascular endothelial growth factor receptor
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JP2006141348A (en) * 2004-11-24 2006-06-08 Zoegene Corp Method for selecting and acquiring domain polypeptide interacting with target substance, method for identifying structural motif sequence, and method for designing molecule
GB0500099D0 (en) * 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
JP2007191477A (en) * 2005-12-22 2007-08-02 Cellfree Sciences Co Ltd Method for producing rubella virus protein
AR059900A1 (en) * 2006-03-17 2008-05-07 Genentech Inc ANTI-TAT226 ANTIBODIES AND IMMUNOCATE PLAYERS
US7749957B2 (en) * 2006-04-06 2010-07-06 E.I. Du Pont De Nemours And Company Clay-binding peptides and methods of use
WO2007136835A2 (en) * 2006-05-19 2007-11-29 Codon Devices, Inc Methods and cells for creating functional diversity and uses thereof

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310652A (en) * 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US5580757A (en) * 1990-10-24 1996-12-03 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A as a fusion protein
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6927025B1 (en) * 1997-09-03 2005-08-09 Biovation Limited Methods for protein screening
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20060246549A1 (en) * 1999-07-27 2006-11-02 Markus Kurz Peptide acceptor ligation methods
US7264932B2 (en) * 1999-09-24 2007-09-04 Applera Corporation Nuclease inhibitor cocktail
US7074557B2 (en) * 2000-03-31 2006-07-11 Cambridge Antibody Technology Limited Ribosome display
US20040018536A1 (en) * 2000-12-14 2004-01-29 Hiroshi Yanagawa Molecule for assigning genotype to phenotype and components thereof as well as method for constructing assigning molecule and method for utilizing assigning molecule
US20050232936A1 (en) * 2001-07-27 2005-10-20 Chiron Corporation Meningococcus adhesins nada, app and orf 40
US20050123900A1 (en) * 2002-05-06 2005-06-09 Dimitrov Dimiter S. Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US20060246515A1 (en) 2002-08-12 2006-11-02 Li Zhu High throughput generation and affinity maturation of humanized antibody
US20050042623A1 (en) * 2002-10-30 2005-02-24 Dana Ault-Riche Systems for capture and analysis of biological particles and methods using the systems
US20070269879A1 (en) * 2004-02-04 2007-11-22 Neose Technologies, Inc. Methods of Refolding Mammalian Glycosyltranferases
US20070218478A1 (en) * 2005-12-16 2007-09-20 Affymetrix, Inc. Methods for fragmentation and analysis of nucleic acid
US20080050370A1 (en) * 2006-03-17 2008-02-28 Scott Glaser Stabilized polypeptide compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IRVING R. ET AL.: "Journal of immunological methods", vol. 248, 1 February 2001, ELSEVIER SCIENCE PUBLISHER B.V., pages: 31 - 45
KURZ ET AL., NUCLEIC ACIDS RESEARCH, 15 September 2000 (2000-09-15), pages E83
See also references of EP2342562A4

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9347058B2 (en) 2011-05-17 2016-05-24 Bristol-Myers Squibb Company Methods for the selection of binding proteins
US10150962B2 (en) 2011-05-17 2018-12-11 Bristol-Myers Squibb Company Methods for the selection of binding proteins
US11060085B2 (en) 2011-05-17 2021-07-13 Bristol-Myers Squibb Company Methods for the selection of binding proteins
US11913137B2 (en) 2011-05-17 2024-02-27 Bristol-Myers Squibb Company Methods for the selection of binding proteins
WO2015120058A2 (en) 2014-02-05 2015-08-13 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity

Also Published As

Publication number Publication date
KR20110076906A (en) 2011-07-06
IL211551A0 (en) 2011-05-31
NZ591544A (en) 2013-01-25
CN102227638B (en) 2015-05-20
ES2434850T3 (en) 2013-12-17
JP5968624B2 (en) 2016-08-10
EP2342562A1 (en) 2011-07-13
AU2009298499A1 (en) 2010-04-08
US20100105569A1 (en) 2010-04-29
BRPI0919426A2 (en) 2015-12-15
CA2737035A1 (en) 2010-04-08
IL211551A (en) 2014-06-30
JP2012504415A (en) 2012-02-23
MX2011003381A (en) 2011-04-21
US8916504B2 (en) 2014-12-23
EP2342562A4 (en) 2012-03-21
ZA201102120B (en) 2011-12-28
HK1159250A1 (en) 2012-07-27
CN102227638A (en) 2011-10-26
RU2011117210A (en) 2012-11-10
EP2342562B1 (en) 2013-09-18
TW201024731A (en) 2010-07-01

Similar Documents

Publication Publication Date Title
US8916504B2 (en) Methods of RNA display
EP2340256A2 (en) Improved antibody libraries
EP3636759B1 (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
WO2016011364A1 (en) Methods and compositions to identify, quantify, and characterize target analytes and binding moieties
EP3516069A1 (en) Affinity-oligonucleotide conjugates and uses thereof
CN107614700A (en) Genotype and phenotype coupling
WO2014144495A1 (en) Single cell bar-coding for antibody discovery
CN114685671B (en) Monoclonal antibody specifically binding to Taq DNA polymerase and application thereof
JP2008505642A (en) Look-through mutagenesis to generate denatured polypeptides with enhanced properties
WO2018057051A1 (en) Affinity-oligonucleotide conjugates and uses thereof
JP2010515463A (en) Combinatorial library of conformationally constrained polypeptide sequences
CN115838429A (en) Taq DNA polymerase antibody combination and application thereof
WO2022124418A1 (en) Antibody capable of binding specifically to 5'→3' exonuclease active domain of dna polymerase
WO2014176327A2 (en) Selection of fab fragments using ribosomal display technology
Zhao et al. Selection and affinity maturation of human antibodies against rabies virus from a scFv gene library using ribosome display
WO2017127556A1 (en) Methods and compositions to identify, quantify, and characterize target analytes and binding moieties
CN110191950A (en) The composition of candidate nucleic acid reagent, method and system for identification
US20230227816A1 (en) Methods and compositions for selective pcr and cloning of antibody sequences
EP1604044A1 (en) Recovery of dna
CN116583600A (en) Antibodies that specifically bind to the 5 '. Fwdarw.3' exonuclease active domain of a DNA polymerase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980147651.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09818450

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 591544

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1709/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2737035

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009298499

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20117007259

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/003381

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011530178

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2009298499

Country of ref document: AU

Date of ref document: 20090930

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009818450

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011117210

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0919426

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110328